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PART 1 
    
 
 
 
Overview of the literature 
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Anyone who has read the literature in cystic fibrosis and isn’t confused is confused 
(Efraim Racker)
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Chapter I: CYSTIC FIBROSIS 
 
I.1 Introduction 
 
Cystic fibrosis (CF) is the most common genetically inherited disease in the Caucasian 
population [1].  It is a recessive disorder which means that CF only occurs when an 
individual inherits two malfunctioning copies (mutated alleles) of the “CF 
transmembrane conductance regulator” gene (CFTR).  When a detrimental mutation 
occurs only on one allele, the individual is called a CF carrier.  In populations of northern 
European or northern American descent approximately one in 25 people are 
asymptomatic carriers while one in 2500 newborns are suffering from CF [1].   
The gene that causes CF, CFTR, was not detected until 1989 and is located on the long 
arm of chromosome 7.  CFTR encodes a cAMP-regulated-chloride channel belonging to 
the ABC (ATP-binding cassette) transporter superfamily and is expressed on the apical 
surface of epithelial cells in different organs [2].  
The protein comprises 5 domains: two membrane-spanning domains (MSD1 and MSD2) 
that form the chloride channel, two cytoplasmic nucleotide-binding domains (NBD1 and 
NBD2) that hydrolyze ATP and a regulatory domain (Figure 1) [2]. 
 
Figure 1: Proposed model for CFTR structure 
(http://www.genemedresearch.ox.ac.uk/cysticfibrosis/protein.html) 
 
8 
 
More than 1000 CF-associated mutations are already recorded but the most prominent 
is a single deletion of phenylalanine at codon 508 in the NBD1, ΔF508 
(http://www.genet.sickkids.on.ca/cftr/).  This mutation gives rise to a protein that is 
incapable of maturing properly and is tagged in the endoplasmic reticulum for 
degradation.   Mutations of the CFTR gene can be divided in 5 classes depending on the 
effects they have on CFTR protein expression and function (Table 1).   The genotype of 
the mutation is in some cases linked to a specific phenotype which reflects the severity 
of the disease.  Some mutations have no or limited effect on CFTR function while others 
are known to cause a severe form of CF disease. [3, 4]  
 
Table 1: Classification of CFTR genotype mutations and the associated CFTR defect. 
Mutation classification CFTR defect 
Class I Absence of CFTR protein because of instable mRNA 
Class II Translation of an abnormal protein that fails to mature properly   
-> little plasma membrane expression of CFTR e.g. ΔF508 
Class III Impaired activation and/or regulation of CFTR at the plasma membrane 
Class IV Reduced chloride transport 
Class V Reduced levels of normal CFTR protein 
 
I.2 Diagnosis 
 
The majority of CF patients has been diagnosed through family history and phenotypic 
features consistent with the disease, including chronic sinopulmonary disease, 
gastrointestinal and nutritional abnormalities, salt loss syndromes and genital 
abnormalities in males.  Today, many organizations, both in Europe and in the United 
States, support the implementation of newborn screening for CF [5, 6] as early diagnosis 
is associated with many benefits.  Early therapeutic intervention can lead to reduced 
disease severity resulting in a decreased burden of care throughout the patient his life 
and reduced medical costs [7].   From the age of five days, newborns can be screened for 
elevated levels of immunoreactive trypsinogen (IRT) in their blood which is indicative 
for CF and is caused by pancreatic dysfunction.  A positive screening has to be confirmed 
by a second IRT test at the age of two weeks or by DNA screening for known CFTR gene 
mutations.  Both strategies have been reported to identify newborns at risk for CF with 
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approximately 90% to 95% sensitivity [6].  A positive screening result means the child is 
at increased risk for developing CF.  The result is communicated to the parents and 
primary care provider and is followed by a sweat test with pilocarpine iontophoresis to 
confirm the diagnosis [5].  
 
I.3 Clinical manifestation 
 
CFTR is expressed on the apical surface of specialized epithelial cells in sweatglands, 
pancreas, gastrointestinal- and reproductive tract, submucosal glands and in the airway 
epithelial cells [8].   Therefore, a malfunctioning chloride channel or other ion transport 
defect which is caused by a mutated CFTR gene leads to complications in all these 
organs, but especially involves the lungs and pancreas. 
I.3.1 Sweat gland 
 
In the sweat gland CFTR channels reabsorb chloride ions out of the sweat.  In CF 
patients, CFTR dysfunction leads to abnormalities in sodium chloride homeostasis 
because of the reduced Cl- reabsorption [9].   This results in a high level of Cl- in the 
sweat emerging on the skin.  The main diagnostic test for CF, the pilocarpine 
iontophoresis sweat test, is based on this clinical manifestation.  In general, the sweat Cl- 
concentration of a healthy individual is below 40 mmol/L.  In CF patiensts Cl- 
concentrations are usually ≥ 60 mmol/L and can be as high as 120 mmol/L [9].  
I.3.2 Intestinal disease 
 
Increased viscosity of intestinal fluids and a delayed intestinal transit time can lead to 
meconium ileus (MI) when a baby with CF is born.  MI is unique to CF and is 
characterized by  a complete obstruction of the intestine of the neonate.  It occurs in 13 
to 17% of all CF newborns and is associated with the CF genotype [10].  Homozygosity 
for the ΔF508 mutation is correlated with the occurrence of  MI [11].   
Later on, in childhood, episodes of distal intestinal obstruction (DIOS) and constipation 
can develop.  Incidence of DIOS in childhood is relatively low (7-8%) but increases as 
patients become older.  In contrast, constipation is very common in both young  and 
older CF patients [10]. 
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I.3.3 Liver disease 
 
Hepatobiliary complications are the third leading cause of death in CF patients, 
accounting for 2.5% mortality [12].  CFTR is expressed on the apical surface of 
cholangiocytes (epithelial cells of the bile duct) where it controls the viscosity and 
alkalinity of the bile fluid [13].  In CF patients an increased viscosity of the bile fluid 
results in an obstruction of the intrahepatic bile ducts.  An inflammation reaction is 
initiated by elevated levels of toxic compounds in these obstructed ducts,  Kupffer cells 
become activated and produce collagen which leads to focal fibrosis, the first stage of  
CF-associated liver disease [14].  The liver fibrosis causes an increased pressure in the 
venae portae which can lead to splenomegaly and oesophagusvarices.  This stage of liver 
disease, where the overall liver function remains relatively unaffected, is still reversible 
but without treatment it can slowly evolve in irreversible  liver cirrhosis eventually 
leading to liver failure [13, 15].   
I.3.4 Reproductive tract disease 
 
Men with CF are almost always infertile (over 98%) [16].  The human epididymis and 
vas deferens are extremely vulnerable to the destructive effects of mutations in the 
CFTR gene.  Mucus plugging in the vas deferens during in utero development leads to 
fibrosis and atrophy of the vas deferens resulting in congenital bilateral absence.  
Although spermatogenesis proceeds normally, absence of the vas deferens causes an 
obstructive azoospermia [17]. 
In women infertility is less common, up to 50% of CF women is able to become pregnant 
[18].  Women usually have a normal anatomy but thick and tenacious cervical mucus 
contributes to the reduced fertility by acting as a penetration barrier to sperm [17]. 
I.3.5 Pancreatic disease 
 
CF is the primary cause of pancreatic exocrine dysfunction in childhood [19].  The 
pancreas secretes digestive enzymes into the duodenum together with bicarbonate 
(HCO3-)- rich fluid to neutralize gastric acid.  When gastric acids enter the duodenum, 
the release of secretin into the blood circulation is triggered.  Secretin binds to its 
receptor on pancreatic duct cells and stimulates the secretion of Cl- by CFTR through 
cAMP production.  Increased Cl- secretion is associated with increased Na+ secretion 
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followed by the movement of water into the lumen.  Active CFTR also positively 
regulates a Cl-/HCO3- exchange channel resulting in increased HCO3- levels in the 
duodenum [20].  (Figure 2)   
 
 
Figure 2: Regulation of pancreatic chloride and bicarbonate secretion. [20] 
 
Reduced Cl- secretion in CF patients leads to a reduced HCO3- secretion by the epithelial 
cells lining the ducts and a reduced water secretion.  The resultant thick pancreatic 
secretions progressively  block the flow of digestive juices from the enzyme-secreting 
cells (acini), leading to impaired digestion of fat, protein and starch.  This causes 
steatorrhoea, fat-soluble-vitamin deficiencies and malnutrition.  A progressive 
accumulation of digestive juices in the pancreatic duct will cause gradual degradation of 
the enzyme-producing cells and subsequent pancreatic fibrosis [19].  Once a certain 
degree of islet cells is no longer functional the patient will develop CF-related diabetes 
mellitus because of insulin insufficiency and carbohydrate intolerance. [19, 21]  
There is a clear correlation between genotype and pancreatic exocrine function.  
Exocrine pancreatic insufficiency has been attributed to the presence of a severe 
mutation in both CFTR alleles (Class I-III).  Patients who carry a mild mutation usually 
remain pancreatic sufficient [22].   
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I.3.6 Respiratory disease 
 
Respiratory failure is the leading cause of morbidity and mortality in CF patients.  The 
lungs of CF patients appear normal at birth but become rapidly colonized by 
Haemophilus influenzae, Staphylococcus aureus or both.  Within a few years Pseudomonas 
aeruginosa becomes the predominant lung pathogen [23]. 
I.3.6.1 Molecular basis of CF lung disease 
 
There are several hypotheses to explain the molecular basis of this vulnerability of the 
CF lung to chronic lung infections, the “low volume” hypothesis, the “high salt” 
hypothesis, increased adherence to epithelial airway cells and reduced clearance of 
bacteria after binding to CFTR receptors [24].   
The “low volume” hypothesis is based on the assumption that the salt concentration in 
airway surface liquid (ASL) in both CF patients and healthy individuals is the same.  
Active CFTR channels in the lung epithelial cells do not only secrete chloride ions but 
also inhibit the epithelial sodium channel, ENac, which reabsorbs sodium from the ASL 
[24].  Therefore, the malfunctioning of CFTR in CF patients results in an increased 
sodium absorption, through activation of ENac, accompanied with a Cl- absorption 
through alternative pathways (either paracellularly or via other ion channels).  This 
increase in ion reabsorption results in the movement of water from the apical side of the 
epithelial cells to the basolateral side to preserve the isotonic character of the ASL 
(Figure 3).  The resulting decrease in apical surface volume makes the cilia collaps, 
impairing the normal ciliary movement of mucus.  This defect in mucociliary clearing 
would make the lungs of CF patients more susceptible to colonization with bacteria [25, 
26]. 
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Figure 3: Mechanism behind the low volume hypothesis. Ion transport in lung epithelial cells of a (A) 
healthy individual compared to that in a (B) CF patient. [24] 
 
The “high salt” hypothesis postulates that salt concentrations in the ASL of CF patients 
are higher than in ASL of normal patients.   Because of the ability of lung epithelial CFTR 
to pump more Cl- ions into the cell compared to the amount of water, a hypotonic 
environment is created outside the cell of healthy individuals.  In CF patients this Cl- 
reabsorption mechanism is disrupted.  As a result, to preserve electroneutrality, less Na+ 
is absorbed, resulting in an increased ASL salt concentration (Figure 4) [25].  The lack of 
an alternative pathway for Cl- absorption and the fact that CFTR does not inhibit the 
ENaC channel are key features of this hypothesis [24].  Smith et al. showed that a salt-
sensitive antimicrobial peptide, of which the antimicrobial activity is inhibited by an 
increased salt concentration, is present in the ASL.  The increased sensibility of CF 
patients for lung infections could thus be explained by this impaired innate host defense 
mechanism [27]. 
 
 
Figure 4: Mechanism behind the high salt hypothesis.  Ion transport in lung epithelial cells of a (A) healthy 
individual compared to that in a (B) CF patient.  According to this hypothesis there is no inhibition of ENaC 
by CFTR nor an alternative Cl- absorption pathway. 
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Both hypotheses offer no explanation for the limited number of pathogens that colonize 
the CF lung.  Adherence of P. aeruginosa to respiratory epithelial cells is increased in CF 
patients and during regeneration of the respiratory epithelium [28].  The basis for this 
increased adherence could be related to the presence of a asialoganglioside-1 protein 
(asialo GM-1)  that is expressed on the apical surface of respiratory epithelial cells and 
acts as a receptor for various pathogens including P. aeruginosa and S. aureus [28].  It 
has been shown that asialo GM-1 is more abundant on the surface of cells expressing 
mutated CFTR and on regenerating epithelial cells [29].  As inflammation frequently 
occurs in the CF lung, areas of regenerating epithelium are likely to be present, 
promoting P. aeruginosa adherence through the increased asialo GM-1 expression.  
Some researchers have described the lack of binding of clinical P. aeruginosa isolates to 
asialo GM-1 receptors, especially those isolates without pili or flagella including mucoid 
strains refuting the relevance of asialo GM-1 in chronic P. aeruginosa infections [30, 31]. 
Another receptor for P. aeruginosa is CFTR itself.  After binding to CFTR, P. aeruginosa is 
internalized and cleared from the airways through shedding of the epithelial cells [32].  
Reduced CFTR expression or expression of mutated CFTR impairs this clearance 
mechanism and allows P. aeruginosa to persist in the airways.  Moreover, the process of 
P. aeruginosa binding to CFTR induces the activation of NF-κB and the production of 
cytokines and antimicrobial peptides (AMPs) which are important factors in the innate 
immunity towards infections [33].  As CFTR mediated internalization is specific for P. 
aeruginosa this hypothesis is the first to provide a molecular basis for the high-level 
association of P. aeruginosa and CF lung disease. [34] 
I.3.6.2 Microbiology of CF lung disease 
 
The upper respiratory tract of a healthy individual is colonized with a wide variety of 
microorganisms, called commensals, including non-typeable H. influenzae and S. aureus.  
In contrast, the lower airways remain sterile by means of various innate defense 
mechanisms present in the lung.  In CF patients some of these defense mechanisms are 
impaired, making them more susceptible to colonization of the lower respiratory tract.  
Only a limited number of different pathogens cause infections in CF patients and they 
are frequently acquired in an age-dependent manner (Figure 5). 
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Figure 5: Isolation of respiratory germs from CF patients by age (adapted from the 2011 annual data 
report published by the US CF Foundation). 
Staphylococcus aureus 
 
In infancy and early childhood, S. aureus is the most frequently detected in BAL 
(bronchoalveolar lavage) samples [35].  The attention towards S. aureus has grown 
during the last decade because of the increased isolation of methicillin-resistant S. 
aureus (MRSA)  from CF patients.  Approximately 15% of CF patients are colonized with 
MRSA and this is associated with poorer lung functions [36].  Although S. aureus has 
been shown to persist in the CF lung over years, controversy about a prophylactic anti-
staphylococcal therapy remains.  Some studies indicate that a reduction in early S. 
aureus infections is associated with earlier or more frequent P. aeruginosa infections 
[37-39].  Moreover, a prophylactic therapy in the presence of MRSA strains could 
enhance the emergence of further resistance. [36] 
Pseudomonas aeruginosa 
 
The most significant pathogen colonizing the lungs of CF patients is P. aeruginosa.  
Approximately 80% of the CF population gets infected with this pathogen [40].  Most P. 
aeruginosa infections are acquired in the environment [41], outside the hospital, or 
through cross-infection between siblings [42, 43].  In general, the overall risk of patient-
to-patient transmission with P. aeruginosa is considered to be low but interpatient 
transmission in different CF care centers has been well documented [41, 44, 45].  
Adequate hygienic measures in hospitals and CF centers and segregation of CF patients 
according to microbiological status reduces the risk of hospital acquired cross-infections 
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[24].  Reducing the risk of acquisition is considered at least equally important as early 
treatment of an established P. aeruginosa infection.   
The average age for the first P. aeruginosa positive lower airway culture from CF 
children is 23 months [46] and acquisition of this pathogen is associated with clinical 
deterioration [47-49].  Early antibiotic treatment can prevent or delay chronic P. 
aeruginosa infections which are usually preceded by a period of recurrent, intermittent 
colonization with P. aeruginosa [50].  During intermittent P. aeruginosa infection 
transition from a planktonic, non-mucoid phenotype to a sessile, mucoid phenotype 
takes place.  This mucoid phenotype, characterized by alginate production, is better 
adapted to persist in the CF lung and grows as a sessile community, called a biofilm [51].  
Microorganisms growing as a biofilm are protected from dehydration and phagocytosis 
and are highly resistant towards antibiotics, providing a survival benefit in the CF lung 
environment.  The mucoid P. aeruginosa phenotype is not observed outside the host 
environment and is associated with a more rapid decline in lung function [52, 53].  
Burkholderia cepacia complex 
 
The Burkholderia cepacia complex (Bcc) is a group of gram-negative β-proteobacteria 
currently consisting of at least 18 closely related species.  All Bcc species have been 
isolated from CF patients except for Burkholderia ubonensis [54].  Burkholderia 
cenocepacia and Burkholderia multivorans are the most frequently recovered Bcc species 
from CF sputum samples followed by Burkholderia gladioli, not belonging to the Bcc 
(Figure 6).  Incidences of B. cenocepacia and B. multivorans infections change over time 
and differ from place to place [55, 56].  Overall prevalence of Bcc infections in CF 
patients varied between 3-5% during the last decade [40]. 
 
 
Figure 6: Distribution of Burkholderia species among U.S. 
CF patients.  “Indeterminate” refers to strains that 
phylogenetically are members of Bcc but that can not be 
placed into one of the 18 defined species. [57] 
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Although the majority of Bcc infections among CF patients are acquired from distinct 
environmental sources, Burkholderia species have an enhanced capacity for interpatient 
transmission compared to P. aeruginosa.  Since the late 1980s, person-to-person spread 
of Burkholderia species has been documented [58-60] followed by the identification of 
epidemic strains, including the B. cenocepacia ET12 (electrophoretic type 12) strain 
[61].  Nevertheless, stringent infection control policies have been shown to fully 
eliminate the acquisition of epidemic strains. 
The acquisition of Burkholderia generally occurs later in the course of CF airway disease 
and most commonly results in chronic infections [62, 63].   
Other pathogens 
   
H. influenzae which is primarily known as a commensal of the upper respiratory tract is 
isolated from the lungs of approximately 20% of CF children under the age of one year 
[40].   
Other pathogens like Stenotrophomonas maltophilia, Achromobacter xylosoxidans, 
Aspergillus fumigatus, Mycobacteria and some viruses are also capable of infecting the 
CF lung but usually in a later stage of CF disease.  S. maltophilia is most likely acquired 
from environmental sources, in- or outside the hospital [64, 65], and primarily causes 
transient and recurrent infections [66].  As with Bcc, the true incidence of S. maltophilia 
infection in CF patients is difficult to ascertain.  The same is true for A. xylosoxidans, 
which has long been recognized as a CF pathogen.  Most A. xylosoxidans infections are 
nosocomially acquired with outbreaks attributed to contaminated solutions [67, 68].  
Although infections with A. xylosoxidans are frequently transient, chronic infections for 
several years have been described [69, 70]. 
I.4 Pulmonary therapy 
 
Pulmonary therapy in CF patients focuses on three main goals: the clearance of viscous 
mucus out of the airways, the eradication of bacterial infections and the reduction of 
pulmonary inflammation.  Patients with end-stage pulmonary damage are considered 
for lung transplantation. 
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I.4.1 Airway clearance 
 
The clearance of airway secretions is a primary therapy for CF patients as the increasing 
volumes of viscous mucus, that can not  be cleared by the cilia, form the main source of 
pulmonary complications.  The accumulation of mucus is associated with the persistence 
of pathogens trapped in this mucus, resulting in inflammation and destruction of lung 
tissue.  In addition, the thickened mucus obstructs the smaller airways leading to the 
formation of hypoxic regions which induces P. aeruginosa biofilm formation [71].  
I.4.1.1 Mechanical clearance 
 
A variety of airway clearance therapies have been developed as primary therapy for CF 
patients.  Although no method has been proven superior to any other, there can be 
differences in effectiveness between patients.  Chest physiotherapy involves chest 
percussion in different positions to mechanically induce the clearance of secretions from 
all lobes of the lungs.  Many clinicians believe in the long-term benefits of this therapy if 
daily maintained.  Nevertheless, the burden on the patient is not to be underestimated 
and clearly influences patient compliance [72, 73].  To put less burden on the patient the 
“High-frequency chest compression” vest can be used.  This airway clearance device 
applies high-frequency oscillations to the patients chest wall assisting in removing the 
secretions [74].   
Other techniques like “Active cycle of Breathing” and “Autogenic drainage” are breathing 
techniques aiming to increase the expiratory airflow accompanied with the movement 
of airway secretions out of the lungs [75, 76].  A PEP (positive expiratory pressure) 
mask also helps in clearing retained mucus from the airways.  By breathing out through 
the mask, with an appropriate resistor in place, a positive pressure is build up in the 
lungs.  This pressure keeps the airways open en allows air to flow behind mucus plugs 
helping them move upwards [77]. 
I.4.1.2 Mucolytics 
 
Reducing the viscosity of the sputum with mucolytics also allows better airway 
clearance.  Both hypertonic saline and mannitol have been demonstrated to reduce 
mucus viscosity [78].  Inhalation of hypertonic saline or mannitol, can correct the 
underlying defect in CF as it induces the flow of water into the lumen of the airways.  
The rehydration of the periciliary layer restores the function of the cilia allowing 
19 
 
improved clearance [79].  In addition, hypertonic saline may have an effect on airway 
inflammation and bactericidal activity within ASL (Figure 7).  Glucosaminoglycans 
present in the ASL are well-known to bind AMPs and cytokines including interleukin-8 
(IL-8) which is considered a key cytokine in the inflammatory respons.  The interaction 
of IL-8 with glucosaminoglycans can be disrupted by hypertonic saline.  While at first 
sight this seems to increase the chemotaxis of neutrophils by increasing the amount of 
free IL-8, the increased susceptibility of IL-8 to proteolytic degradation reduces the 
overall IL-8 burden [80].  By disrupting the electrostatic interactions between AMPs and 
glucsoaminoglycans the bactericidal effect of ASL can also be improved [81].  Still, the 
long-term effects of chronic hypertonic saline therapy have not been defined. 
 
 
Figure 7: Different effects of hypertonic saline therapy in CF ASL [79]. 
 
Another widely administered treatment for this purpose is the once-daily inhalation of 
recombinant human DNAse (rhDNAse), which was FDA (Food and Drug Administration) 
approved in 1994 under the proprietary name of Pulmozyme [82].   rhDNAse decreases 
the viscosity of CF mucus by cleaving polymeric extracellular DNA (eDNA), mainly 
derived from damaged neutrophils as a result of progressive inflammation.    It is shown 
that rhDNAse improves lung function and decreases the risk of pulmonary 
exacerbations over a relatively short period of time.  A reduction in mortality and/or 
morbidity after long-term Pulmozyme therapy still has to be proven [83, 84]. 
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I.4.2 Anti-inflammatory therapy 
 
Neutrophil-driven inflammatory reactions are characteristic for CF airway disease.  If 
untreated this results in localized dilatation of parts of the bronchial tree, caused by 
destruction of muscle- and elastic lung tissue, and ultimately respiratory failure.  Airway 
inflammation has been observed in young patients, sometimes even without identifiable 
infection [85, 86].  Some investigators believe that malfunctioning of CFTR directly 
dysregulates the host inflammatory response leading to an imbalance between pro-
inflammatory and anti-inflammatory mediators and favouring excessive inflammation 
[87].   
The most promising anti-inflammatory agent at the moment is azithromycin which has 
both an anti-inflammatory and antimicrobial effect [88].  Chronic therapy with 
ibuprofen and/or oral corticosteroids are no first choice treatment for CF lung 
inflammation because of their adverse effects.  In some cases, high dose administration 
of ibuprofen is associated with serious gastric bleedings [89] while chronic oral 
prednisone significantly reduces growth [90].  
I.4.3 Antibiotic therapy 
 
Effective antibiotic therapy to treat CF lung disease has undoubtedly contributed to the 
increasing live expectancy of CF patients and is directed at preventing, eradicating and 
controlling bacterial lung infections.   
I.4.3.1 Early antibiotic treatment 
 
Early antibiotic treatment following the first isolation of bacteria from the lower 
respiratory tract can delay the onset of a chronic colonization associated with 
progressive lung damage [91].  Different studies described a total eradication of P. 
aeruginosa following early antibiotic therapy [92, 93].  Prophylactic therapy in infants in 
order to prevent acquisition of CF pathogens, like S. aureus, is under debate as several 
studies question the benefit of such a therapeutic approach [36]. 
I.4.3.2 Maintenance therapy 
 
Once chronic colonization with P. aeruginosa takes place, maintenance therapy is 
needed in order to delay progressive lung damage and reduce the frequency of 
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pulmonary exacerbations.  Chronic P. aeruginosa infections are generally treated with 
inhaled colistin or tobramycin as first choice maintenance therapy [91, 94, 95].  
Ciprofloxacin has a bactericidal activity against many CF pathogens and is orally active.  
Nevertheless, the emergence of resistance in S. aureus and P. aeruginosa prevented its 
use as first choice therapy [96, 97] and limited its use to treatment of P. aeruginosa 
exacerbations [98].   
Aztreonam lysine solution for inhalation has recently become an alternative for 
managing chronic P. aeruginosa infections as it results in greater reduction in the 
number of exacerbations and better pulmonary function compared to tobramycin 
nebulizer solution when administered over a short period of time [99].  Another new 
treatment option for CF pulmonary infections, once daily inhalation of levofloxacin, is 
currently undergoing phase III trials and looks promising for treating P. aeruginosa 
infections [100].   
Although macrolides, like erythromycin and azithromycin, have little activity against 
planktonic P. aeruginosa cells they are effectively used in the treatment of pulmonary P. 
aeruginosa infections in CF patients.  Sub-inhibitory concentrations of macrolides are 
shown to inhibit alginate production, an important exopolysaccharide in the transition 
of non-mucoid to mucoid P. aeruginosa strains [103].  Macrolides can thus prevent or 
delay the transformation of early P. aeruginosa strains into a sessile, more resistant 
phenotype which is better adapted to persist in the CF lung.  It is even suggested that 
apart from the antibiotic effect, macrolides exert an additional anti-inflammatory effect 
which often leads to an overall improvement of the clinical status of the patient.  Just like 
for ciprofloxacin, the administration of macrolides is not recommended for children 
younger than 6 years and long term impact of the treatment is yet to be investigated 
[104]. 
A culture-driven approach in which the antibiotic therapy is stopped once sputum 
cultures reappear sterile, is proven as effective as routine cycles of antibiotic therapy 
every 3 months regardless of culture results [101], but because of the reduced time of 
antibiotic treatment, a culture-driven approach is preferred.  In the case of young 
children, who are often unable to expectorate sputum, treatment decisions are 
commonly based on oropharyngeal cultures which are poorly reflective of lower airway 
colonization and thus not a good base for culture-driven therapy [102].  
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I.4.3.3 Exacerbation therapy 
 
Once patients are chronically infected with CF pathogens they experience episodes of 
pulmonary exacerbations.  Repeated exacerbations have to be avoided because of their 
negative effect on pulmonary function and life expectancy of the patient.  Therapy for 
these exacerbations include intravenous administration of antibiotics based on recent 
cultures of airway secretions.  A combination therapy of a β-lactam and an 
aminoglycoside is often recommended for exacerbations caused by P. aeruginosa or B. 
cenocepacia because of the provided synergy and the slow emergence of resistance 
[103].  Therapy is initiated in the hospital to allow immediate follow up of the patients 
clinical status and to monitor drug concentrations if necessary, especially for 
aminoglycosides [98]. 
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Chapter II: BIOFILMS 
 
II.1 Introduction 
 
In 1933 Henrici described the adherence of aquatic bacteria to a glass surface [104].  
These bacteria presented on the glass in the form of microcolonies that increased in size, 
indicating that these bacteria were actually growing.  Henrici came to the conclusion 
that most water bacteria are not free-swimming organisms but rather sessile organisms 
that grow on submerged surfaces.  Zobell continued in 1935 his research on fouling 
based on the findings of Henrici.  He also observed the adherence of water bacteria to 
submerged surfaces and indicated them as “primary film formers” that favor the 
attachment of subsequent fouling organisms by providing them with nutrients [105].   
These findings together with the work of Bill Costerton (published in 1978) gave rise to 
the realization that sessile communities, referred to as biofilms, dominate in different 
microbial ecosystems [106].  Biofilm formation even lies at the basis of many, if not all, 
persistent human infections.  Antibiotic therapy towards biofilms often fails and 
eradication by the host defense mechanism rarely takes place [107].  Many 
investigations led to our current definition of a biofilms as a highly structured microbial 
community enclosed in a self-produced matrix.  However, biofilm cells differ from their 
planktonic counterparts not only in a conformational point of view as also gene 
expression in sessile cells differs profoundly from that in planktonic cells [108].  
 
II.2 Biofilm formation 
 
The application of confocal laser scanning microscopy (CLSM) for studying the 
development of a biofilm dates from 1991.  CLSM images show a sessile community of 
bacterial cells enclosed in a matrix penetrated with open water channels.  Through these 
channels, biofilm cells have access to nutrients, including oxygen [109]. 
The structural development of a biofilm is often described as a five-stage process 
(Figure 8). 
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Figure 8: Five stages of biofilm development.  Each stage in the developmental process is associated with a 
microscopic picture of a developing P. aeruginosa biofilm.  All photomicrographs are shown at the same 
scale (Modified from [110]). 
 
The first step in biofilm formation is the reversible attachment of cells to the surface.  
Attached bacterial cells can redistribute through surface motility, called twitching.  Type 
IV pili, which extend and contract, are responsible for this kind of movement.  Through 
twitching motility, attached cells move towards each other, aggregate and form 
microcolonies [111].  Binary division of attached cells also contributes to this 
microcolony formation.  The second step in biofilm development is the production of 
extracellular polymeric substances (EPS) providing irreversible attachment of bacteria 
to the surface [112].  This self-produced matrix also provides structural support during 
further development of the biofilm architecture (step 3 and 4).  The matrix is composed 
of polysaccharides, proteins and nucleic acids and is essential for acquiring structural 
complexity in a biofilm.  Less EPS production is associated with a flat, undifferentiated 
biofilm while EPS overproduction stimulates the formation of mushroom- and tower-
shaped cell clusters [113, 114].  The viscoelastic character of the biofilm is also 
determined by EPS.  Through cross-linking of negatively charged polymers in the 
extracellular matrix, with the aid of multivalent cations, biofilms possess a certain 
degree of cohesive strength [115].  The strong well-organized unit makes it possible for 
the biofilm to persist in detrimental environmental conditions.  The last stage in biofilm 
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development is the dispersion of single cells.  These cells can colonize new surfaces 
starting the development of a new biofilm community.  
II.3 Resistance of biofilms 
 
Standard antimicrobial therapies often fail to eradicate a biofilm infection.  Both biofilm 
structure and the phenotype of microorganisms living in the biofilm are responsible for 
this resistance to killing by cidal antimicrobial agents as well as by the innate human 
defense system.  Cells living in a biofilm can be 10 to 1000 times more resistant to 
antimicrobial killing [116, 117].  Several resistance mechanisms have been suggested to 
explain these great differences in susceptibility of planktonic cells and biofilm associated 
cells [118]. 
II.3.1 Restricted penetration of the antimicrobial agent 
 
It has been suggested that the biofilm matrix has the capacity to prevent the access of 
antimicrobial agents to the biofilm cells.  Although not all equally important, different 
factors are involved in this penetration barrier, including sorption, electrostatic 
interactions and enzymatic reactions [119]. 
II.3.1.1 Diffusion barrier 
 
For a solute that does not react with biofilm matrix components the theoretically 
calculated diffusion barrier can not account for the observed resistance of biofilms 
towards antibiotics [119].  However, many matrix polymers are charged, allowing 
electrostatic interactions with oppositely charged antimicrobials.  These electrostatic 
interactions (or even sorption to matrix components) can delay the penetration of 
antimicrobials into the biofilm [120, 121].  In most cases, the penetration of small 
antibiotic molecules is not entirely blocked, leading to a postponed antibiotic effect 
rather than a lack of effect which does not explain the increased resistance of biofilms.  If 
electrostatic interactions are the primary cause of the delayed antibiotic penetration, 
chronic administration during patient therapy should rapidly lead to saturation of these 
binding sites resulting in increased diffusion rates in vivo.  Still, biofilm infections located 
in poorly accessible regions will be continuously exposed to lower antibiotic 
concentrations.  In these regions a delayed penetration of the antimicrobial agent 
through the biofilm may play a role in biofilm tolerance [122].   
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II.3.1.2 Enzymatic reactions 
 
When biofilm cells produce antibiotic modifying enzymes like β-lactamases, these 
enzymes will be present in the biofilm matrix degrading the antimicrobial agent while it 
penetrates into the biofilm.  The combination of restricted penetration and degradation 
has been shown to contribute to the resistance of β-lactamase producing biofilms [123].  
β-lactamases can appear in the biofilm matrix either through membrane vesicles 
containing the enzyme or through lysis of bacteria after exposure to antibiotics.  For 
imipenem and piperacillin it has been shown that they induce the production of β-
lactamase in P. aeruginosa biofilms, leading to their own degradation [124].  Similarly, 
the production of catalase in a P. aeruginosa biofilm protects the cells from being killed 
by hydrogen peroxide [125]. 
II.3.2 Altered growth rate/metabolic activity of biofilm cells 
 
Because of the limited nutrient supply in a biofilm environment, biofilm cells grow 
slower and present with lower metabolic activity than their planktonic counterparts.  
Soren Molin’s research group indicated that microorganisms located in the center of 
biofilm clusters are often even in a dormant phase, are characterized by a decreased 
sensitivity to antimicrobials and can provide a nucleus for regrowth after antibiotic 
treatment (Figure 9) [126]. 
 
 
Figure 9: Metabolic activity in a biofilm microcolony.  Biofilm cells residing near the surface present with 
greater metabolic activity than cells residing in the center of a microcolony. [110] 
 
Many antibiotics are more effective in killing growing cells and some, like penicillin and 
ampicillin, even totally lack killing activity against non-dividing cells [127].  It is 
important to notice that bacterial cells growing in different regions of the biofilm will 
experience different environmental stresses.  Cells at the bulk water interface will grow 
faster and have a higher metabolic activity compared to cells located deeper in biofilm 
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clusters.  Therefore, the activity of many antimicrobials will be greater at the surface of 
microcolonies than in the center [128].  In sputum of chronically infected CF patients a 
stationary phase-subpopulation of P. aeruginosa cells seems to be present [129].  This 
explains why monotherapy with antibiotics that are only active against dividing cells is 
not efficient in eradicating these infections.  In contrast, colistin is primarily active 
against non-dividing biofilm cells.  Metabolically active cells confer resistance to colistin 
through the addition of aminoarabinose to the lipid A moiety of lipopolysaccharide 
(LPS) molecules, resulting in decreased uptake of the antibiotic in the cell [130, 131].  In 
addition, upregulation of efflux pumps in metabolically active cells also contributes to 
this tolerance to colistin [131].  
In general, an overall slow down of metabolic activity can protect bacterial cells from 
environmental stresses.  This can be regulated by the expression of RpoS, a sigma factor 
known as a general regulator of stress responses [132].  By regulating the transcription 
of other proteins, RpoS protects cells from environmental challenges  and prepares them 
for subsequent stresses.  RpoS is transcribed in late-exponential growth phase in 
planktonic cultures [133] as well as in environments with high cell density [134], like 
biofilms, where it contributes to the increased resistance towards antimicrobial killing.  
II.3.3 Increased frequency of mutation 
 
Biofilm-growing bacteria have an increased mutation frequency compared to isogenic 
planktonic bacteria.  Downregulation of antioxidant enzymes in P. aeruginosa biofilms 
increases the prevalence of DNA damage, enhancing the frequency of mutagenic events 
[135]. Single mutations in specific genes can lead to e.g. altered antimicrobial targets, 
reduced antimicrobial uptake and increased expression of efflux pumps.  Because of 
their close proximity, biofilm cells are also amenable to horizontal gene transfer by 
which they can acquire genes, encoding antibiotic modifying enzymes or efflux pumps, 
from other isolates [136, 137]. 
Because of the great incidence of mutation within a biofilm population some 
investigators suggest the presence of hypermutable strains in biofilms.  In CF patients 
the isolation of hypermutable P. aeruginosa strains, associated with increased antibiotic 
resistance,  has been described [138].  The increased mutation rate of these isolates is 
often due to alterations in genes of the DNA repair system.  The increased amount of 
oxidative stress present in a biofilm also influences the formation of hypermutable 
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strains.  During antibiotic therapy resistant mutants will have better chances of survival 
and will be selected for, making the problem of persistent infections even bigger. 
II.3.4 Quorum sensing 
 
Bacteria use signaling molecules to communicate with each other, a process referred to 
as quorum sensing (QS) [139].  The accumulation of these signaling molecules enables 
the bacteria to estimate the number of other bacteria in their environment.  When the 
signaling molecules reach a threshold concentration, bacteria can respond by inducing 
transcription of specific genes.  By this means bacteria can respond quickly to 
environmental threats as a group rather than as autonomous individuals.  The QS 
molecules described for gram-positive bacteria are usually small peptides while gram-
negative bacteria communicate primarily through members of the class of N-acyl-L-
homoserine lactones [140].  It has been described that QS is responsible for the 
tolerance to tobramycin and the innate inflammatory respons by polymorphonuclear 
leucocytes in P. aeruginosa biofilm cells [140, 141]. 
II.3.5 Biofilm phenotype 
 
The “biofilm phenotype”, described by Costerton, is characterized by a unique gene 
expression pattern following attachment to a surface [142].  These gene expression 
patterns are not observed in their planktonic counterparts what makes biofilm cells 
morphologically and biochemically distinct from free-living cells.  It is likely that 
activation of certain genes during biofilm formation contributes to biofilm resistance.  
Several biofilm resistance mechanisms are under the same regulatory control indicating 
that multiple resistance mechanisms might be operating at the same time within the 
biofilm population [107]. 
II.3.6 Persister cells 
 
The majority of cells in a biofilm is often rapidly killed by bactericidal antibiotics that are 
active against slow growing cells.  A small fraction, referred to as persisters, is able to 
survive the presence of such a bactericidal antibiotic [143].  The same observation has 
been made in planktonic cultures (Figure 10A), although biofilms typically have a larger 
fraction of persisters.  The surviving fraction of a planktonic culture can normally be 
cleared by a healthy immune system in contrast to the persistant fraction in a biofilm 
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which is protected by the polymeric matrix [144].  The immune system fails to clear 
these biofilm persisters therefore providing a niche for regrowth once antibiotic 
pressure is elevated.  After regrowth of these persisters, a biofilm population 
indistinguishable from the original biofilm is created (Figure 10B) [145].  This indicates 
that persisters are not mutants.  Until now the nature of persistence is unknown.  It is 
possible that the growth rate of persisters affects their resistance.  
 
 
Figure 10: A) Biphasic killing pattern in response to antibiotics B) Biofim model of persister survival.  Red 
circles represent cells susceptible to antibiotic killing; blue circles respresent cells resistant to antibiotic 
killing (persister cells).  Once antibiotic concentration drops, persister cells regrow and form a new 
biofilm population consisting of normal and persister cells. This clearly indicates that persister cells are 
no mutants as they do not pass their phenotypic characteristics to their progeny. [145, 146] 
 
II.4 Biofilm formation in the CF lung 
 
The number of infectious diseases associated with biofilms is large.  Especially oral 
infections, chronic infections and colonization of medical devices are often related with 
biofilm formation.  The difficulty of eradicating these biofilm infections is of major 
concern [107].   
Biofilm infections can be confirmed by direct examination of infected tissue, often by 
CLSM and scanning electron microscopy (SEM).  If biofilms are present, microscopic 
images show microorganisms living in clusters, surrounded by an extracellular matrix.  
Such biofilm-like structures have been detected in different samples related to chronic 
infections, including the sputum and autopsy specimens of CF lungs chronically infected 
with P. aeruginosa (Figure 11) [147].  The presence of P. aeruginosa biofilms is thought 
to be associated with the onset of chronic infections.  Isolates colonizing the CF lung can 
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convert to a phenotype with better adherence properties and an increased production of 
extracellular matrix material which coincides with permanent infection [148, 149].  
Another sign that indicates biofilm phenotype is the absence of flagella, pili and motility 
in many CF P. aeruginosa isolates from chronically infected patients [150].  It has been 
described that when cells adhere to a surface and form a biofilm they adapt to their 
environment by decreasing the expression of their motility machinery making them 
more persistent and less invasive.  
 
 
Figure 11: SEM images of P. aeruginosa PAO1 in artificial sputum medium (left image) and sputum 
extracts (right image).  In both conditions bacterial cells are encapsulated by polymeric substances 
indicating biofilm formation in the CF lung environment. [147] 
 
One of the problems with the formation of a biofilm during infections is that they 
provide a niche for the persistence of bacteria at the place of infection.  Through the 
detachment of cells or cell aggregates from the biofilm, microbial cells can distribute and 
colonize new uninfected surfaces.  In addition, through the encapsulation in an 
extracellular polymeric matrix, the opsonisation of bacteria mediating phagocytosis and 
elimination of cells is impeded [151]. 
 
II.5 Intervention strategies related to CF biofilm infections 
 
All components involved in biofilm formation can be considered as possible targets for 
biofilm therapy.  Components like pili that are important in the initial steps of biofilm 
formation are possible targets for prophylactic therapy while exopolysaccharides that 
are required for the maintenance of biofilm structure can be promising targets for 
biofilm eradication.   
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II.5.1 Inhibition of microbial attachment 
 
The protein lactoferrin is a component of the innate human defense system.  
Independent from its antimicrobial activity it also prevents P. aeruginosa biofilm 
formation, probably through the chelation of ferric iron [152].  Moreover, a destructive 
effect on mature P. aeruginosa biofilms is noted.   
Superti and colleagues described the binding of lactoferrin to B. cenocepacia cable pili, 
thereby inhibiting bacterial attachment to mucin and epithelial cells [153].  These 
results provide evidence for a role of this natural protein in preventing P. aeruginosa 
and B. cenocepacia biofilm infections.  
II.5.2 Matrix degradation 
 
The biofilm matrix which is sometimes referred to as “the house of biofilm cells”, is 
essential for biofilm stability [154].  The biofilm matrix is for over 90% comprised of 
water next to EPS like lipids, polysaccharides, proteins and nucleic acids.  The exact 
composition can vary greatly among biofilms.  Even different compositions between 
strains of a single species have been described [155]. 
Degradation of the biofilm matrix as a remedy against biofilm infections is increasingly 
being investigated.  Matrix degrading components can either be used as monotherapy to 
prevent biofilm formation or in combination with antibiotics to improve their 
penetration into the biofilm.   
II.5.2.1 Exopolysaccharides 
 
In many bacteria exopolysaccharides are essential for biofilm formation and/or biofilm 
maintenance.  Exopolysaccharides serve a wide range of functions involving structural 
stability, adherence and protection against environmental predators.   
Alginate, Psl and Pel 
 
Alginate which is abundantly present in the biofilm matrix of mucoid P. aeruginosa 
strains is one of the best studied exopolysaccharides.  It is a high molecular mass linear 
copolymer, consisting of homopolymeric blocks of 1→4 linked β-D-mannuronate and 
heteropolymeric sequences with random distribution of β-D-mannuronate and α-L-
guluronate residues (Figure 12A).  P. aeruginosa alginate molecules are partially 
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acetylated at the O-2 and/or the O-3 positions on the mannuronate residues which is 
important for cell-cell and cell-surface interactions [156].  Although alginate is not 
essential for biofilm formation, it contributes to the development of a complex biofilm 
architecture.  Because of its polyanionic character, alginate can interact with positively 
charged antibiotics, like aminoglycosides, thereby reducing the antibiotic effect and 
protecting the biofilm community [157].   
Non-mucoid P. aeruginosa biofilms contain little if any alginate.  By contrast, two 
carbohydrate-rich polymers, Pel and Psl, are the primary matrix polysaccharides.  Psl 
which is anchored to the cell surface, plays an important role in surface attachment and 
cell aggregation by providing cell-cell and cell-surface interactions [158].  A recent study 
indicated that this polysaccharide also plays a crucial role in mucoid biofilm 
development [159].  In addition, Psl is able to protect P. aeruginosa from neutrophilic 
phagocytosis by inhibiting efficient opsonization, providing a survival advantage for 
non-mucoid P. aeruginosa strains in vivo [160]. 
A second important polysaccharide in a non-mucoid biofilm matrix is Pel which plays a 
key role in maintaining cell-cell interactions in a developing biofilm.  Apart from its 
structural importance it also protects against aminoglycosides, probably through 
sequestering or binding of the antibiotics [161].   
poly-β-1,6-N-acetylglucosamine 
 
Poly-β-1,6-N-acetylglucosamine (PNAG) is a positively charged linear homoglycan 
composed of β-1,6-N-acetylglucosamine residues with approximately 20% deacetylated 
residues (Figure 12B).  It has primarily been described as a major component and 
virulence factor in staphylococcal biofilms where it is referred to as “polysaccharide 
intercellular adhesin” (PIA) [162].  Its production in other bacteria like Escherichia coli 
[163], Actinobacillus pleuropneumoniae [164], Acinetobacter baumannii [165], 
Aggregatibacter actinomycetemcomitans [166], Bordetella spp. [167], Yersinia pestis 
[168] and some Bcc species [169] has also been confirmed.  PNAG is attached to the 
bacterial cell surface and provides protection against specific and non-specific human 
defense mechanisms [162].  Degradation of PNAG by Dispersin B inhibits biofilm 
formation and disperses established biofilms [169, 170].  This anti-biofilm effect has 
been confirmed in some Burkholderia species although PNAG is only a minor component 
of these biofilms [169]. 
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Cepacian 
 
The mucoid phenotype in B. cepacia complex strains is characterized by the production 
of an exopolysaccharide, named cepacian (Figure 12C).  Synthesis of cepacian occurs in 
approximately 80 to 90% of Bcc strains isolated from CF patients where it contributes to 
both colonization and biofilm persistence [171].  Cepacian is not essential for biofilm 
formation but it contributes to the formation of thick and mature biofilms.  In 2006, 
Cescutti et. al. reported for the first time the isolation of a lyase for cepacian, produced 
by a bacterium of the genus Bacillus [172].  Another study described the degradation of 
cepacian after short exposure to NaClO implicating its role as a scavenger of reactive 
oxygen species (ROS) produced by the innate immune system [173].  
 
 
Figure 12: A) heteropolymeric region of alginate with α-L-guluronate (G) and  β-D-mannuronate residues 
(M) B) repeating unit of PNAG  C) primary structure of cepacian repeating unit. 
(http://www.intechopen.com)[172] 
36 
 
II.5.2.2 Extracellular DNA 
 
eDNA has been detected in many different biofilms from various origins and species 
composition.  It is believed to be present in every biofilm as a residual material from 
lysed cells.  Some studies however indicate differences between genomic DNA and eDNA 
indicating that an additional active secretion system should be involved [174, 175].   
Whitchurch et al. were the first who reported on the functional relevance of eDNA in 
biofilms [176].  They indicated that eDNA is essential for P. aeruginosa biofilm formation 
and that young biofilms are amenable to dispersion by DNAse treatment, suggesting that 
this could be useful to prevent biofilm-related infections.  Apart from the structural 
function of eDNA,  Mulcahy et. al described a mechanism by which small amounts of 
eDNA contribute to antibiotic resistance [177].  Through the chelation of divalent 
cations that are essential for stabilizing the outer membrane, large amounts of eDNA can 
exert an antibiotic effect in P. aeruginosa.  In contrast, when eDNA is present in the 
biofilm matrix at sub-inhibitory concentrations it induces antibiotic resistance.  Through 
the creation of a cation-limited environment the PhoPQ and PmrAB two-component 
regulatory systems are activated, inducing the expression of a “cationic antimicrobial 
peptide” (CAP)  resistance operon.  This increased expression of the CAP operon 
initiates the activation of an LPS modification pathway resulting in the addition of 4-
amino arabinose molecules to the lipid A moiety of LPS.  Through the addition of 4-
amino arabinose molecules, the overall negative charge of lipid A decreases, hampering 
the initial binding and subsequent intracellular uptake of AMPs, aminoglycosides and 
polymyxin in gram-negative bacteria.  The abundance of eDNA in the sputum of CF 
patients could also in part contribute to the resistance of P. aeruginosa biofilms to 
positively charged antimicrobials. 
The group of Bakaletz indicated that free- or eDNA is often stabilized by the presence of 
an “integrating host factor” (IHF) [178].  IHF is a DNA binding protein that contributes to 
the structural lattice formation of free DNA and is located at those points where DNA 
strands are bending to form this grid-like structure.  They showed that the presence of 
such IHF molecules protect free DNA from being degraded by DNAse.  Therefore, a 
combination therapy of DNAse and anti-IHF serum could considerably improve 
therapeutic outcomes in decreasing mucus viscosity and eradicating biofilm infections 
in CF patients [179].  
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II.5.3 Other anti-biofilm strategies 
 
Conventional antimicrobial therapy is usually ineffective in eradicating biofilm-
associated infections.  There is an urgent need for the development of new antibiotics, 
new delivery systems or effective combination therapies that will benefit patients 
suffering from persistent biofilm infections. 
II.5.3.1 Antimicrobial peptides 
 
Over the last years natural AMPs, like colistin, have gained a lot of interest as promising 
agents to treat biofilm infections [180].  Their bactericidal effect relies on their 
capability of permeabilizing the outer membrane and/or forming pores in the 
cytoplasmic membrane.  The relatively low stability  and a certain degree of non-specific 
toxicity of AMPs have led to an increasing effort in the development of new AMPs and 
peptidomimetics [181-183].  In general, AMPs have a broad antimicrobial spectrum, 
there is a low incidence of resistance development and they remain active against slow 
or even non-growing cells.  As a large part of biofilm cells present with low metabolic 
activity, AMPs could be a promising approach for eradicating biofilm-related infections, 
either alone or in combination with antimicrobials active against fast-growing cells. 
II.5.3.2 Fosmidomycin and fosmidomycin derivatives 
 
Biofilm growth is associated with increased levels of mutations often resulting in 
increased resistance and contributing to the survival of biofilms.   This increases the 
need for new treatment strategies even further.  The non-mevalonate pathway is a 
promising new target for antibiotic development [184].  Fosmidomycin and FR900098 
are two well-known inhibitors of Dxr, the key enzyme in this non-mevalonate pathway 
which is essential for isoprenoid synthesis.  Apart from its traditional use against 
Plasmodium falciparum to treat malaria, fosmidomycin is also active against some 
bacteria, including E. coli and P. aeruginosa [185].  The major cause of fosmidomycin 
resistance for treating bacterial infections is poor cell penetration [186].  Therefore, the 
focus of several studies lies on the development of fosmidomycin derivatives that could 
overcome this problem of poor uptake [187]. 
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II.5.3.3 Quorum sensing inhibitors 
 
The contribution of QS to the development of biofilm tolerance towards several 
antimicrobials has been the subject of some debate.  Several researchers noticed an 
increased susceptibility of QS-deficient mutants of P. aeruginosa towards several 
antimicrobials, including tobramycin, hydrogen peroxide, ciprofloxacin and ceftazidime 
[140, 141, 188].  However, the QS-regulated genes involved in these processes still have 
to be identified.  It has also been shown that QS-deficient mutants were less virulent and 
cleared faster compared to the wild type, indicating the involvement of QS in chronic P. 
aeruginosa infections [189, 190].  The contribution of QS during chronic P. aeruginosa 
lung infections was confirmed by the detection of QS signals in sputum of CF patients 
[191, 192]. 
These observations led to the investigation of QS inhibitors as a treatment for various 
biofilm related infections [193, 194]. Wu et. al. indicated that synthetic furanones, which 
interfere with the P. aeruginosa QS system, attenuated the virulence of the pathogen 
resulting in a reduced severity of the lung infection [195].  QS inhibitors to treat 
Burkholderia biofilm infections have also been proposed as it was described that QS is 
presumably involved in Burkholderia biofilm formation [196].  Several QS inhibitors 
have already been shown to reduce biofilm formation of B. cenocepacia and B. 
multivorans [197]. 
II.5.3.4 D-amino acids 
 
In 2010, Kolodkin-Gal et. al. indicated that a mixture of D-amino acids, produced by 
Bacillus subtilis, could disrupt existing biofilms as well as prevent biofilm establishment 
of B. subtilis, P. aeruginosa and S. aureus [198].  Further research indicated that a 
mixture of four different D-amino acids was responsible for this effect.  D-leucine, D-
methionine, D-tryptophan and D-tyrosine were all active in preventing biofilm 
formation at micromolar to millimolar concentrations, with D-tyrosine being the most 
potent.  In B. subtilis and S. aureus these amino acids replace D-alanine in the 
peptidoglycan side chain where they dislodge anchored amyloid fibers [198, 199].  In 
general these amyloid fibers connect cells present in a biofilm, explaining the dispersal 
effect of these D-amino acids.  Bacteria produce D-amino acids in stationary phase 
planktonic cultures and mature biofilms, probably regulating biofilm disassembly when 
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nutrients become limiting.  This implies that these amino-acids could complement 
existing therapies for treatment or prevention of biofilm-associated infections. 
II.5.3.5 Nitric oxide 
 
The mucus layer lining CF airways represents an area with reduced oxygen 
concentrations, stimulating robust P. aeruginosa biofilm formation [200].  As chronic 
lung disease progresses, mucoid P. aeruginosa strains become the predominant 
phenotype in the CF lung through the overproduction of alginate.  P. aeruginosa 
continues respiring under anaerobic conditions, using nitrate (NO3-) or nitrite (NO2-) as 
terminal electron acceptors.  Both NO3- and NO2- have been shown to be present at high 
concentrations in CF ASL and sputum [201].  Nitrate reductase and nitrite reductase are 
used to reduce NO3- to NO2- and NO2- to nitric oxide (NO), respectively (Figure 13).  
Increased levels of NO have to be controlled through the production of NO reductase 
(NOR) as overproduction of toxic NO would cause cell death [202].  As mucoid strains 
present with very low NOR activity, increasing NO levels could be a possible novel 
approach for treating mucoid P. aeruginosa biofilms.  The increase of NO concentrations 
through the addition of acidified nitrite (HNO2) derivatives under CF conditions,  
resulted in a bactericidal effect on mucoid P. aeruginosa strains [203]. 
 
Figure 13: Anaerobic respiration in P. aeruginosa.  NOR activity in mucoid strains is very low, resulting in 
toxic NO concentrations when NO2- levels increase. (Modified from http://www.spring8.or.jp) 
 
Moreover, general responses to low non-toxic levels of NO in P. aeruginosa include 
upregulation of genes involved in motility and downregulation of virulence factors and 
adhesins [204].  This implies that low levels of NO can increase the antibiotic sensitivity 
of P. aeruginosa biofilms, suggesting a promising role for NO as adjunctive therapy for 
treating CF chronic lung infections. 
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II.5.3.6 Iron depletion 
 
Moreau-Marquis et. al. have observed that CF airway cells, expressing ∆F508 CFTR, 
release more iron compared to airway cells from a healthy individual [205].  These 
elevated iron concentrations have been shown to enhance P. aeruginosa biofilm 
development in the CF lung.  Reducing the availability of free iron through the addition 
of iron chelators resulted in prevention of P. aeruginosa biofilm formation and/or  
disruption of established biofilms.  This effect was even more pronounced under 
anaerobic conditions, which are frequently encountered in chronically infected CF lungs 
[206].  In addition, clinical isolates seem to respond differently to various iron chelators, 
indicating possible differences in effectiveness and mechanism of working between 
various naturally and synthetic iron chelators.  To date, two FDA approved iron 
chelators, deferoxamine (DFO) and deferasirox (DSX), have been shown to potentiate 
the bactericidal effect of tobramycin on P. aeruginosa biofilm formed on live CF airway 
epithelial cells [207].  Moreover, this combination therapy prevented the formation of P. 
aeruginosa biofilms under these conditions.  Although the mechanism underlying this 
improved bactericidal effect on P. aeruginosa biofilms is not yet fully understood, the 
combination of tobramycin with DFO or DSX looks promising to treat CF P. aeruginosa 
lung infections.  As P. aeruginosa has an uptake mechanism for DFO-Fe, this could 
explain why DFO is less effective compared to DSX in disrupting biofilms.  
A second approach to disrupt the essential iron metabolism in bacteria is the use of the 
transition metal gallium (also FDA approved) as many biologic systems are unable to 
distinguish between iron and gallium [208].  Unlike Fe3+, Ga3+ can not be reduced, which 
is an essential reaction in many iron-dependent bacterial processes [209].  Gallium is 
taken up by P. aeruginosa cells and simultaneously reduces iron uptake.  It has been 
shown to inhibit P. aeruginosa growth, prevent biofilm formation and exert a 
bactericidal effect on established biofilms.  The activity of gallium is based in part on 
repressing an Fe-responsive transcriptional regulator [208].  An additional advantage of 
gallium is its activity against cells located in the center of biofilm clusters which are 
usually the most resistant towards conventional antibiotics.  Banin et. al.  suggested a 
novel approach for delivering gallium to P. aeruginosa cells [210].  They used a metallo-
complex, with DFO as siderophore (DFO-gallium), as P. aeruginosa is believed to have 
two uptake systems for DFO [211].  This metallo-complex can function as a “Trojan 
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horse” improving the uptake of gallium into P. aeruginosa cells and resulting in 
increased bacterial killing.  DFO-gallium has been shown effective in killing P. aeruginosa 
biofilm cells and this effect even became synergistic when DFO-gallium was combined 
with gentamicin. 
II.5.3.7 Improved drug delivery 
 
In 1997 a tobramycin inhalation solution, called TOBI, has been FDA approved and is 
now routinely used in CF patients with a P. aeruginosa lung infection [212].  Through 
inhalation, the tobramycin concentration in the infected CF airways can easily be 
increased compared to IV therapy resulting is less toxic effects of the aminoglycoside.  
When taking TOBI in a 28 days on-off cycle a decreased need for IV anti-pseudomonal 
therapy accompanied with a decreased rate of hospitalization has been demonstrated, 
clearly improving patient comfort.  This could be further improved by a dry powder 
inhalation formulation which is at the moment being investigated for approval by the 
FDA [213, 214].    The dry powder formulation can be administered by the use of a 
handheld manually operated inhaler while TOBI has to be inhaled via a nebulizer and 
compressor.  Not only for the administration of tobramycin but also for other antibiotics 
the use and development of inhalable formulations is investigated [215]. 
Inhalation therapy can be combined with nanoparticle engineering for the development 
of inhalable antibiotic-loaded nanoparticles. Encapsulation of antibiotics in 
nanoparticles prevents the interaction with sputum and biofilm components improving 
antibiotic delivery near the biofilm cells.  Antibiotics can be encapsulated in liposomes, 
micelles or polymers that have to meet certain requirements.  The carrier should be 
smaller than 300 nm to avoid alveolar phagocytosis and should consist of biodegradable 
and biocompatible components (Figure 14).  The release of the antibiotic from its carrier 
can be accomplished by an active process, e.g. an enzymatic reaction, as well as by 
passive diffusion like is the case for Arikace [216].  Arikace is a liposomal encapsulated 
amikacin for inhalation which is currently in clinical phase III trials.  Amikacin has long 
been recognized as an effective treatment for different gram-negative infections, 
including P. aeruginosa infections.  By encapsulation into liposomes the antibiotic can be 
delivered closer to the bacteria improving both efficacy and safety of amikacin 
treatment.  By modification of the liposomes in which an antibiotic is encapsulated these 
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particles can even be targeted towards certain areas in the human body.  Currently a lot 
of research is focusing on such targeted and encapsulated drug design [217, 218].  
 
 
Figure 14: The use of antibiotic-loaded nanoparticles to treat CF biofilm infections.  The perfect carrier 
must be able to penetrate deep into the mucus and biofilm matrix, deliver its encapsulated antibiotic near 
the biofilm cells and evade phagocytosis by the innate  immune system. 
(http://www.ntu.edu.sg/home/kunnong/Research/default.html) 
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Chapter III: BURKHOLDERIA CEPACIA COMPLEX 
 
III.1 General introduction 
 
The Bcc consists of at least 18 closely-related species belonging to the group of β-
proteobacteria [219].  Members of this complex are gram-negative, rod-shaped bacteria 
that are widespread in natural and clinical environments where they exert both 
beneficial and detrimental effects (Figure 15).   
Burkholderia cepacia (formerly referred to as Pseudomonas cepacia) was first identified 
by W. H. Burkholder in 1950 as the causative agent of soft onion rot [220].  Nevertheless, 
several members of the Bcc live as plant commensals in close proximity to the 
rhizosphere protecting them from plant disease by the synthesis of antimicrobial 
metabolites and siderophores.  The production of siderophores is implicated in 
biocontrol through competition for iron, an essential component for bacterial growth.  
Through the production of plant hormones, Bcc strains can even promote the growth of 
certain crops like maize, rice and wheat.  Another great advantage of environmental Bcc 
strains is their unique metabolic capacity that allows them to be used as a 
bioremediation agent.  Bcc can degrade a wide variety of man-made pollutants like 
phthalates, herbicides and chlorinated hydrocarbons [221].   
In marked contrast with their ecologically beneficial effect, Bcc bacteria emerged as 
highly problematic opportunistic human pathogens during the past 30 years in both CF 
patients and immunocompromised patients [63, 222].  As Bcc bacteria are not carried as 
commensals, infections are acquired either in hospital settings (from other patients or 
from contaminated devices) or from the environment.  The first reports of Bcc infection 
in CF patients date from the late 1970s [223] and reported nosocomial outbreaks were 
often due to contaminated devices, disinfectants and antiseptics [224].  The first 
isolation of Bcc strains from the sputum of CF patients was described by Ederer in 1972 
[225]. 
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Figure 15: Role of Bcc bacteria in environmental and clinical environments.  Most environmental effects 
are ecologically beneficial while in clinical environments Bcc bacteria have emerged as highly problematic 
opportunistic pathogens in CF and immunocompromised patients. [226] 
 
III.2 Taxonomy 
 
After extensive research on DNA-DNA homology, 16S rRNA sequences, cellular lipid and 
fatty acid compositions, seven Pseudomonas species were in 1992 transferred to a new 
genus Burkholderia [227].  In 1997, the group of Peter Vandamme investigated 89 
isolates primarily isolated form CF patients and identified as B. cepacia.  A marked 
heterogeneity among these strains has led to the subdivision of “B. cepacia” strains in at 
least five distinct genomic species, referred to as genomovars [228].  This group of five 
genomovars, representing phenotypically similar but genotypically distinct species, was 
collectively referred to as the Bcc.  Over the years more diversity was revealed and more 
genomovars were described.  Currently, at least 18 species belonging to the Bcc are 
described and each has received a formal binomial designation (Table 2) [229].  
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Table 2: Overview of the Bcc [229] 
Species  
(former genomovar designation) 
Natural environment Clinical environment 
B. cepacia (I) Rhizosphere, soil, water CF, medical solutions 
B. multivorans (II) Rhizosphere, soil, water CF, CGD, non-CF 
B. cenocepacia (III) Rhizosphere, soil, water, plant, animal CF, non-CF 
B. stabilis (IV) Rhizospere CF, hospital equipment 
B. vietnamiensis (V) Rhizosphere, soil, water, plant, animal CF 
B. dolosa (VI) Maize rhizosphere, plant CF 
B. ambifaria (VII) Rhizosphere, soil CF 
B. anthina (VIII) Rhizosphere, soil CF 
B. pyrrocinia (IX) Rhizosphere, soil, water, plant CF, non-CF 
B. ubonensis Soil Nosocomial infection 
B. latens No environmental strain reported CF 
B. diffusa Soil, water CF, hospital equipment, non-CF 
B. arboris Rhizosphere, soil, water CF, non-CF 
B. seminalis Rice rhizosphere CF, nosocomial infection 
B. metallica No environmental strain reported CF 
B. contaminans Soil, water, animal CF, non-CF, hospital equipment 
B. lata 
B. pseudomultivorans 
Soil, water, flower 
Rhizosphere 
CF, non-CF 
CF, non-CF 
CF: CF 
CGD: chronic granulomatous disease 
 
III.3 Human pathogenesis 
 
Bcc strains are encountered as opportunistic pathogens, which means that they do not 
usually infect healthy persons but only those that are immunocompromised.  Lungs of 
CF patients are particularly susceptible to infections with Bcc strains.  Isles et. al. were 
the first to describe Bcc strains as emerging problematic pathogens in CF patients 
during a Bcc epidemic in Toronto (Canada) in the early 1980s [63].  They observed an 
accelerated and uncontrollable decline in overall clinical status in about 10% of infected 
CF patients.   
Patients suffering from chronic granulomatous disease (CGD) also have an increased 
risk of developing Bcc infections.  In patients with CGD a genetic defect results in the 
inability of polymorphonuclear leukocytes to produce ROS [230].  Therefore, these 
patients are not capable of clearing Bcc strains from their lungs resulting in sepsis 
(invasive Bcc infections) and pneumonia, the second leading cause of death in CGD 
patients [226].   
In addition, Bcc strains have been isolated from immunocompetent individuals, like 
patients with chronic otitis media and pharyngeal infections [231-234].  Because of their 
tolerance to various disinfectants and antiseptics, Bcc bacteria can persist in hospital 
environments, resulting in an increased number of cases of Bcc-related septicaemia; 
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even in non-CF patients.  Among these hospitalized patients, hemodialysis, permanence 
in intensive care units and use of central venous catheters, urinary catheters and 
endotracheal tubes are recognized as risk factors contributing to Bcc acquisition [235]. 
During the last 10 years B. cenocepacia is also increasingly being recognized as an 
emergent nosocomial pathogen among immunocompromised oncology patients [236]. 
III.3.1 Bcc in CF infection 
 
The number of Bcc infections in CF patients increased dramatically during the 1980s.  
Compared to P. aeruginosa, Bcc strains infect a relatively small fraction of CF patients.  
Nevertheless, pulmonary colonization with Bcc strains is often correlated with a worse 
prognosis, longer hospital stays and an increased risk of death [23, 237].  A great 
variability in clinical outcome has been noted among Bcc infected CF patients, even 
among patients infected with the same clonal strain.  Some patients are asymptomatic 
carriers while others experience a rapid decline in clinical status associated with 
necrotizing pneumonia and septicemia (cepacia syndrome) [238].  Both strain and host 
factors are thought to be responsible for these differences in disease pathogenesis.  All 
Bcc strains, except for B. ubonensis, have been isolated from the lungs of CF patients.  
Still, the most prevalent isolated pathogens are B. cenocepacia and B. multivorans [239].  
Strains belonging to several species of the Bcc complex like B. cenocepacia, B. cepacia, B. 
multivorans and Burkholderia dolosa, have been shown to be highly transmissible among 
CF patients with B. cenocepacia being the most notorious among them [60, 239].  B. 
cenocepacia has been shown to replace B. multivorans during chronic CF infection [240] 
and epidemic strains with international impact, like B. cenocepacia ET12, have been 
described [61].  During the late 1980s and throughout much of the 1990s this highly 
epidemic lineage spread among CF patients from Canada to the United Kingdom 
resulting in high mortality rates mainly because of its ability to cause cepacia syndrome.  
Although transmission of Bcc strains between siblings is most frequently reported,  
transmission between hospitalized CF patients [60] and even between CF patients and 
non-CF patients [241] has been noted.  As transmission occurs by direct contact or by 
inhalation of aerosol droplets, several infection control guidelines recommend to 
segregate people with Bcc infections from each other and from non-Bcc infected CF 
patients in clinical settings [242, 243].  They also advise to minimalize close contact 
outside the hospital environment.  Although such segregation policies have proven to be 
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efficient not everyone agrees with these guidelines because of the great impact on social 
and psychological well-being of CF patients [244]. 
III.4 Genomics 
 
The first genetic map of a Bcc strain, later identified as a B. multivorans strain, was 
published in 1994 by Cheng and Lessie [245].  Apart from the overall large genome size 
(∼ 7 Mb), it demonstrated a rather unusual genomic organisation.  The genome of this B. 
multivorans strain (ATCC 17616) was made up of three large replicons (3.4 Mb – 2.5 Mb 
– 0.9 Mb) and a plasmid (170 kb).  The large replicons were referred to as chromosomes 
as they all encoded ribosomal RNA operons.  One year later, Rodley et al. confirmed this 
genomic arrangement for another Bcc strain, the B. cepacia type strain [246].  During the 
following years different other Bcc genomes were sequenced and until now they all 
possess the same genomic structure of three chromosomes in combination with one to 
five plasmids [247].  In general, chromosomes are never lost although they could 
undergo several rearrangements and all chromosomes encode essential genes, with 
most housekeeping genes located on the largest chromosome [248]. 
The genome of B. cenocepacia J2315, a reference strain of the ET12 epidemic lineage, 
was published in 2009 and gave more insight into the success of this pathogen in 
colonizing and persisting in the CF lung [249].  This genome consists of three large 
circular chromosomes and one small plasmid and has a total size of 8.056 Mb.  The 
presence of several types of insertion sequences, small transposable mobile DNA 
fragments, is possibly involved in genomic plasticity and regulation of gene expression.  
The genome also contains a large amount of genomic islands which are regions of 
genomic DNA with unusual characteristics compared to the most of the genomic DNA 
sequence, indicating that they may have been acquired during evolution.  Genomic 
islands are present in the genome of many gram-negative bacteria although normally to 
a lesser extent [250].  Approximately 10 % of the total genome of B. cenocepacia J2315 is 
comprised of genomic islands, occurring on all three chromosomal replicons [249].  The 
B. cenocepacia pathogenicity island (cci) was the first to be defined in the entire Bcc and 
its contribution to B. cenocepacia virulence has been described [251].  Interest in this 
region was prompted because of the presence of a “B. cenocepacia epidemic strain 
marker” which is associated with virulent B. cenocepacia strains capable of infecting CF 
patients and transmission between patients.  Apart from this marker, cci also contains 
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an amidase gene playing  a role in persistence and two signaling genes and a porin gene 
also involved in virulence.  In B. cenocepacia J2315, 14 genomic islands have been 
identified [249] contributing to the pathogens genomic plasticity and metabolic 
diversity. 
III.5 Virulence factors 
 
Bcc strains are intrinsically resistant towards a broad range of antibiotics and are 
perfectly adapted to colonize and persist in the CF lung.  Putative virulence factors and 
pathogenic mechanisms contributing to these traits are extensively being investigated. 
III.5.1 Lipopolysaccharides 
 
LPS are a general virulence factor in gram-negative bacteria and are located on the outer 
leaflet of the outer membrane.  LPS are composed of a lipid A moiety, a core 
oligosaccharide and an O-antigen (Figure 16).   
 
Figure 16: LPS from the outer membrane of gram-negative bacteria.  The two glucosamine molecules 
(oblongs) of the lipid A moiety contain phosphodiester-linked 4-amino-4-deoxyarabinoses (brown circles) 
in Burkholderia.  The inner core which is attached to lipid A is comprised of less 3-deoxy-D-manno-oct-2-
ulosonic acids (KDO; dark blue hexagon) compared to LPS molecules of other gram-negative organisms. 
[226] 
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The LPS of Burkholderia species can be distinguished from LPS of other gram-negative 
bacteria as it contains less phosphate and/or KDO residues on their core 
oligosaccharide, making it less negatively charged.  In addition, 4-amino-4-
deoxyarabinose molecules are bound to the phosphate residues on the lipid A moiety 
also reducing the negative charge of this LPS component [252].  The addition of 4-
amino-4-deoxyarabinose molecules to lipid A phosphate residues is a well described 
mechanism used by gram-negative bacteria, like P. aeruginosa, to confer resistance 
against positively charged antimicrobials [253].  The uptake of such positively charged 
antimicrobials, e.g. aminoglycosides, polymyxin and AMPs, is initiated by the binding to 
lipid A phosphate.  By binding to these molecules, divalent cations cross-bridging two 
adjacent LPS molecules are displaced, destabilizing the outer membrane and improving 
the antimicrobial’s uptake. 
LPS from Bcc species is four to five times more endotoxic than P. aeruginosa LPS [254].  
Therefore, most B. cenocepacia strains consistently induce cytokine production, 
including tumor necrosis factor (TNF) and IL-8, leading to inflammation reactions.  This 
endotoxic effect is considered to be attributed to the lipid A moiety of LPS which is 
biologically the most active component. 
III.5.2 Biofilm formation 
 
Bcc strains are believed to persistently colonize the CF lung as a biofilm.  In vitro biofilm 
formation of all Bcc strains and even the formation of mixed biofilms with P. aeruginosa 
strains has been confirmed [255].  Biofilm formation is a complex process involving 
many different determinants.  The first requisite for biofilm formation is the initial 
attachment to a surface which is influenced by the availability of iron and the presence 
of cable pili and adhesins on the surface of Bcc.  The overload of free iron in CF sputum 
can induce both P. aeruginosa and B. cenocepacia non-motile growth forms leading to 
aggregate formation and biofilm development [256].  Interaction between these 
aggregated bacteria through the production of acyl-homoserine lactone signaling 
molecules has been shown to be  important in Bcc biofilm formation although not under 
all growth conditions [196].  The production of cepacian by mucoid Bcc strains partly 
contributes to the formation of thick, mature biofilms [171].  EPS production in Bcc also 
inhibits neutrophil chemotaxis and allows to scavenge ROS protecting Bcc biofilm 
bacteria from innate neutrophil-mediated host defenses [257].  In general, biofilm 
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formation is associated with increased resistance towards different antibiotics and 
components of the innate human defense system contributing to the persistence of Bcc 
infections in CF patients. 
III.5.3 Quorum sensing 
 
QS implies a cell-to-cell communication system that is cell density dependent and allows 
bacteria to behave as a multicellular entity.  The first QS system detected in Bcc was in a 
B. cencocepacia K56-2 strain and was designated as the cepRI quorum-sensing system 
[258].  Similar QS systems have currently been detected in all Bcc species through which 
bacteria produce and respond to N-acyl-homoserine lacton molecules.  The cepRI system 
is involved in the regulation of many different Bcc virulence phenotypes including 
biofilm formation, motility, toxin production and protease and lipase production [259].  
In addition, it is also suggested to be important in communicating with P. aeruginosa in 
mixed species biofilms.  Certain strains of B. cenocepacia possess a second acyl-
homoserine lacton producing cell-to-cell communication system.  This system is 
designated as cciRI as is encoded on the B. cenocepacia pathogenicity island [251].   The 
presence of this second QS system even further emphasizes the complexity of bacterial 
cell communication. 
III.5.4 Innate resistance to antibiotics 
 
Bcc organisms are intrinsically resistant to a broad range of antibiotics.  This is partly 
due to the special structure of their LPS molecules which make the outer membrane 
impermeable for certain antimicrobials.  Antibiotics that do manage to penetrate the 
bacterial membrane can be excluded again by the activity of different efflux pumps 
[226].  Resistance towards β-lactam antibiotics can be explained by the induction of 
chromosomally encoded β-lactames [260].  These enzymes can reside in the biofilm 
matrix or in other in vivo environments like sputum, hydrolyzing the β-lactams while 
approaching the bacteria.   
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The primary pathogen isolated from the CF lung is P. aeruginosa.  Infections with Bcc 
bacteria are much less prevalent compared to P. aeruginosa infections but the clinical 
outcome of Bcc infected CF patients is highly variable and often associated with a rapid 
decline of the lung function.  In addition, as Bcc bacteria are capable of person-to-person 
transmission, isolation measures for Bcc infected patients have been frequently 
implemented in many different CF care centres.  Eradication of Bcc infections is difficult 
because of the innate resistance of the Bcc to many antibiotics and the ability of biofilm 
formation, providing additional protection against both antibiotics and host immune 
components.  The urge for new treatment modalities to deal with Bcc infections is high 
as the development of new antibiotics to potentially overcome the problem of innate 
resistance is on decline.   
The aim of my PhD thesis was to investigate different strategies to treat Bcc infections.  
A first aim was to investigate whether fosmidomycin and fosmidomycin derivatives 
could be useful to treat Bcc infections.  Secondly, we investigated also whether Bcc 
bacteria use self-promoted uptake for tobramycin; this could pave the path for the 
development of selective tobramycin derivatives.  To overcome the problem of a 
decreased bioavailability of free tobramycin because of interaction with biofilm matrix 
components, the combination of tobramycin with matrix degrading components was 
investigated in a third study.  We hypothesised that these antibiotic-matrix interactions 
can also be inhibited by the encapsulation of tobramycin in liposomal carriers. This has 
the additional advantage of targeted drug delivery near the biofilm cells.  Therefore, a 
fourth objective was to investigate the potential of different liposomal tobramycin 
formulations to treat Bcc biofilm infections. 
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Chapter IV: RESISTANCE OF THE BURKHOLDERIA CEPACIA COMPLEX 
AGAINST FOSMIDOMYCIN AND FOSMIDOMYCIN DERIVATIVES 
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ABSTRACT 
 
The Bcc is a group of at least 18 closely related opportunistic pathogens that are able to 
infect the respiratory tract of CF patients.  Bcc bacteria are intrinsic resistant to many 
antibiotics and are therefore difficult to eradicate.  Fosmidomycin could be a new 
therapeutic agent to treat Bcc infections as it inhibits Dxr, a key enzyme in the non-
mevalonate pathway essential in Bcc bacteria for isoprenoid synthesis.  In the present 
study the antimicrobial activity of fosmidomycin and eight fosmidomycin derivatives 
towards 40 Bcc strains was investigated.  All Bcc strains were resistant, although the 
addition of glucose-6-phosphate reduced MIC values of FR900098, the fosmidomycin 
acetyl derivative, from 512 mg/L to 64 mg/L for B. multivorans and B. cepacia.  This 
enhanced activity was linked to an increased expression of the genes involved in 
glycerol-3-phosphate transport, which seems to be the only route for fosmidomycin 
import in Bcc bacteria.  Further, the upregulation of a fosmidomycin resistance gene 
(fsr), encoding an efflux pump, was observed during fosmidomycin and FR900098 
treatment.  These results strongly suggest that the observed resistance in Bcc bacteria is 
due to an insufficient uptake accompanied by fosmidomycin and FR900098 efflux.
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Introduction 
In the early 1980s Bcc bacteria emerged as problematic pathogens in CF patients, with B. 
cenocepacia and B. multivorans being the most frequently isolated species.  Compared to 
P. aeruginosa, Bcc infections only account for a small percentage of the respiratory 
infections within the CF population, however, they are often associated with rapid 
deterioration of the lung function and increased mortality [1].  Once infection with Bcc 
bacteria is established, therapeutic options are limited because of the innate resistance 
of these bacteria to many antibiotics.  Different resistance mechanisms have already 
been described, including increased efflux and decreased permeability of the outer 
membrane [2].  Despite these high levels of resistance there has been little progress in 
developing new therapeutic strategies to fight these infections. 
The non-mevalonate pathway for isoprenoid synthesis was discovered in the early 
1990s as an alternative to the classical mevalonate pathway.  While most bacteria 
exclusively synthesize isoprenoids, like coenzyme Q, through this pathway, mammalian 
cells do not possess it [3].  Fosmidomycin, a natural phosphonic acid antibiotic, is a 
specific inhibitor of a key enzyme of the non-mevalonate pathway, i.e. Dxr.  Although it 
has shown good safety and efficacy, e.g. for the treatment of uncomplicated Plasmodium 
falciparum malaria [4], the rapid development of resistance during therapy is of great 
concern.  White et al. suggest that this resistance is due to a decreased uptake of the 
compound [5].  The uptake of fosmidomycin is hypothesized to follow the same route as 
its structural analog fosfomycin, either through hexose-phosphate or through glycerol-
3-phosphate transporters because mutations in genes encoding these transport systems 
confer resistance to both fosmidomycin and fosfomycin [6].  Further, the B. cenocepacia 
genome contains a fosmidomycin resistance gene (fsr), encoding an efflux pump, which 
transports fosmidomycin out of the cell [7].  
The aim of the present study was to evaluate the in vitro activity of fosmidomycin and 
eight derivatives against the Bcc and to elucidate the mechanisms of resistance in this 
group of organisms. 
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Materials and methods 
Strains 
The following 40 Bcc strains were used: B. cepacia LMG 18821 and LMG 1222T; B. 
multivorans LMG 18822, LMG 18825, LMG 13010T and LMG 17588; B. cenocepacia LMG 
16656T, LMG 18828, LMG 18829, LMG 18830, LMG 6986 and K56-2; B. stabilis LMG 
14294T and LMG 14086; B. vietnamiensis LMG 18835 and LMG 10929T; B. dolosa LMG 
18943T and LMG 18941; B. ambifaria LMG 19182T and LMG 19467; B. anthina LMG 
20980T and LMG 20983; B. pyrrocinia LMG 14191T and LMG 21824; B. ubonensis LMG 
20358T and LMG 24263; B. latens R-11768 and LMG 24264; B. diffusa LMG 24065T and 
LMG 24266; B. arboris LMG 24066T and R-132; B. seminalis LMG 24067T and LMG 
24272; B. metallica LMG 24068T and R-2712; B. lata LMG 6992 and R-9940; and B. 
contaminans LMG 16227 and R-12710.  All strains were obtained from the BCCM/LMG 
Bacteria Collection (Ghent, Belgium) or were kindly provided by Dr P. Vandamme 
(Ghent University, Belgium).  We used two E. coli K-12 strains as positive controls as it 
was previously shown that fosmidomycin is active against these isolates [8]. 
Antimicrobial agents 
Fosmidomycin was obtained from Invitrogen (Eugene, OR).  All fosmidomycin 
derivatives were synthesized as previously described [9-13] (See Figure 1 for an 
overview of the structures). 
 
Figure 1: Overview of the 
molecular structures of 
fosmidomycin and the 
fosmidomycin derivatives 
used in the present study. 
 
1: fosmidomycin;  
2: FR900098; 3: TVI 064;  
4: Schl 7150;  
5: Schl 7498; 6: TVII 046;  
7: TVII 007; 8: TVB 006;  
9: TVI 118. 
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Determination of the MIC 
MICs were determined according to the EUCAST standard broth microdilution protocol 
[14].  A two-fold antibiotic dilution series ranging from 1 to 512 mg/L was tested.  MICs 
were also determined in the presence of glucose-6-phosphate and glucose-1-phosphate 
as sole carbon sources.  To this end, a chemically defined minimal salt medium 
supplemented with 50 μM FeCl3.6H2O (designated as CDM) [15] and equimolar 
concentrations of glucose-6-phosphate and glucose-1-phosphate instead of glucose 
(designated as CDM-G) was used. 
RNA extraction and cDNA synthesis 
Cells were cultured in either CDM or CDM-G medium.  Antibiotic concentrations, 
corresponding to the previously determined MIC values were used during treatment.  If 
MIC values were > 512 mg/L, cultures were grown in medium containing 512 mg/L of 
the antimicrobial agent.  After 24 h of incubation, with constant agitation, cells were 
collected and RNA was extracted using the Ambion RiboPure Bacteria Kit (Ambion, 
Austin, TX).  Manufacturer’s instructions were followed except for the DNAse treatment 
that was prolonged to 1 h.  After RNA extraction, RNA yields were assessed using the 
RNA Quant-iT kit  (Invitrogen).  15 μL RNA samples were used to synthesize cDNA using 
the iScript cDNA Synthesis Kit. 
Quantitative real time PCR 
The expression of 7 genes (including 2 reference genes) was investigated by means of 
quantitative RT-PCR (qPCR).  Primers were developed using the website of NCBI 
(http://www.ncbi.nlm.nih.gov) and their specificity was checked using BLAST (See 
Table 1 for primer sequences).  All qPCR experiments were performed on a Bio-Rad 
CFX96 Real-Time System C1000 Thermal Cycler using the iQ SYBR Green Supermix kit 
(Bio-Rad, Hercules, CA) according to the manufacturer’s instructions.  To activate the 
polymerase included in the iQ SYBR Green Supermix kit the reaction mixture was heated 
at 95°C for 3 min, followed by 40 amplification cycles, consisting of 15 s at 95°C and 60 s 
at 60°C.  A melting curve analysis was included at the end of each run.  Real-time PCR 
data were normalized to the geometric mean of the expression of two reference genes 
(BCAL0289 and BCAL1861), which were stably expressed in all conditions investigated 
in the present study (data not shown). 
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    Table 1: Forward (FW) and reverse (RV) primers used in real-time PCR experiments. 
 
 
Gene Annotation Orientation Primer sequence (5’ to 3’) Concentration 
BCAL2085 Dxr 
FW GCGCTCGAGGAAGGCGGTAT 600 nM 
RW TCCGGCGCTCGAGAAATGCT 600 nM 
BCAL1451 Efflux pump 
FW TGTTCCAGGTGGGCGGCAAT 300 nM 
RW CCAGTGGCCGATCTGCGTGA 300 nM 
BCAL0282 Glycerol-3P-transporter 
FW ATGCGAAGACGGGCCACCTC 200 nM 
RW GCCCGCCTTCTTGAACGCATC 200 nM 
BCAL0284 
Glycerol-3P transporter membrane 
protein 
FW GGGCTTCGACCTGTTCTGCCA 200 nM 
RW ACGCGACGTAGACGGGGAAC 200 nM 
BCAL0285 
Glycerol-3P transporter ATP binding 
subunit 
FW CTGAGCTTGAAGGGCGTCAGGA 200 nM 
RW GGGCCGACCAGCACGATGAA 200 nM 
BCAL0289 Glutamate synthase 
FW ATCATCCAGCAGGGTCTGAAGA 600 nM 
RW GCCATTTCCTCGCGATAGAA 600 nM 
BCAL1861 Acetoacetyl-CoA reductase 
FW GATCACCTGCTTCGTGACGTT 600 nM 
RW GACGTCGTGTTCCGCAAGAT 600 nM 
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Results 
Susceptibility testing in Mueller Hinton broth 
For all Bcc strains tested, MICs of fosmidomycin were > 512 mg/L, whereas those for the 
two E. coli K-12 strains, serving as positive controls, ranged from 0.5 to 2 mg/L, which is 
in agreement with previously reported data [8]. 
The acetyl derivative, FR900098, was capable of inhibiting growth of 18 of the 40 strains 
tested at concentrations ≤ 512 mg/L.  B. multivorans LMG 18822 and LMG 18825, B. 
cenocepacia LMG 18830 and LMG 6986, B. stabilis LMG 14294T, B. vietnamiensis LMG 
18835 and LMG 10929T, B. dolosa LMG 18941, B. pyrrocinia LMG 21824, B. ubonensis 
LMG 20358T and LMG 24263, B. seminalis LMG 24067T and B. metallica LMG 24068T and 
R-2712 were inhibited at concentrations of 512 mg/L.  Further, B. cepacia LMG 1222T, B. 
multivorans LMG 13010T and B. lata LMG 6992 were inhibited at concentrations of 256 
mg/L and B. anthina LMG 20983 at a concentration of 128 mg/L. 
The seven other derivatives were tested against three Bcc type strains, B. cepacia LMG 
1222T, B. multivorans LMG 13010T and B. cenocepacia LMG 16656T, but growth 
inhibitory concentrations of these derivatives were never below 512 mg/L (Table 2). 
 
 Table 2: MICs of fosmidomycin and 8 fosmidomycin derivatives for 3 Bcc type strains (experiments 
were performed in duplicate). 
Fos: fosmidomycin 
 
 
 
 
MIC (mg/L) 
Strain Fos FR900098 TVII 007 TVII 046 TVI 064 TVI 118 TVB 006 Schl 7150 Schl 7498 
B. cepacia  
LMG 1222T 
> 512 256 512 > 512 512 > 512 > 512 512 > 512 
B. multivorans 
LMG 13010T 
> 512 256 512 > 512 512 512 > 512 512 > 512 
B. cenocepacia 
LMG 16656T 
> 512 > 512 > 512 > 512 512 > 512 > 512 512 > 512 
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Susceptibility testing in the presence of glucose-6-phosphate 
First, the activity of fosmidomycin in the presence of glucose-6-phosphate was 
investigated by adding 25 mg/L glucose-6-phosphate to Mueller Hinton (MH) broth.  
However, MICs remained > 512 mg/L for all 40 strains tested (data not shown). 
To investigate the activity of fosmidomycin in the presence of glucose-6-phosphate as 
sole carbon source, CDM medium supplemented with Fe3+ [15] (designated CDM) and 
CDM with glucose-6-phosphate replacing glucose at equimolar concentrations 
(designated as CDM + G6P) was used.  Although it should be noted that the reduced 
growth in these media precluded the determination of the exact MIC value, an increased 
sensitivity of B. multivorans LMG 13010T and B. cepacia LMG 1222T to fosmidomycin in 
CDM + G6P compared to CDM was observed (Figure 2). 
 
Figure 2: Activity of fosmidomycin in the presence of glucose-6-phosphate as sole carbon source. 
  
Full line: activity of 
fosmidomycin in CDM + G6P 
medium. 
Dotted line: activity of 
fosmidomycin in CDM 
medium;    
∎ : B. multivorans LMG 
13010T; ▲ : B. cepacia LMG 
1222T.  
 
 
Because of the higher activity of FR900098 the effect of glucose-6-phosphate was 
further investigated using this acetyl derivative.  MICs for B. cenocepacia LMG 6986, B. 
multivorans LMG 13010T and B. cepacia LMG 1222T were determined in CDM with 
glucose-6-phosphate and glucose-1-phosphate as sole carbon sources (designated as 
CDM-G).  Glucose-1-phosphate had no effect on MIC values but improved growth to 
levels equivalent to the growth in MH broth (data not shown).  MICs of FR900098 for all 
three strains tested were 64 mg/L in CDM-G compared to 512 mg/L for B. cenocepacia 
LMG 6986 and 256 mg/L for B. multivorans LMG 13010T and B. cepacia LMG 1222T in 
MH. 
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Effect of glucose-6-phosphate on the expression of genes involved in glycerol-3-phosphate 
transport during FR900098 treatment 
The expression of three genes involved in glycerol-3-phosphate transport in B. 
cenocepacia LMG 16656T (BCAL0282, BCAL0284 and BCAL0285) during treatment with 
64 mg/L FR900098 was investigated.  The expression levels for the three genes tested 
were significantly higher (p < 0.05) in the presence of glucose-6-phosphate (CDM-G) 
compared to controls (CDM) (Figure 3a).  The expression of BCAL0283, which encodes a 
putative ABC transporter permease involved in glycerol-3-phosphate transport was too 
low to allow accurate quantification (data not shown). 
Expression of BCAL2085 (dxr) and BCAL1451 (fsr) 
The expression levels of dxr and fsr in the presence of fosmidomycin or FR900098 (64 
mg/L) in CDM-G medium relative to untreated controls are shown in Figure 3b.  The fsr 
gene encoding the efflux pump was significantly upregulated during treatment 
compared to untreated controls (p < 0.05), while the gene encoding the target enzyme 
(Dxr) was stably expressed in both conditions. 
 
Figure 3: Gene expression data (Experiments were performed in triplicate). 
 
a) Transcriptional response of genes belonging to the glycerol-3-phosphate transport system to the 
addition of glucose-6-phosphate in both untreated and FR900098 treated conditions (expressed as fold 
change in CDM-G compared to CDM). 
b) Expression of BCAL2085 (dxr) and BCAL1451 (fsr) in the presence of fosmidomycin and FR900098 (64 
mg/L) (expressed as fold change in CDM-G with fosmidomycin or FR900098 compared to CDM-G).   
Mean values of three replicates are displayed with error bars representing standard deviations.  A more 
than 1.5 fold change in expression is considered upregulated (*). 
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D iscussion 
Bcc bacteria are known for their resistance against a wide range of antimicrobial agents.  
The aim of the present study was to evaluate the potential of fosmidomycin for the 
treatment of Bcc infections.  
Despite the presence of dxr (BCAL2085) in the B. cenocepacia J2315 genome, a clear 
resistance against fosmidomycin and its derivatives was observed for all Bcc strains 
tested.  This indicates that the presence of the non-mevalonate pathway, and more 
specifically Dxr, does not guarantee susceptibility towards inhibitors of this pathway 
and that the resistance may be due to altered transport.  The glycerol-3-phosphate 
transporter (GlpT) is reportedly the main importer of fosmidomycin in E. coli [6].  No 
glpT homologs were found in the B. cenocepacia J2315 genome, nevertheless an 
alternative system involved in glycerol-3-phosphate import is present.  This transporter 
belongs to the ABC transporter superfamily and consists of a periplasmic substrate 
binding protein (ugpB; BCAL0282), two permease proteins (ugpA; BCAL0283 and ugpE; 
BCAL0284) and an ATP binding protein (ugpC; BCAL0285).  Because of the structural 
similarity of fosmidomycin to glycerol-3-phosphate we suspect that fosmidomycin can 
enter B. cenocepacia cells through this alternative glycerol-3-phosphate transport 
system as well. 
The activity of both fosmidomycin and FR900098 was enhanced in the presence of 
glucose-6-phosphate when used either as a sole carbon source or in combination with 
glucose-1-phosphate, suggesting the presence of an inducible sugar phosphate transport 
system through which fosmidomycin can be imported into Bcc bacteria.  The hexose 
phosphate transporter (UhpT) is a main transport system for fosfomycin, a structural 
analog of fosmidomycin, in E. coli cells [6, 16].  Based on the genes involved in the 
hexose-phosphate transport system in E. coli, we searched for their homologs in the 
genome of B. cenocepacia J2315 using BLAST.  However, we did not identify uhp 
homologs, suggesting that B. cenocepacia lacks a specific sugar-phosphate transport 
system. 
This indicates that fosmidomycin can only be imported into B. cenocepacia cells through 
its glycerol-3-phosphate transport system.  Therefore, we investigated the effect of 
glucose-6-phosphate on the expression of ugpB, ugpC and ugpE.  A significant 
upregulation of these genes in CDM-G medium, compared with CDM medium, was 
observed.  As the only difference between these media is the carbon source, the 
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upregulation must be attributed to the presence of glucose-6-phosphate or glucose-1-
phosphate in CDM-G medium.  As previous observations indicated that glucose-1-
phosphate had no influence on MIC values, the upregulation is likely caused by glucose-
6-phosphate. 
A gene conferring resistance to fosmidomycin (fsr) was shown to be involved in 
fosmidomycin efflux in E.coli [7].  As a fsr homolog is present in the genome of B. 
cenocepacia J2315 and is significantly upregulated in treated samples this could in part 
explain the observed resistance in Bcc bacteria. 
In conclusion, our results suggest that the only transport system for fosmidomycin in 
Bcc bacteria is a glycerol-3-phosphate transport system, which is induced in the 
presence of glucose-6-phosphate.  Consequently, the uptake of fosmidomycin can be 
increased by the addition of glucose-6-phosphate.  However, a fosmidomycin efflux 
pump is capable of compensating for this increased fosmidomycin uptake, providing 
resistance of Bcc bacteria against fosmidomycin and FR900098. 
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ABSTRACT 
 
Chronic P. aeruginosa infections, the main cause of morbidity and mortality in CF 
patients, are often treated with daily tobramycin inhalation therapy.  The cellular uptake 
of aminoglycosides, including tobramycin, can be divided in three phases: an initial 
energy-independent electrostatic interaction at the cell surface and subsequently two 
energy-dependent phases.  Nevertheless, fundamental differences exist in 
aminoglycoside uptake between different Gram-negative and Gram-positive bacteria.  In 
Gram-negative bacteria, aminoglycosides can cross the outer membrane either through 
diffusion through hydrophilic channels formed by porin proteins or through a process 
referred to as self-promoted uptake.  In the present study, we investigated the mode of 
uptake of tobramycin in different Gram-negative bacteria, including P. aeruginosa, E. coli 
and Bcc organisms.  To this end we determined the activity of tobramycin in the 
presence and absence of Mg2+.  In addition, we determined the activity of three 
tobramycin derivatives, i.e. tobramycin-OH-BODIPY, tobramycin-N-Me2 and tobramycin-
OH-EDTA, on both planktonic and biofilm cells.  Increased tobramycin MICs in the 
presence of Mg2+ confirmed self-promoted uptake in P. aeruginosa.  In contrast, 
decreased MICs in the presence of Mg2+ for Bcc organisms suggested alternative uptake 
mechanisms.  Based on the MIC of tobramycin-OH-BODIPY for planktonic cells and the 
high activity of tobramycin-OH-EDTA towards biofilms, we hypothesized that 
tobramycin is at least in part taken up through self-promoted uptake in E. coli, as both 
derivatives are too large to be taken up through porins.  The observed selective activity 
of tobramycin-N-Me2 against P. aeruginosa biofilms appears to be biofilm specific. 
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Introduction 
CF is the most prevalent genetically inherited disease in the Caucasian population and is 
caused by mutations in both copies of the CFTR gene [1].  CFTR encodes a chloride 
channel which is expressed on the apical surface of different organs, including the lung 
[2].  A malfunctioning chloride channel in lung epithelial cells results in the secretion of 
thick viscous mucus which impairs mucociliary clearance and thereby sensitizes the CF 
lung to chronic bacterial infections [3].  Within a few years after birth, P. aeruginosa 
becomes the predominant pathogen isolated from the CF lung.  Early treatment of these 
infections is essential as they are the main cause of morbidity and mortality in CF 
patients [4].  Chronic P. aeruginosa infections are often treated with tobramycin which 
has been shown to improve lung function and reduce P. aeruginosa cell numbers in CF 
sputum samples [5].  Aminoglycosides, including tobramycin, promote mRNA 
mistranslation, resulting in the incorporation of incorrect amino acids into the 
elongating peptide strain [6].  Mistranslated membrane proteins play a crucial role in 
the bactericidal effect of aminoglycosides.  These proteins are incorporated in the 
bacterial cell membrane, thereby creating non-specific channels through which small 
molecules, including aminoglycosides (500 to 600 daltons), can diffuse.  The increased 
access of the drug results in increased ribosome inhibition and ultimately leads to cell 
death [7].  In addition, by the incorporation of mistranslated proteins into the bacterial 
cell membrane, an envelope stress and redox responsive two-component system is 
activated, resulting in the production of ROS involved in bacterial killing [8].   
The uptake of aminoglycosides in bacterial cells is an active process which can be 
divided in three phases.  The first phase involves the initial binding of the positively 
charged aminoglycoside to the bacterial cell membrane, which is energy-independent, 
followed by two energy-dependent phases, EDPI and EDPII [9-11].  In Gram-negative 
bacteria, the initial binding of the aminoglycoside is mainly directed towards negatively 
charged  LPS, located on the outer leaflet of the outer membrane.  In Gram-positive 
bacteria, aminoglycosides can bind to the polar heads of the phospholipids and to 
teichoic acids [12].  After initial binding, the antibiotic is transported across the outer 
membrane of Gram-negative bacteria by either non-specific hydrophilic diffusion 
channels formed by membrane porin proteins or by a self-promoted transport 
mechanism, like has been observed for P. aeruginosa [13].  During the EDPI phase, 
aminoglycosides cross the cytoplasmic membrane in response to the membrane 
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potential of the bacterial cell [14, 15].  The mechanism by which this occurs is still 
unclear.  Nevertheless, it has been demonstrated that this process is energy-dependent 
as it can be blocked by inhibitors of the electron transport chain [10, 11] or oxidative 
phosphorylation [16].  EDPI is characterized by a slow rate of uptake of aminoglycosides 
preceding the inhibition of protein synthesis and bacterial killing [14].  During the EDPII 
phase, aminoglycosides are transported more rapidly across the cytoplasmic membrane, 
also in an energy-dependent manner.  Active protein synthesis by aminoglycoside 
sensitive ribosomes is essential for the initiation of and continuation of the EDPII phase.  
The increased permeability of the cytoplasmic membrane caused by the incorporation 
of aminoglycoside-induced mistranslated proteins could explain the necessity for active 
protein synthesis for this accelerated uptake phase [17].   
Apart from these three major phases in aminoglycoside uptake, fundamental differences 
exist in aminoglycoside uptake between different Gram-negative and Gram-positive 
bacteria.  In Gram-negative bacteria, divalent cations stabilize the outer membrane by 
cross linking adjacent LPS [18].  Therefore, by adding divalent cations, the outer 
membrane is increasingly stabilized and less permeable to aminoglycosides which 
compete for the same binding sites on LPS molecules during the energy-independent 
uptake phase [19].  Donovick et al. were the first to observe an effect of different 
electrolytes on the activity of streptomycin, with the greatest interference caused by 
magnesium and calcium [20].  Later, it was observed that Mg2+ and Ca2+ significantly 
increased MIC values of gentamicin for P. aeruginosa strains while for other Gram-
negative bacteria, including E. coli, Klebsiella pneumoniae and Serratia marcescens, this 
effect was less pronounced [21, 22].  This is in agreement with data from Gray and 
Wilkinson who observed a greater bactericidal effect of the divalent cation chelator, 
EDTA, on P. aeruginosa compared to E. coli, suggesting that LPS are more essential for 
structural integrity of the outer membrane of P. aeruginosa than for E. coli [23].  It was 
hypothesized that polycationic antibiotics cross the outer membrane of different Gram-
negative bacteria by replacing Mg2+ at their binding site on LPS, resulting in increased 
outer membrane permeability [13, 24], a process referred to as self-promoted uptake. 
In the present study we investigated the activity of tobramycin against several bacterial 
species in the presence and absence of divalent cations in order to determine whether 
self-promoted uptake is involved.  Based on these data, we developed tobramycin 
derivatives with possible selective activity.  The activity of these tobramycin derivatives 
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was tested on P. aeruginosa, E. coli, S. aureus and E. faecalis planktonic and biofilm 
cultures. 
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Materials and methods 
Strains 
Throughout the present study, different P. aeruginosa, E. coli, S. aureus and Bcc strains 
were used (Table 1, see Results section) to study tobramycin uptake.  MICs and 
bactericidal activity of tobramycin derivatives were determined for 4 quality control 
strains recommended by EUCAST for monitoring the microbroth dilution protocol for 
tobramycin MIC determinations, i.e. P. aeruginosa ATCC 27853, E. coli ATCC 25922, S. 
aureus ATCC 29213 and E. faecalis ATCC 29212.  All strains were obtained from the 
BCCM/LMG Bacteria Collection (Ghent University, Belgium) or were kindly provided by 
Dr. P. Vandamme.  Isolates from endotracheal tubes were previously isolated by our 
research group [25].  The bacteria were stored in Microbank tubes at -80°C and were 
transferred twice on MH agar before use in any experiment. 
Synthesis of tobramycin derivatives 
Three new tobramycin derivatives were synthesized and evaluated in this study (Fig. 1).   
 
Figure 1: Chemical structures of the tobramycin derivatives used in the present study. 
 
 
To allow derivatisation at position 6”, tobramycin was converted to the BOC-protected 
6”-azide intermediate 1 using known procedures (Scheme 1)[26]. Briefly, the sequence 
commenced with BOC-protection of all amine groups followed by regiospecific (6”-OH) 
sulfonylation using triisopropylbenzenesulfonyl chloride. Displacement of this sulfonate 
with sodium azide at elevated temperature afforded the azide intermediate 1. 
Staudinger reduction of 1 to the corresponding amine and subsequent conjugation with 
the activated succinimidyl ester of 4-azidobutyric acid [27] gave azidobutyramide 2. A 
second azide reduction, PyBop mediated condensation of known C-carboxy-EDTA 
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(5)[28], followed by acid mediated deprotection yielded EDTA fuctionalized tobramycin 
3 as the TFA salt in 72% yield.   
Since initial experiments indicated that the BODIPY fluorophore proved incompatible 
with the typical acidic conditions used to remove BOC groups, we pursued a strategy in 
which these protecting groups could be removed prior to introduction of the BODIPY 
fluorophore.  It was estimated that the copper catalyzed 3+2 azide alkyne cycloaddition 
(CuAAC), in which the 6”-azido group was used as ligation handle, would fit.  Thus, TFA-
mediated removal of the BOC groups of 1, followed by CuAAC with alkyne 6 [29], 
afforded, after purification by preparative TLC, the tobramycin-OH-BODIPY derivative 4. 
 
Scheme 1: Synthesis of tobramycin-OH-EDTA (3) and tobramycin-OH-BODIPY (4). Reagents and 
conditions: i) Me3P, THF, H2O. ii) 4-Azidobutyric acid N-hydroxysuccinimide ester, Et3N, DMF (82% 
two steps). iii) 5, PyBOP, DiPEA, DMF. iv) TFA, CH2Cl2 (3: 72% two steps 4: quant.). v) 6, CuI, DMF, 
H2O, Et3N (68 %). 
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The synthesis of tobramycin-N-Me2 commenced with the regiospecific Cbz protection of 
tobramycin using carbonate 9 and concomitant BOC protection of the remaining four 
amino groups (Scheme 2).  Hydrogenation in the presence of formaldehyde conveniently 
transformed the Cbz protected amine to the dimethylamino species in one step.  Acidic 
deprotection yielded 6-N,N-dimethyltobramycin (8) in 68% over two steps as the TFA 
salt.  Additional information concerning the synthesis of the tobramycin derivatives is 
added as supporting information at the end of this chapter. 
 
Scheme 2: Synthesis of tobramycin-N-Me2 (8). Reagents and conditions: i) 9, Et3N, DMSO, water. ii) 
Boc2O, Et3N, THF/H2O, 45°C (40% two steps). iii) H2, Pd/C, H2CO, HCO2H, MeOH. iv) TFA, CH2Cl2 
(68% two steps). 
 
 
 
Determination of the MIC of tobramycin and tobramycin derivatives in the presence and 
absence of Mg
2+
 
MICs were determined in duplicate according to the EUCAST standard broth 
microdilution protocol [30] using unsupplemented MH for standard MIC tests.  MICs 
were also determined in the presence of Mg2+ at concentrations without any effect on 
bacterial growth.  Mg2+ was added as magnesium acetate because acetate has no 
antagonistic effect on the growth inhibiting action of aminoglycosides [20].  Differences 
in MIC values in the presence of Mg2+ were considered biologically relevant if the 
decrease or increase observed was more than 2-fold compared to MICs determined in 
the absence of Mg2+.  Concentrations of all tobramycin derivatives are shown as the 
quantity of underivatized tobramycin per mL of antibiotic solution. 
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Determination of the MBC of tobramycin after EDTA pretreatment 
Standardized bacterial suspensions (OD=0.05; λ= 595 nm) were prepared in MH broth 
and were aerobically incubated in falcon tubes at 37°C with constant agitation.  After 
24h of incubation, tubes were vortexed until a homogenous suspension was obtained 
and centrifuged at 5000 rpm at 20°C during 5 min.  The supernatant was discarded and 
10 mL of physiological saline (0.9 % NaCl) (PS) was added in which the pellets were 
resuspended.  Suspensions were centrifuged a second time, supernatant was discarded 
and pellets were resuspended in 10 mL of PS.  4 mL of the bacterial suspension was 
transferred to a control tube and 4 mL was transferred to a test tube.  Both falcon tubes 
were centrifuged and supernatants were discarded.  Pellets were resuspended in 4 mL 
of Tris-HCl buffer (0.1 M, pH 8).  Subsequently, 4 mL of Tris-HCl buffer supplemented 
with 0.8 mM EDTA was added to the test tube.  The tube was vortexed and after exactly 
1 min, 100 µL of the suspension was transferred to 10 mL of PS in order to stop the 
EDTA chelating reaction.  This EDTA concentration and treatment duration had no 
growth inhibiting or bactericidal effect on its own (data not shown).  The control tube 
was treated with 4 mL of unsupplemented Tris-HCl buffer during 1 min before 100 µL 
was transferred to 10 mL of PS.  These suspensions (∼ 5 X 105 CFU/mL) were used to 
inoculate the wells of a 96 well mictrotitre plate filled with tobramycin at concentrations 
ranging from 2048 mg/L to 16 mg/L for Bcc strains and ranging from 128 mg/L to 1 
mg/L for P. aeruginosa, S. aureus and E. coli strains.  Control wells without antibiotic 
were also included.  After 24h of incubation at 37°C the content of the wells was 
streaked on agar plates and these were incubated for another 24h at 37 °C.  CFUs were 
determined and compared to control conditions.  The MBC was considered as the 
concentration of the antibiotic required to kill at least 99.9% of the bacteria.  Differences 
in MBC values were considered biologically relevant if the increase or decrease 
observed was more than 2-fold compared to MBCs determined without EDTA 
pretreatment. 
Bactericidal effect of tobramycin and tobramycin derivatives on biofilms 
Biofilms were grown in a round-bottomed 96-well microtitre plate.  Wells were 
inoculated with 100 µL of a standardized bacterial suspension in MH broth (108 
CFU/ml).  After 4h of incubation at 37°C, the supernatant containing planktonic cells 
was aspirated from the wells and adhered cells were carefully rinsed with PS.  
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Subsequently, 100 µL of fresh sterile MH was added to the wells and plates were 
incubated for another 20h at 37°C.  After 24h of biofilm formation, biofilms were rinsed 
with PS and treated with tobramycin or with a tobramycin derivative at concentrations 
4XMIC in PS.  Plates were incubated for an additional 24h at 37°C, followed by 
determination of cell numbers by plate counting.  These experiments were performed in 
12 wells per condition and the content of the wells was pooled before plate counting.  
Experiments were repeated three times on three separate occasions (n=3).  The 
significance of differences between treatment groups was determined using the Mann-
Whitney non-parametric test, with p < 0.05 considered significant. 
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Results and discussion 
MICs of tobramycin in the presence and absence of Mg2+ 
The self-promoted uptake mechanism is associated with a well-known antagonistic 
effect between divalent cations and aminoglycosides in several Gram-negative 
organisms as both molecules compete for the same binding site on LPS [31].  In the 
present study, we investigated the effect of Mg2+ on the activity of tobramycin against 6 
P. aeruginosa strains, 2 S. aureus strains, 8 E. coli strains and 26 Bcc strains (Table 1) in 
order to determine if tobramycin uptake occurs through self-promoted uptake.   
 
Table 1: Strains used in the present study with their corresponding tobramycin MICs in the 
presence and absence of Mg2+. 
Strain Isolation source 
Tobramycin 
MIC 
Tobramycin MIC in 
the presence of Mg2+ 
Pseudomonas aeruginosa ATCC 9027 Outer ear infection 1 8-16 * 
P. aeruginosa ATCC 15442 Animal room water bottle 1 8 * 
P. aeruginosa PAO1 Infected wound 1-2 4 * 
P. aeruginosa JWJ Endotracheal tube 2 4 
P. aeruginosa LMW 1 Endotracheal tube 1-2 4 * 
P. aeruginosa MPM 1 Endotracheal tube 32 32-64 
Staphylococcus aureus HYL MRSA+ Endotracheal tube 2 4 
S. aureus DWR 1 Endotracheal tube 1 2 
Escherichia coli K12 Human faeces 1 1 
E. coli ATCC 8739 Faeces 4 2 
E. coli DH5α Developed in the laboratory 1-2 0.5-1 
E. coli BC 1 Endotracheal tube 2 2-4 
E. coli ECE Endotracheal tube 2 2-4 
E. coli HYL Endotracheal tube 2 2 
E. coli VA Endotracheal tube 2-4 2-4 
E. coli BC 2 Endotracheal tube 2 2 
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Burkholderia cepacia LMG 1222 Onion 16-32 8 
B. multivorans LMG 18822 CF (CF) patient, Canada 128 32-64 
B. multivorans LMG 18825 CF patient, UK 128 64 
B. multivorans LMG 13010 CF patient, Belgium 32-64 32 
B. multivorans LMG 17588 Soil, USA 64 16 * 
B. cenocepacia LMG 16656 CF patient, sputum, UK 256 256 
B. cenocepacia LMG 18828 CF patients, Canada 128 128 
B. cenocepacia LMG 18829 CF patient, USA 128 32 * 
B. stabilis LMG 14086 Respirator, UK 16 16 
B. vietnamiensis LMG 10929 Rhizosphere soil, Vietnam 16 4-8 
B. dolosa LMG 18943 CF patient, USA 64-128 64 
B. dolosa LMG 18941 CF patient, USA 256 128 
B. ambifaria LMG 19182 Pea rhizosphere 16 8 
B. ambifaria LMG 19467 CF patients, Australia 128 64 
B. anthina LMG 20980 Soil, USA 8-16 8 
B. antina LMG 20983 CF patient, sputum, UK 16 4 * 
B. pyrrocinia LMG 14191 Soil, Japan 32 8-16 
B. ubonensis LMG 20358 Soil, Thailand 32-64 32 
B. ubonensis LMG 24263 Nosocomial infection, Thailand 64 32 
B. diffusa LMG 24065 CF patient, USA 64 64 
B. diffusa LMG 24266 CF patient, Canada 32-64 32 
B. seminalis 24067 CF patient, USA 64 64 
B. seminalis LMG 24272 Nosocomial infection, Thailand 32-64 32 
B. metallica LMG 24068 CF patient, USA 64 32 
B. metallica R-2712 CF patient, Canada 64 64 
B. lata LMG 6992 Soil, Trinidad & Tobago 64 64 
All MICs were determined in duplicate; if two different values were obtained, both are represented in the 
table. 
Mg2+ was added at concentrations of 25 mM to P. aeruginosa, E. coli and S. aureus cultures and at 
concentrations of 6.25 mM to Bcc cultures as 25 mM had a growth inhibiting effect on Bcc strains. 
*: Different MIC compared to MIC determined in the absence of Mg2+. 
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Four P. aeruginosa strains showed an increased MIC in the presence of Mg2+ compared 
with control MICs, confirming the hypothesis of self-promoted uptake of 
aminoglycosides in P. aeruginosa [32].  MICs of tobramycin for the E. coli strains tested 
were not altered by the presence of Mg2+.  Medeiros et al. previously investigated the 
effect of different salt concentrations on the in vitro susceptibility of some Gram-
negative bacteria to aminoglycosides [21].  Although they observed an antagonistic 
effect of 30 mM MgCl2 on gentamicin and kanamycin activity for E. coli in nutrient broth, 
this could not be confirmed in MH broth.  In contrast, the antagonistic effect of Mg2+ on 
gentamicin and kanamycin activity for P. aeruginosa was retained both in nutrient and 
MH broth, suggesting that additional environmental factors play a role in the uptake of 
aminoglycosides in E. coli, e.g ionic strength (conductivity in MH broth is five times 
higher than in nutrient broth).  The addition of Mg2+ had a growth inhibiting effect on 
Bcc strains (data not shown),  therefore, Mg2+ concentrations used were 4 times lower 
(6.25 mM) compared to the concentrations used for MIC determinations for P. 
aeruginosa, E. coli and S. aureus (25 mM).  Still, even at these lower concentrations, an 
overall trend of decreased MIC values in the presence of Mg2+ was observed.  This effect 
was biologically relevant for B. multivorans LMG 17588, B. cenocepacia LMG 18829 and 
B. anthina LMG 20983.  Although it has been demonstrated that polymyxin binds to 
purified Burkholderia LPS molecules at the same binding sites of Mg2+, it was not capable 
of binding to whole cells [33].  Probably, the negative charges on Burkholderia LPS are 
partially shielded, inhibiting binding of polycationic antibiotics.  Some Gram-negative 
organisms, including Bcc, modify their LPS through the addition of 4-amino-4-deoxy-L-
arabinose molecules to the lipid A residue, neutralizing the negative charge of the 
phosphate groups to which polycations bind [34].  It has been shown that Bcc lipid A 
molecules contain at least one 4-amino-4-deoxy-L-arabinose molecule [35], resulting in 
poor binding of polycationic antibiotics to Bcc outer membrane LPS.  In accordance with 
previous data, our results suggest that another mechanism besides self-promoted 
tobramycin uptake exists in Bcc strains [33, 36] and that Mg2+ ions probably influence 
other processes involved in tobramycin susceptibility.   
Because of the lack of an outer membrane, Gram-positive microorganisms are not 
capable of carrying out self-promoted uptake and as was expected, no influence of Mg2+ 
ions on the MIC of tobramycin for S. aureus was observed.     
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MBC of tobramycin after EDTA pretreatment 
If tobramycin enters the bacterial cell through self-promoted uptake, its uptake should 
increase after pretreating bacterial cells with divalent cation-chelating components, 
including EDTA.  It is essential to perform these EDTA assays on bacteria grown in 
media with sufficiently high Mg2+ concentrations as the effect of EDTA is correlated with 
the quantity of Mg2+ ions in the bacterial outer membrane.   
 
Table 2: MBC of tobramycin after EDTA pretreatment. 
Strain MBC MBC after EDTA pretreatment 
P. aeruginosa ATCC 9027 2 0.5* 
P. aeruginosa MPM 1 > 64 32* 
S. aureus HYL MRSA+ 32 32 
S. aureus DWR 1 4 4 
E. coli K12 64 32 
E. coli HYL 32 16 
B. cenocepacia LMG 16656 256 512 
B. multivorans LMG 13010 128 128 
*: Different MBC compared to MBC determined without  EDTA pretreatment. 
 
We observed an increased susceptibility of P. aeruginosa to tobramycin when cells were 
pretreated with EDTA, confirming the hypothesis of self-promoted uptake for 
tobramycin in P. aeruginosa (Table 2).  No difference in MBC values, determined with or 
without EDTA pretreatment, was observed for E. coli (Table 2).  This observation 
confirms that self-promoted uptake is not the only route for tobramycin uptake in E. coli, 
and that it is likely that E. coli also uses the hydrophilic porin-protein uptake pathway 
for aminoglycosides [37, 38].  Hancock et al. noticed an outer membrane permeabilizing 
effect of aminoglycosides in E. coli favouring the self-promoted uptake mechanism [39].  
However, they also observed a superior affinity of aminoglycosides for LPS compared to 
Mg2+, indicating that Mg2+ could only compete for the aminoglycoside binding site at 
sufficiently high concentrations.  This could explain the lack of biologically relevant 
differences in MIC and MBC values in the presence and absence of divalent cations in the 
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present study.  For the Bcc strains tested no difference in MBC values determined with 
or without EDTA pretreatment was observed, confirming our hypothesis that Bcc strains 
are not using the self-promoted uptake pathway for tobramycin.  As was expected, S. 
aureus strains also showed no difference in MBC values with or without EDTA 
treatment.   
MICs of tobramycin derivatives 
Based on previous studies we chose to modify the 6’’ primary alcohol of tobramycin 
with two different substituents.  Tobramycin-OH-BODIPY was synthesized for another 
study on biofilm penetration of this aminoglycoside using confocal scanning microscopy. 
The results obtained with pretreatment of EDTA on the activity of tobramycin against P. 
aeruginosa, encouraged us to synthesize a tobramycin conjugate with this cation 
chelator, tobramycin-OH-EDTA.   
Aminoglycoside modifying enzymes play an important role in bacterial resistance 
against aminoglycosides.  Aminoglycoside acetyltransferases are known to be one of the 
most important determinants to infer resistance to aminoglycosides [40].  Recently, Yan 
et al. have demonstrated that acetylation at the 6’-NH2 group is sufficient to increase the 
MIC to a clinically ineffective level [41].  Possibly the loss of the positive charge at 
physiological conditions is at the basis of this loss of activity.  This led us to synthesize a 
6’-dimethylamine derivative (tobramycin-N-Me2) that is insusceptible to the 
abovementioned acylation.  We tested the activity of these three tobramycin derivatives 
(Table 3).  Tobramycin-OH-BODIPY and tobramycin-N-Me2 were the most active 
derivatives, with the lowest MIC values for P. aeruginosa.  According to NCCLS 
breakpoints for tobramycin intravenous therapy [42], E. coli ATCC 25922, S. aureus 
ATCC 29213 and E. faecalis ATCC 29212 are resistant to all of these derivatives, while P. 
aeruginosa ATCC 27853 is intermediately susceptible to tobramycin-OH-BODIPY and 
tobramycin-N-Me2 and is resistant to tobramycin-OH-EDTA.  Surprisingly, the 
tobramycin-OH-EDTA derivative shows the highest MICs for all organisms tested while 
we expected that by chelating divalent cations it would be more active against P. 
aeruginosa compared to other organisms in which self-promoted uptake does not occur.  
In P. aeruginosa, a mechanism conferring resistance against polycations is regulated by 
the PhoPQ and PmrAB two-component systems [43, 44].  Under low Mg2+ conditions 
these two-component systems are activated, resulting in the addition of 4-amino-deoxy-
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L-arabinose to lipid A which reduces the outer membrane permeability to polycations 
[45].  Through the Mg2+ chelating capacity, a Mg2+-limited environment can be created 
which could explain the high MIC values of tobramycin-OH-EDTA for P. aeruginosa.  If E. 
coli would use the hydrophilic pathway for aminoglycoside uptake one would expect a 
high MIC value for bulky tobramycin derivatives, including tobramycin-OH-BODIPY and 
tobramycin-OH-EDTA, as these molecules are too big to be taken up through E. coli 
porins.  Porins on the outer membrane of E. coli cells exclude molecules bigger than 500 
to 600 daltons, approaching the size of aminoglycosides [16].  The MIC value of 
tobramycin-OH-BODIPY for E. coli is not that high (32 mg/L) as would  be expected 
based on uptake exclusively through porins.  Therefore, we hypothesize that E. coli, at 
least in part, uses self-promoted uptake for aminoglycosides, including tobramycin.  It 
has been shown that EDTA and polycations can permeabilize the outer membrane of P. 
aeruginosa to lysozyme, a protein of 14000 daltons [13].  This suggests that self-
promoted uptake can facilitate the uptake of large molecules while the hydrophilic 
uptake route through outer membrane porins is dependent on porin sizes.  The 
exclusion limits of these porins likely only permit the uptake of smaller molecules like 
tobramycin-N-Me2. 
 
Table 3: MICs of tobramycin and tobramycin derivatives (experiments were performed in 
duplicate). 
Strain Tobramycin 
Tobramycin + 
25 mM Mg2+ 
Tobramycin-
BODIPY-OH 
Tobramycin-
NMe2 
Tobramycin-
EDTA-OH 
P. aeruginosa 
ATCC 27853 
0.5 4 8 8 512 
E. coli  
ATCC 25922 
1 2 32 32 512 
S. aureus  
ATCC 29213 
1 1 > 32 16 256 
E. faecalis 
 ATCC 29212 
16 32 > 32 > 32 > 512 
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Bactericidal effect of tobramycin and tobramycin derivatives on biofilms 
The activity of tobramycin-OH-BODIPY and tobramycin-N-Me2 was tested on P. 
aeruginosa, E. coli, S. aureus and E. faecalis biofilms at concentrations of 64 mg/L.  The 
tobramycin-OH-EDTA derivative was only tested on P. aeruginosa and E. coli biofilms 
(Figure 2).   
 
Figure 2: Number of CFU in biofilms after treatment with tobramycin or tobramycin derivatives.  
Cell numbers of untreated biofilms are added as a reference. (Data shown are averages ± SD) 
 
*: Significantly different from untreated biofilms (p < 0.05) (n=3) 
 
Tobramycin at concentrations of 4 mg/L did not result in a significant bactericidal effect 
for any of the strains tested.  The tobramycin-OH-BODIPY derivative showed a small, but 
significant bactericidal effect on S. aureus ATCC 29213 biofilms.  The tobramycin-N-Me2 
demonstrated a selective bactericidal effect towards P. aeruginosa ATCC 27853 biofilms.  
This selective activity is likely linked to the biofilm phenotype as the MIC value of this 
derivative for P. aeruginosa did not differ from the MIC for S. aureus and differed only 4 
fold from the MIC for E. coli.  Finally, tobramycin-OH-EDTA had approximately the same 
activity against P. aeruginosa biofilms as the tobramycin-N-Me2 derivative.  Surprisingly, 
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this derivative showed high activity against E. coli biofilms.  Although MIC values of 
tobramycin-OH-EDTA for E. coli and P. aeruginosa were the same (512 µg/mL), this 
antibiotic was capable of almost totally eradicating E. coli biofilms (∼ 7 log reduction in 
CFUs compared to untreated controls) while resulting only in approximately 2 log 
reductions for P. aeruginosa biofilms.  A possible explanation for the lower activity of 
tobramycin-OH-EDTA against P. aeruginosa biofilms could be that by chelating divalent 
cations, more negatively charged groups are exposed in the biofilm matrix.  These 
negatively charged groups, e.g. on alginate or eDNA, can interact with positively charged 
tobramycin residues, delaying the penetration of the antibiotic into the biofilm [46].  It is 
well-known that P. aeruginosa biofilms have large amounts of eDNA in their biofilm 
matrix, and that this eDNA is capable of binding Mg2+ [47].  Less is known about the 
amount of eDNA in E. coli biofilms and further research would be needed to confirm our 
hypothesis.  The high activity of tobramycin-OH-EDTA against E. coli biofilms implies 
that this molecule is taken up into the cell.  As this molecule is too large to be taken up 
by porins, this supports our hypothesis that E. coli also uses self-promoted uptake for 
aminoglycosides. 
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Conclusion 
In the present study, we investigated the mode of uptake of tobramycin in different 
Gram-negative bacteria.  The self-promoted uptake route for aminoglycosides in P. 
aeruginosa was confirmed.  Our data also indicated the lack of self-promoted uptake in 
Bcc strains.  For E. coli, we hypothesized that tobramycin is taken up, at least in part, 
through self-promoted uptake.  We identified a tobramycin derivative (tobramycin-N-
Me2) with selective activity against P. aeruginosa biofilms and one (tobramycin-OH-
EDTA) with high activity towards E. coli biofilms.  The use of selective antibiotics could 
have major advantages in the clinic.  By selectively targeting some or only one 
pathogenic species, the commensal flora of the patient will be less disturbed compared 
to traditional antibiotic therapy.  This will reduce the number and frequency of side 
effects associated with antibiotic therapy, including gastro-intestinal complaints.  In 
addition, the selection for antibiotic-resistant organisms during therapy will diminish. 
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Supporting information 
 
General experimental organic synthesis 
All reactions described were performed under an argon atmosphere and at ambient 
temperature unless stated otherwise. Tobramycin was purchased from TCI Europe  All 
other reagents and solvents were purchased from Sigma, Aldrich, Acros Organics used 
as received. Reactions were monitored by TLC analysis using TLC aluminum sheets 
(Macherey-Nagel, Alugram Sil G/UV254) with detection by spraying with a solution of 
(NH4)6Mo7O24•4H2O (25 g/L) and (NH4)4Ce(SO4)4•2H2O (10 g/L) in H2SO4 (10%) 
followed by charring or Ninhydrin (2% in ethanol). Column chromatography was 
performed on Biosolve 60Å silica gel (32-63 μm). High resolution mass spectra were 
recorded with a Waters LCT Premier XE Mass spectrometer. 1H-and 13C-NMR spectra 
were measured on a Varian Mercury-300BB (300/75 MHz), an Avance II Bruker 
(700/176 MHz) spectrometer equipped with a 1H/13C/15N TXI-Z probe or an Avance III 
Bruker spectrometer operating at a 1H frequency of 500 MHz, equipped with a BBI 
probe. Chemical shifts are given in ppm (δ) relative to tetramethylsilane as an internal 
standard (1H NMR) or CDCl3, CD3OD or SO(CD3)2 (13C NMR). Coupling constants are 
given in Hz.  
 
 
 
To a solution of 6”-azido-(penta-NHBoc)-tobramycin (1)[1] (0.50 mmol, 497 mg) in THF 
(5 mL) is added Me3P (5.0 mL, 1.0M in THF, 10eq.). After stirring for 4h, the solution is 
concentrated in vacuo and the residue is dissolved in water (5 mL). After 1h the solution 
is taken to dryness, coevaporated thrice with (ClCH2)2 (2 mL) and taken up in DMF (5 
mL). 4-Azidobutyric acid N-hydroxysuccinimide ester [2] (0.7 mmol, 159 mg) and 
triethylamine (200 µl) are added and the solution is stirred overnight. The reaction is 
taken to dryness and purified via silica gel chromatography (015% MeOH in CH2Cl2). 
Product fractions are collected concentrated and taken up in CH2Cl2 and precipitated 
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with cold hexane yielding the product (2) (442 mg, 0.41 mmol, 82%) as an off white 
amorphous solid. (ESI-MS for C47H84N9O19 [M+H] found, 1078.5933 ; calcd, 1078.5883) 
 
 DMSO-d6  
1H 
700/176 
MHz 
13C 
   
1H 
 
13C 
Ring A    Ring C   
1 4.97 98.0  1  4.93 98.3 
2 3.50 50.0  2 3.26 70.8 
3 1.89 33.6  3 3.52 55.6 
 1.51   4 3.00 68.8 
4 3.36 65.1  5 3.92 71.7 
5 3.55 71.8  6 3.40 40.3 
6 3.29 41.8   3.19  
 3.24   Linker   
Ring B    1 - 173.0 
1 3.44 81.8  2 2.21 32.4 
2 3.49 75.2  3 1.76 24.9 
3 3.39 82.2  4 3.34 50.8 
4 3.39 49.8     
5 1.83 35.2     
 1.43      
6 3.37 50.2     
 
 
 
To a solution of 4-Azidobutyryl tobramycin (2) (400 mg, 0.37 mmol) in THF (10 mL) is 
added Me3P (3.0 mL, 1.0 M, 3.0 mmol) and the mixture is stirred for 4h. Water (1 ml) is 
added and stirring is continued for 1h. The mixture ins concentrated in vacuo and 
coevaporated twice with (ClCH2)2 (3 mL). The residue is dissolved in DMF (20 mL). To 
the solution are added EDTA-tetra-tert-butylester carboxylic acid [3] (280 mg, 0.5 
mmol), PyBop (234 mg, 0.45 mmol) and triethylamine (300 µl). The mixture is stirred 
overnight, concentrated in vacuo and the residue is purified on silica gel 
chromatography (015% MeOH in CH2Cl2) to yeld the fully protected derivative (ESI-
MS for C74H132N9O28 [M+H] found, 1594,9191 ; calcd, 1594,9176).  The material is taken 
up in a mixture of CH2Cl2 (4 mL) and TFA (4mL) for 90 minutes and concentrated in 
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vacuo yielding the deprotected product (3) (444 mg, 0.27 mmol, 72%) as a beige 
amorphous powder. (ESI-MS for C33H60N9O18 [M+H] found, 870.4066 ; calcd, 870.4056) 
 
 DMSO-d6  
1H 
700/176 
MHz 
13C 
   
1H 
 
13C 
Ring A    Ring C   
1 5.81 91.9  1  4.96 99.8 
2 3.41 47.5  2 3.70 68.1 
3 1.97 29.9  3 3.10 54.3 
 2.03   4 3.31 66.1 
4 3.40 64.3  5 3.78 70.7 
5 3.74 69.7  6 3.79 54.2 
6 3.24 39.7  Linked EDTA   
 2.92   1 - 173.3 
Ring B    2 2.14 32.3 
1 3.55 83.3  3 1.63 24.97 
2 3.63 73.7  4 3.04 38.1 
3 3.79 75.7  5 - 170.0 
4 3.28 48.0  6 3.67 60.7 
5 2.40 27.4  7 3.19 53.7 
 1.75   8 3.38 38.9 
6 3.39 49.4   3.03  
    9 3.56 52.6 
     3.46  
 
 
 
6”-azido-(penta-NHBoc)-tobramycin (149 mg, 0.15 mmol)  was taken up in a mixture of 
TFA and CH2Cl2 (5mL, 1:1 v/v) and stirred for 2h. The solution was taken to dryness and 
dissolved in DMF (2.5 mL). Added are CuI (29 mg, 0.15 mmol, 1 eq), Et3N (50 µL) and 
BODIPY alkyne 6 [4] (50 mg, 0.15 mmol, 1 eq). The reaction mixture was stirred for 4h 
at room temperature and concentrated in vacuo. Purification with preparative TLC 
(CH2Cl2/MeOH/NH4OH) afforded the desired fluorescent triazole conjugate (4) (102 mg, 
0.10 mmol 68 %). ESI-MS for C37H59BF2N10O8 [M+H] found, 821.4665; calcd, 821.4651. 
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 DMSO-d6  
1H 
700/176 
MHz 
13C 
   
1H 
 
13C 
Ring A    Ring C   
1 4.80 100.36  1  4.94 99.53 
2 2.75 49.26  2 3.06 72.08 
3 1.42 37.12  3 2.87 55.07 
 1.82   4 2.80 70.71 
4 3.17 65.97  5 4.21 69.69 
5 3.44 73.27  6 4.39 50.35 
6 2.57 42.15   4.49  
 2.86   BODIPY   
Ring B    1/12 2.38 13.91 
1 2.98 86.08  2/4/9/11 - 140.7 
2 3.29 74.06  5/13 2.37 15.82 
3 2.92 89.7  3/10 6.21 121.43 
4 2.54 49.65  15 1.63 30.54 
5 0.99 38.39  16 1.81 29.18 
 1.77   17 2.68 24.49 
6 2.56 51.44  14 2.95 27.43 
    19 7.86 122.78 
    6/8 - 130.6 
    7 - 152.9 
    18 - 146.8 
 
 
 
Tobramycin (1.87 g, 4 mmol) is taken up in a mixture of DMSO (200 mL) and water (20 
mL). To this solution are added: N-Benzyloxycarbonyloxy-5-norbornene-2,3-
dicarboximide [5] (1.253 g, 4.0 mmol) and triethylamine (600 µl). The mixture is stirred 
overnight and concentrated in vacuo. The residue is purified by silica gel 
chromatography (CH2CH2/MeOH/NH4OH, 5/4/1, v/v/v). The monoprotected 
aminoglycoside (950 mg, 1.57 mmol) is dissolved in a mixture of THF (70 mL) and water 
(70mL). Next di-tert-butylpyrocarbonate (1.75 g , 8.0 mmol) and triethylamine (500µL) 
are added and the mixture is heated to 45°C for 16 h. The solution in concentrated 
vigorously and the residue is precipitated from a mixture of dichloromethane and 
hexanes to yield the protected tobramycin (7) (1.6 g, 1.57 mmol, 40% based on 
tobramycin) as an off white amorphous powder. ESI-MS for C46H76N5O19 [M+H] found, 
1002,5151; calcd, 1002,5129. 
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 DMSO-d6  
1H 
700/176 
MHz 
13C 
   
1H 
 
13C 
Ring A    Ring C   
1 4.92 98.0  1  4.92 98.3 
2 3.49 50.0  2 3.28 70.7 
3 1.88 33.7  3 3.52 56.2 
 1.51   4 3.28 67.5 
4 3.36 64.9  5 3.76 73.6 
5 3.56 71.8  6 3.55 60.6 
6 3.43 42.2     
 3.26   Cbz   
Ring B    C=O  157.1 
1 3.41 82.3  CH2 5.04 65.7 
2 3.48 75.2  Ph 7.32 128.2 
3 3.38 82.2   7.37 128.8 
4 3.38 49.7   7.37 128.2 
5 1.85 35.3     
 1.38      
6 3.36 50.0     
 
 
 
Protected tobramycin 7 (501 mg, 0,5 mmol) is taken up in methanol (50 mL) and the 
vessel is purged with nitrogen. To the solution are added formaldehyde (1 mL, 38% aq.), 
formic acid (1 mL) and Palladium on charcoal (50 mg, 10% Pd). Hydrogen is bubbled 
through the black suspension for 2 h. The mixture is filtered taken to dryness and the 
residue is purified by silica gel chromatography (CH2Cl2/MeOH/Et3N 40:10:0.1 v/v/v) 
to yield the protected dimethylamino species. (ESI-MS for C40H74N5O17 [M+H] found, 
896.5109; calcd, 896.5080). The material is taken up in CH2Cl2 (5 mL) and TFA (5mL) 
for 1h and taken to dryness. The residue is lyophilized (tBuOH/H2O) to yield the product 
(8) (362 mg, 0.34 mmol, 68%)  as a beige amorphous solid. ESI-MS for C20H42N5O9 
[M+H] found, 496,2967; calcd, 496,2977. 
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 D2O 
1H 
700/176 
MHz 
13C 
   
1H 
 
13C 
Ring A    Ring C   
1 5.72 93.8  1  5.03 100.7 
2 3.61 47.5  2 3.88 67.9 
3 2.21 29.0  3 3.41 54.7 
 1.97 29.0  4 3.63 65.3 
4 3.69 64.7  5 3.84 73.0 
5 4.06 69.6  6 3.78 59.7 
6 3.46 58.2   3.71 59.7 
    NMe2   
Ring B    Mea 2.90 43.9 
1 3.71 83.7  Meb 2.93 45.1 
2 3.80 74.0     
3 3.92 77.4     
4 3.49 48.3     
5 2.48 27.7     
 1.88 27.7     
6 3.53 49.5     
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ABSTRACT 
 
Bcc organisms produce a wide variety of potential virulence factors, including 
exopolysaccharides, and exhibit intrinsic resistance towards many antibiotics.  In the 
present study we investigated the contribution of Bcc biofilm matrix components, 
including eDNA, cepacian and PNAG, to tobramycin susceptibility.  To this end, the in 
vitro bactericidal activity of tobramycin in combination with rhDNase, NaClO and 
dispersin B was tested against Bcc biofilms.  Exopolysaccharide degradation by NaClO 
pretreatment and specific PNAG degradation by dispersin B significantly increased the 
bactericidal effect of tobramycin towards some of the Bcc biofilms tested, including 
strains of B. cenocepacia, B. cepacia and B. metallica.  The presence of rhDNase during 
biofilm treatment and/or development had no influence on tobramycin activity.  These 
results suggest that exopolysaccharides play a role in tobramycin susceptibility of Bcc 
biofilms and that matrix degrading combination therapy could improve treatment of Bcc 
biofilm infections. 
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Introduction 
Chronic P. aeruginosa lung infections are the primary cause of morbidity and mortality 
in CF patients [1].  Although P. aeruginosa is the dominant pathogen isolated from the 
chronically infected CF lung, infections with Bcc species often lead to a more rapid 
decline in lung function, resulting in increased mortality [2].  Chronic Bcc infections are 
very difficult to eradicate because of the capacity of Bcc species to cause invasive disease  
and their high level of intrinsic antibiotic resistance.  The production of different 
exopolymeric substances by mucoid Bcc bacteria provides additional protection against 
both antibiotics and host immune components [3].  Exopolysaccharides produced by 
Burkholderia cenocepacia have been shown to inhibit neutrophil chemotaxis and to 
reduce the levels of neutrophil derived ROS [4].  This reduction in ROS levels is caused 
by the ROS-scavenging capacities of these exopolysaccharides [4].  Cuzzi et al. observed 
a protective effect of cepacian, a Bcc specific exopolysaccharide, against hypochlorite 
(ClO-), a highly bactericidal ROS produced by neutrophils.  This protective effect was 
also provided by scavenging, resulting in extensive deacetylation of cepacian followed 
by degradation of the polysaccharide backbone [5].  Although cepacian is the most 
common exopolysaccharide produced by Bcc species, the production of at least six other 
polysaccharides, either synthesized alone or in combination with cepacian, has been 
demonstrated [6].  B. vietnamiensis LMG 10929, used in this study, has been shown not 
to produce cepacian as main exopolysaccharide but a polysaccharide containing a fucose 
residue in its backbone. In addition, the production of PNAG, also known as PIA, an 
important virulence factor and major constituent of staphylococcal biofilms, has been 
documented in several Bcc biofilms [7].  Although it appears to be a minor component 
compared to cepacian it seems essential for initiating biofilm formation as well as 
maintaining biofilm integrity.  Dispersin B, an enzyme capable of degrading PNAG, was 
first isolated from the periodontal pathogen Actinobacillus actinomycetemcomitans [8].  
Since its discovery in 2004, dispersin B is widely investigated as a biofilm removing 
agent and as a possible coating agent to prevent biofilm formation primarily focusing on 
Staphylococcus epidermidis biofilms [9-11].  Apart from exopolysaccharides, another 
important constituent of the biofilm matrix  is eDNA.  Most research about the 
contribution of eDNA to biofilm formation and resistance has focused on P. aeruginosa in 
which eDNA appears to be essential for the formation and stabilization of a complex 
biofilm structure [12].  Witchurch et al. first demonstrated a reduction in P. aeruginosa 
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biofilm formation in the presence of DNase.  Subsequently, the contribution of eDNA to 
biofilm formation of a variety of bacterial species, including S. epidermidis and S. aureus, 
was investigated [13-15].  In P. aeruginosa and Salmonella enterica biofilms the 
contribution of eDNA to aminoglycoside tolerance has already been shown.  By binding 
divalent cations, a cation-limited environment is created which in turn induces the 
expression of pmr genes conferring resistance towards aminoglycosides [16, 17].  In 
addition, Chiang et al. observed a shielding effect of eDNA in P. aeruginosa biofilms, 
mediating a delayed penetration of aminoglycosides [18].  Still, little is known about the 
role of eDNA in Burkholderia biofilms, although it seems to be essential for cellular 
aggregation in Burkholderia thailandensis [19]. 
The aim of the present study was to investigate whether Bcc biofilm matrix components, 
including eDNA, cepacian and PNAG play a role in the protection of biofilm cells against 
tobramycin.  To this end, the bactericidal effect of tobramycin in combination with 
matrix degrading components (rhDNase, NaClO and dispersin B) was tested against 
several in vitro grown Bcc biofilms and compared with the bactericidal effect of 
tobramycin alone. 
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Materials and methods 
Bcc Strains 
Strains used (Table 1) were obtained from the BCCM/LMG Bacteria Collection (Ghent, 
Belgium) or were kindly provided by Dr. P. Vandamme (Ghent University, Belgium).  The 
bacteria were stored in Microbank tubes (Prolab Diagnostics, Richmond Hill, ON, 
Canada)  at -80°C and transferred twice on MH (Lab M, Heywood, UK) agar plates before 
use in any experiment.  All cultivations were performed under aerobic conditions at 
37°C. 
Table 1: Bcc strains used in the present study. 
Strain Isolation source Tobramycin MIC (µg/mL) 
Burkholderia cenocepacia LMG 16656 CF patient 256 
Burkholderia multivorans LMG 13010 CF patient 64 
Burkholderia cepacia LMG 1222 Onion 32 
Burkholderia anthina LMG 20980 Soil 16 
Burkholderia vietnamiensis LMG 10929 Soil 16 
Burkholderia metallica LMG 24068 CF patient 64 
Reagents 
A highly purified solution of rhDNase (1.0 mg/mL) (Pulmozyme, Genentech Inc., San 
Francisco, CA, USA) which selectively degrades DNA, was obtained from the pharmacy of 
the Ghent University hospital (Ghent, Belgium).  It was stored between 2-8°C, protected 
from light.  A NaClO solution (4–4.99% available chlorine), was purchased from Sigma-
Aldrich (St. Louis, MO, USA) and stored between 2-8°C protected from light.  Lyophilized 
dispersin B was obtained from Kane Biotech Inc. (Winnipeg, MB, Canada) and was 
dissolved in equal volumes of glycerol and 100 mM phosphate buffer pH 5.9, 
supplemented with 200 mM NaCl.  The dispersin B solution was stored at -20°C. 
Biofilm formation 
An inoculum was prepared by suspending bacteria from a pure culture on MH agar in 
MH broth.  The inoculum was standardized at ∼108 CFU/mL and the wells of a round-
bottomed 96-well microtitre plate (TPP, Trasadingen, Switzerland) were filled with 100 
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µL of this standardized bacterial suspension.  Plates were incubated at 37°C for 4h 
without shaking.  After 4h, the supernatant, containing planktonic cells, was aspirated 
from the wells.  Adhered cells were carefully washed with 100 µL of PS and 100 µL of 
fresh sterile MH broth was added.  Plates were incubated for another 20h at 37°C 
without shaking. 
Quantification of eDNA in the biofilm matrix 
Eppendorf protein LoBind microcentrifuge tubes (1.5 mL) (Eppendorf AG, Hamburg, 
Germany) were inoculated with 600 µL of a standardized bacterial solution (∼108 
CFU/mL) in cation-supplemented MH broth (0.015 % (w/v) CaCl2; 2.0 mM MgCl2) (csMH 
broth), with or without the addition of rhDNase (50 µg/mL).  Experiments were 
performed in csMH broth as Ca2+ and Mg2+ are essential for DNase I activity [20].  Tubes 
were incubated aerobically for 4h at 37°C without shaking.  After 4h, the supernatant 
was gently poured from the tubes to remove non-adhered planktonic cells.  Tubes were 
rinsed with PS followed by the addition of 600 µL of fresh sterile csMH broth, with or 
without 50 µg/mL rhDNase.  After 20h of additional incubation, a biofilm had formed on 
the walls of the tubes (Figure 1) and these were gently rinsed with PS without 
disturbing the adherent film.  Subsequently, 300 µL of DNA rehydration solution 
(Promega, Madison, WI, USA) was added and biofilms were dispersed in this solvent by 
vortexing the tubes. 
 
Figure 1: Determination of cell numbers in Burkholderia biofilms in the presence (grey bars) and 
absence (white bars) of rhDNase when grown in centrifuge tubes.  (Data shown are averages ± SD) 
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Biofilm cells were separated from the matrix by centrifugation at 5000g for 10 min at 
4°C.  The supernatant was aspirated and filtered through a 0.2 µm cellulose acetate filter 
(Whatman GmbH, Dassel, Germany) and the amount of eDNA was quantified using the 
Quantifluor dsDNA System kit (Promega, Madison, WI, USA) (The manufacturer claims 
that the Quantifluor dye is an intercalating DNA dye which usually does not bind to DNA 
fragments smaller than 5 bp).  It can not entirely be excluded that a small amount of 
eDNA is remaining on the filter after filtration of the supernatant.  eDNA concentrations 
were normalized to the number of biofilm cells, determined by plate counting after 24h 
of biofilm growth. 
Determination of tobramycin MICs 
MICs were determined in duplo according to the EUCAST broth microdilution protocol 
using unsupplemented MH broth.  In brief, bacterial suspensions were standardized at 
∼5 × 105 CFU/mL before inoculating a flat-bottomed 96-well plate filled with 100 µL of 
tobramycin serial dilutions in MH.  The range of tobramycin concentrations used was 
from 2 to 1024 mg/L.  Plates were incubated at 37°C for 20 h and the optical density was 
determined at 590 nm using a multilabel microtitre plate reader (Envision, Perkin Elmer 
LAS, Waltham, MA, USA).  The MIC is the lowest concentration of antibiotic for which a 
similar optical density was observed in the inoculated and blank wells. 
Effect of rhDNase on tobramycin susceptibility of 24h-old Bcc biofilms 
Biofilm formation was carried out in csMH broth with or without 50 µg/mL of rhDNase.  
After 24h, the supernatant was discarded and biofilms were washed with PS.  
Subsequently, 100 µL of tobramycin in cation adjusted PS (0.9% NaCl; 0.015% CaCl2) 
with or without 50 µg/mL of rhDNase was added.  A tobramycin concentration of 4XMIC 
was used as previous research from our group indicated that these concentrations 
resulted in a substantial bactericidal effect against Bcc biofilms [21].  After 24h of 
additional incubation at 37°C, cell numbers were determined by plate counting. 
Effect of NaClO on tobramycin susceptibility of 24h-old Bcc biofilms 
Biofilm formation was carried out as described above.  After 24h, the supernatant was 
aspirated from the wells and biofilms were washed with PS.  Before treatment with 
tobramycin (4XMIC in PS), biofilms were exposed to a 15 min pretreatment with NaClO 
(60 µM) (pH 7-8) in phosphate buffered saline (PBS; pH 7) or with non-supplemented 
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PBS.  The NaClO concentration used was based on data published by Cuzzi et al. [5].  
Subsequently, biofilms were incubated for another 24h, followed by the determination 
of cell numbers by plate counting. 
Effect of dispersin B on tobramycin susceptibility of 24h-old Bcc biofilms 
After 24h of biofilm formation, biofilms were washed with PS and treated either with 
phosphate buffer (100 mM, pH 5.9), with phosphate buffer supplemented with 
tobramycin (4XMIC) (pH 7) or with phosphate buffer supplemented with tobramycin 
(4XMIC) and dispersin B (final concentration of 100 µg/mL) (pH 7).  Plates were 
incubated for an additional 24h, followed by determination of cell numbers by plate 
counting. 
Statistical analyses 
Microtitre plate biofilm assays were performed in 12 wells per condition and their 
content was pooled before plate counting.  All experiments were repeated three times 
on three separate occasions (n=3).  Data are represented as means ± SD of the mean.  
The significance of differences between treatment groups was determined using the 
Mann-Whitney non-parametric test, with p < 0.05 considered as significant. 
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Results 
Quantification of eDNA in biofilm matrix 
Biofilms were grown on the walls of eppendorf tubes for 24h in the presence or absence 
of rhDNase (50 µg/mL) (Figure 1).  Treatment with rhDNase alone did not lead to 
dispersion of the biofilm, as no difference in cell numbers was observed when biofilms 
were grown in the presence or absence of rhDNase.  The eDNA content of the biofilm 
differs considerably between the six Bcc strains investigated, with B. multivorans LMG 
13010 showing the highest amounts (Figure 2).  By adding rhDNase to the growth 
medium, a significant reduction in the amount of eDNA was observed for B. multivorans 
LMG 13010, B. anthina LMG 20980, B. cepacia LMG 1222 and B. cenocepacia LMG 16656 
(Figure 2).  No such difference was observed after rhDNase treatment for biofilms of B. 
metallica LMG 24068 and B. vietnamiensis LMG 10929. 
 
Figure 2: Quantification of eDNA in 24h-old Burkholderia biofilms in the presence and absence of 
rhDNase.  (Data shown are averages ± SD) 
 
The amount of eDNA was normalized for the number of cells adhered to the tube walls.   
*: significantly different compared to biofilms grown in the absence of rhDNase  (p < 0.05).
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Figure 3: Average number of biofilm cells after 24h of growth and 24h of treatment in the presence (grey bars) and absence (white bars) of a matrix 
degrading component.  (Data shown are averages ± SD) 
 
Medium-only biofilms were grown in MH (NaClO and dispersin B assay) or csMH (rhDNase assay) and treated with PS (rhDNase and NaClO assay) or phosphate 
buffer (dispersin B assay).   For the NaClO assay, medium-only biofilms were pretreated with PBS for 15 min before treatment with PS.  To determine the 
bactericidal activity of the matrix degrading components, rhDNase was added at concentrations of 50 µg/mL to csMH (this was used for growing biofilms)  and to 
cation-supplemented PS (0.9% NaCl; 0.015% CaCl2) (this was used for treating the biofilms),  NaClO was added (final concentration of 60 µM in PBS buffer) for 15 
min before treatment with PS and  Dispersin B was added at concentrations of 100 µg/mL to phosphate buffer. 
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Effect of rhDNase on tobramycin susceptibility of 24h-old Bcc biofilms 
rhDNase (50 µg/mL) alone had no effect on the viability or dispersion of Bcc biofilms 
(Figure 3).  The bactericidal activity of tobramycin was tested in three experimental 
conditions.  Firstly, tobramycin (4XMIC) was added to a biofilm formed in the presence 
of 50 µg/mL rhDNase.  Secondly, tobramycin (4XMIC) in combination with 50 µg/mL 
rhDNase was added to a biofilm formed in the presence of 50 µg/mL rhDNase.  Finally, 
tobramycin (4XMIC) was added to a biofilm formed in the absence of rhDNase.  No 
additional bactericidal effect, caused by the presence of rhDNase during biofilm 
treatment and/or during biofilm formation, was observed (Table 2). 
 
Table 2: Average log reductions (±SD) in biofilm cell numbers after tobramycin (4XMIC) treatment 
alone or in combination with rhDNase.  (n=3) 
Biofilm 
formation 
Biofilm 
treatment 
B. cenocepacia 
LMG 16656 
B. multivorans 
LMG 13010 
B. cepacia 
LMG 1222 
B. anthina 
LMG 20980 
B. 
vietnamiensis 
LMG 10929 
B. metallica 
LMG 24068 
csMH  Tobra 3.87 (±0.13) 3.01 (±0.13) 3.14 (±0.37) 4.00 (±0.33) 4.46 (±0.10) 3.55 (±0.18) 
csMH + 
rhDNase 
Tobra 3.75 (±0.19) 3.05 (±0.30) 2.89 (±0.39) 3.70 (±0.33) 4.50 (±0.11) 3.60 (±0.16) 
csMH + 
rhDNase 
Tobra + 
rhDNase 
3.66 (±0.18) 2.78 (±0.08) 2.74 (±0.37) 3.44 (±0.24) 4.17 (±0.16) 3.52 (±0.18) 
Tobramycin was added to biofilms formed in csMH broth (control), biofilms formed in csMH broth in the 
presence of rhDNase and  biofilms formed and treated in the presence of rhDNase.  No statistically 
significant difference between the control condition and the conditions in which rhDNase was added was 
observed. 
Effect of NaClO pretreatment on tobramycin susceptibility of 24h-old Bcc biofilms  
A short pretreatment of the biofilms with a 60 µM NaClO solution (pH 7-8) had no 
bactericidal effect on its own for all Bcc biofilms tested (Figure 3).  For some Bcc species, 
tobramycin (4XMIC) added to NaClO pretreated biofilms resulted in a significantly 
increased bactericidal effect compared to tobramycin added to PBS pretreated biofilms 
(Table 3).  The most pronounced effect of NaClO pretreatment was noticed for B. 
metallica LMG 24068, for which an additional 1.42 log reduction in cell numbers was 
observed compared to tobramycin treatment alone.  No increased bactericidal effect of 
tobramycin was observed in NaClO pretreated B. anthina LMG 20980 and B. 
vietnamiensis LMG 10929 biofilms.   
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Table 3: Average log reductions (±SD) in biofilm cell numbers after tobramycin (4XMIC) treatment 
and pretreatment with PBS or NaClO. (n=3) 
Pretreatment 
B. cenocepacia 
LMG 16656 
B. multivorans 
LMG 13010 
B. cepacia 
LMG 1222 
B. anthina 
LMG 20980 
B. vietnamiensis 
LMG 10929 
B. metallica 
LMG 24068 
PBS 3.92 (±0.19) 3.09 (±0.19) 4.01 (±0.13) 3.21 (±0.18) 4.24 (±0.17) 3.83 (±0.22) 
NaClO (60 µM) 4.67* (±0.24) 4.25* (±0.16) 4.86* (±0.13) 3.38 (±0.30) 4.41 (±0.17) 5.25* (±0.12) 
*: statistically significant difference compared to PBS pretreatment (p < 0.05). 
 
Effect of dispersin B on tobramycin susceptibility of 24h-old Bcc biofilms 
Dispersin B at concentrations of 100 µg/mL had no bactericidal effect on any Bcc biofilm 
tested (Figure 3).  The bactericidal effect of tobramycin dissolved in phosphate buffer 
(100 mM, pH 5.9) (Table 4; first row) was significantly reduced compared to the 
bactericidal effect of tobramycin dissolved in PS (Table 3 and Table 2; first row).  Still, 
for three Bcc isolates, B. cenocepacia LMG 16656, B. cepacia LMG 1222 and B. metallica 
LMG 24068, dispersin B significantly increased the bactericidal effect of tobramycin.   
 
Table 4: Average log reductions (±SD) in biofilm cell numbers after tobramycin (4XMIC) treatment 
alone (controls) or in combination with dispersin B of 24h-old biofilms. 
Treatment 
B. cenocepacia 
LMG 16656 
B. multivorans 
LMG 13010 
B. cepacia 
LMG 1222 
B. anthina 
LMG 20980 
B. vietnamiensis 
LMG 10929 
B. metallica 
LMG 24068 
Tobramycin 0.21 (±0.18) 0.71 (±0.12) 2.73 (±0.20) 2.11 (±0.26) 1.22 (±0.20) 2.57 (±0.15) 
Tobramycin + 
dispersin B 
0.46* (±0.16) 0.72 (±0.16) 3.03* (±0.27) 2.06 (±0.23) 1.38 (±0.18) 2.91* (±0.14) 
*: statistically significant difference compared to controls (p < 0.05) (n=3).  
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D iscussion 
In the present study we investigated the role of different Bcc biofilm matrix components 
in the protection against the antimicrobial activity of tobramycin.  Tobramycin, a 
positively charged aminoglycoside antibiotic, is likely to bind to EPS or eDNA, which will 
decrease the bioavailability of free tobramycin. 
Pulmozyme (a highly purified solution of rhDNase) was approved in 1993 by the US FDA 
for the treatment of CF lung disease.  rhDNase degrades eDNA, which is present in large 
amounts in the sputum of CF patients, resulting in reduced sputum viscosity and 
improved cough clearance and mucociliary transport [22].  In addition, rhDNase may 
have an impact on biofilm lung infections.  By degrading eDNA present in the biofilm 
matrix it could sensitize bacteria to antibiotic therapy.  In the present study we 
demonstrated the presence of eDNA in all Bcc biofilms investigated.  The amount of 
eDNA differed among Bcc strains with the highest amount of eDNA measured for B. 
multivorans LMG 13010.  These high levels of eDNA could possibly contribute to the 
virulence of the bacteria as eDNA has previously been shown to induce cationic 
antimicrobial resistance in P. aeruginosa and S. enterica [17].  rhDNase added at the start 
of biofilm formation significantly reduced the amount of eDNA in some Bcc strains.  For 
two Bcc strains, B. metallica LMG 24068 and B. vietnamiensis LMG 10929 no decrease in 
eDNA concentration was measured after rhDNase treatment.  Increasing the enzyme 
concentration could potentially increase the effect of rhDNase but we did not explore 
this further, as the concentrations used (50 µg/mL) were already at least 5 times higher 
than the concentrations measured in sputum of CF patients after inhalation of 2.5 mg 
rhDNase I [23].  When added alone, rhDNase had no effect on the viability or dispersion 
of Bcc biofilm cells, which is in contrast with the observations of Tetz and Tetz for 
Escherichia  coli and S. aureus biofilms [24].  The ability of DNase to disperse established 
P. aeruginosa biofilms has also been described [12].  However, although DNase I was 
capable of dispersing young biofilms, older biofilms were much less affected by DNase I, 
suggesting that other matrix components became increasingly important in stabilizing P. 
aeruginosa biofilms during growth.  We subsequently investigated whether rhDNase 
could increase tobramycin susceptibility of Bcc biofilm cells.  No increased bactericidal 
effect of tobramycin was observed if Bcc biofilms were formed in the presence of 50 
µg/mL of rhDNase, nor if they were formed and treated in the presence of rhDNase, 
which is in agreement with tests previously performed in CF sputum [25].  Possible 
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explanations are that, although eDNA is depolymerized by rhDNase, tobramycin can still 
bind to small eDNA molecules or that eDNA is not sufficiently degraded by rhDNase.  
Goodman et al. indicated that DNA binding (DNAB II) proteins contribute to the 
stabilization and structural integrity of eDNA within the matrix of different bacterial 
biofilms, including Bcc biofilms, which could protect eDNA from degradation by 
rhDNase [26, 27].  Recently, it has been observed that antiserum directed against DNAB 
II proteins was capable of reducing B. cenocepacia biofilm mass, sensitizing the biofilm 
towards antimicrobials.  In contrast, a rhDNase treatment increased the biofilm biomass 
[27].  A possible explanation for this is that smaller eDNA fragments, present in the 
biofilm matrix after rhDNase treatment, are increasingly stabilizing the Bcc biofilm 
matrix by cross-linking with other EPS, including polysaccharides.   
Cepacian is considered the major exopolysaccharide produced by isolates of the Bcc 
[28].  A protective effect of B. cenocepacia exopolysaccharides, and more specifically 
cepacian, towards ROS has been demonstrated [4].  By scavenging NaClO, the backbone 
of cepacian was degraded and acetyl substituents were cleaved off [5].  The loss of these 
acetyl substituents hampered the ability of cepacian chains to aggregate, reducing the 
viscosity of the polysaccharide network around Bcc cells [29].  To date, apart from 
PNAG, the production of seven different exopolysaccharides by Bcc species has been 
demonstrated.    The exact contribution of exopolysaccharides in biofilm formation and 
protection against stress  has yet to be determined [30].    Benincasa et al. already 
demonstrated a considerable decrease of the antibacterial activity of antimicrobial  
peptides in the presence of polysaccharides produced by members of the Bcc [31].  To 
study the effect of cepacian on tobramycin bioactivity, we pretreated Bcc biofilms with 
60 µM NaClO solution, in order to degrade cepacian, before adding tobramycin.  When 
combined with tobramycin, we observed a significantly improved bactericidal activity of 
the latter against B. cenocepacia LMG 16656, B. multivorans LMG 13010, B. cepacia LMG 
1222 and B. metallica LMG 24068 biofilms.  On average, 30% less biofilm cells survived 
after combination therapy compared to tobramycin alone.  The reactivity of ROS is most 
likely not limited to the degradation of cepacian but could also affect the integrity of 
other exopolysaccharides.  This is corroborated by our results which demonstrate a 
significantly increased bactericidal effect of tobramycin after NaClO pretreatment for B. 
cenocepacia LMG 16656, although this strain had previously been shown not to produce 
cepacian [32].  The use of a cepacian specific degrading enzyme, like the cepacian lyase 
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isolated by Cescutti et al., would allow for better differentiation between the role of 
cepacian and other exopolysaccharides in reducing the activity of tobramycin [33]. 
The production of PNAG has been described for B. multivorans, B. vietnamiensis, B. 
ambifaria, B. cepacia and B. cenocepacia where it seemed to be important for biofilm 
formation and maintenance [7].  In addition, a mutant incapable of producing PNAG 
showed increased sensitivity to tobramycin, which suggests a role for PNAG in Bcc 
antibiotic resistance [7].  In contrast to these findings of Yakandawala et al., we did not 
observe a biofilm dispersing effect of dispersin B on Bcc biofilms.  The relatively small 
biofilm killing effect of tobramycin monotherapy in this experiment is likely attributed 
to the buffer recommended for optimal dispersin B activity (100 mM phosphate buffer 
supplemented with 200 mM NaCl).  As it has previously been noticed that tobramycin 
activity can be significantly reduced in high ionic strength solutions [34], this could 
explain the decreased bactericidal effect of tobramycin.  Nevertheless, the combination 
of dispersin B (100 µg/mL) with tobramycin significantly increased the latter’s 
bactericidal effect against B. cenocepacia LMG 16656, B. cepacia LMG 1222 and B. 
metallica LMG 24068. The combination therapy resulted in a 10-45% decrease in 
biofilm cell numbers compared to tobramycin treatment alone for these isolates.   
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Conclusion 
We investigated the in vitro bactericidal activity of tobramycin in combination with 
matrix degrading substances.  rhDNase did not show any additional effect on antibiotic 
killing which could be due to a biofilm stabilizing effect of small eDNA fragments present 
in the biofilm matrix after rhDNase treatment.  Exopolysaccharide degradation, by 
NaClO pretreatment, significantly increased the bactericidal effect of tobramycin 
towards some of the Bcc biofilms tested, as did selective PNAG degradation by dispersin 
B.   
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ABSTRACT 
 
Due to the intrinsic resistance of the Bcc to many antibiotics and the production of a 
broad range of virulence factors, lung infections by these bacteria, primarily occurring in 
CF patients, are very difficult to treat.  In addition, the ability of Bcc organisms to form 
biofilms contributes to their persistence after colonization of the CF lung.  As Bcc 
infections are associated with poor clinical outcome, there is an urgent need for new 
effective therapies to treat these infections.  In the present study, we investigated 
whether the encapsulation of tobramycin in liposomes could increase its anti-biofilm 
effect against Bcc.  Single particle tracking (SPT) was used to study the transport of 
positively and negatively charged nanospheres in Bcc biofilms as a model for the 
transport of liposomes.  Negatively charged nanospheres became immobilized in close 
proximity of biofilm cell clusters, while positively charged nanopsheres interacted with 
fiber-like structures, probably eDNA. Based on these data, encapsulation of tobramycin 
in negatively charged liposomes appeared promising for targeted drug delivery.  
However, the anti-biofilm effect of tobramycin encapsulated into neutral or anionic 
liposomes did not increase compared to that of free tobramycin.  Probably, the fusion of 
the anionic liposomes with the negatively charged bacterial surface of Bcc was limited 
by electrostatic repulsive forces at close proximity.  The lack of a substantial anti-biofilm 
effect of tobramycin encapsulated in neutral liposomes could be further investigated by 
increasing the liposomal tobramycin concentration.  However, this was hampered by the 
low encapsulation efficiency of tobramycin in these liposomes.  
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Introduction 
CF is the most prevalent hereditary disease in the Caucasian population and is caused by 
mutations in both cftr alleles encoding a chloride channel [1].  The absence of a 
functional chloride channel (CFTR channel) results in the secretion of thick, viscous 
mucus in several organs, including the lungs and the gastrointestinal tract [2]. The thick 
mucus in CF lungs impairs the mucociliary clearance, rendering them more susceptible 
to infections.  In CF patients, lung infections can not be cleared easily and rapidly evolve 
to chronic infections, the main cause of morbidity and mortality [3].  The most 
significant pathogen colonizing the lungs of CF patients is P. aeruginosa.  Over time, 
approximately 80% of the CF population becomes infected with this pathogen [4].  
Compared to P. aeruginosa, Bcc infections only account for a small percentage of the 
respiratory infections within the CF population.  However, they are often associated 
with rapid deterioration of the lung function and increased mortality [5].  The capacity 
of Bcc species to cause invasive disease and their high level of intrinsic antibiotic 
resistance make them particularly difficult to eradicate.  Through the production of 
different EPS additional protection is provided against antibiotics and host immune 
components [6].  As there is still no optimal treatment regimen for Bcc infections in CF 
patients [7], these pathogens continue to be highly problematic [8] and there is an 
urgent need for effective antibiotic therapies.  As for P. aeruginosa, the production of EPS 
by Bcc strains is essential for the formation of thick and mature biofilms [9].  These EPS, 
including polysaccharides and eDNA, can delay the penetration of an antibiotic through 
the biofilm [10].  By the encapsulation of the antibiotic in  a liposomal carrier,  
interactions between the antibiotic and EPS could probably be avoided, resulting in an 
improved anti-biofilm effect.  In addition, liposome-encapsulated antibiotics would be 
protected from degradation by antibiotic-inactivating enzymes (like β-lactamases) 
which can accumulate in the biofilm matrix [11].  Another important factor contributing 
to antibiotic resistance in several Gram-negative bacteria, including P. aeruginosa and 
Bcc species, is their low outer membrane permeability [12-14].  The uptake of 
antibiotics encapsulated in neutral liposomal carriers is not affected by this outer 
membrane barrier as this occurs through direct fusion of the liposome with the bacterial 
membrane [15].  It has been shown that subinhibitory concentrations of tobramycin 
encapsulated in neutral liposomes has high bactericidal activity against planktonic 
cultures of several bacterial species, including P. aeruginosa and B. cenocepacia [16-18], 
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probably due to an enhanced uptake of the antibiotic.  Besides the improved transport 
through the biofilm and a better uptake in the cell, liposomes could provide selective 
delivery to the target site by incorporating specific ligands to the liposome surface. 
Currently, several liposome based drugs have been approved for clinical use and various 
others are in clinical trials [19].  Arikace, a neutral liposomal  amikacin formulation, 
currently undergoes phase III clinical trials for the treatment of lung infections [19, 20].  
It is the first liposomal drug being investigated for aerosol delivery.  
In the present study, we investigated whether the bactericidal effect of tobramycin 
against Bcc biofilms could be increased by encapsulating the antibiotic in liposomes.  
Therefore, we analyzed the behavior of positively and negatively charged nanoparticles 
in Bcc biofilms by means of SPT as a model for liposomal transport.  In contrast to 
liposomes, which are composed of phospholipids, the nanoparticles used in the model 
are made up of polystyrene and thus can not be degraded by enzymes or other 
components present in the biofilm matrix.  According to our observations, negatively 
charged particles were directed towards cell clusters, while positively charged particles 
became immobilized by interactions with fiber-like structures (likely eDNA) in the 
biofilm matrix.  Based on these results, tobramycin encapsulated into negatively charged 
liposomes could be promising in terms of targeted drug delivery.  We consequently 
evaluated the activity of neutral and anionic liposomal tobramycin formulations against 
Bcc biofilms. 
  
134 
 
Materials and methods 
Strains 
We used 5 Bcc strains in the present study: B. cenocepacia LMG 16656 and LMG 18829, 
B. cepacia LMG 1222, B. multivorans LMG 18825 and B. dolosa LMG 18943.  All Bcc 
strains were obtained from the BCCM/LMG Bacteria Collection (Ghent, Belgium) or were 
kindly provided by Dr. P. Vandamme (Ghent University, Belgium).  The bacteria were 
stored in Microbank tubes (Prolab Diagnostics, Richmond Hill, ON, Canada) at -80°C and 
transferred twice on MH (Lab M, Heywood, UK) agar plates before use in any 
experiment.     
Lipids 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol were obtained 
from Sigma-Aldrich (St. Louis, MO, USA) and stored at -20°C.  1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol sodium salt 
(DPPG), were obtained from Corden Pharma International (Plankstadt, Germany) and 
stored at -20°C.  Lipids were dissolved in chloroform and stock solutions were stored 
between 2-8°C. 
Nanoparticles 
Yellow-green (λex: 505/ λem: 515) fluorescent carboxylate-modified polystyrene 
FluoSpheres of 0.2 μm diameter were purchased from Invitrogen (Carlsbad, CA, USA).  
Positively charged nanospheres were prepared from the carboxylate-modified 
FluoSpheres by modification with N,N-dimethylethylenediamine (DMEDA) (Sigma-
Aldrich) as described previously [21].  The size and zeta-potential of the positively 
charged nanospheres were measured in HEPES (pH 7.3, 20 mM) using the Zetaziser 
Nano-ZS (Malvern, Worcestershire, UK).   
Single Particle Tracking  setup 
All SPT measurements were performed on a custom-built laser wide-field fluorescence 
microscope setup  as described previously [22].  Briefly, two solid-state lasers, a 100 
mW Calypso 491 nm (Cobolt, Solna, Sweden) and a 100 mW Spectra Physics Excelsior 
642 nm (CA, USA), were used to excite the fluorophores in samples mounted on a 
TE2000-E (Nikon BeLux, Brussels, Belgium) inverted microscope equipped with a Plan 
Apo VC 100× 1.4 NA oil immersion objective lens (Nikon).  A diffuser in the illumination 
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path ensured even illumination of the sample.  An acousto-optical tunable filter (AOTF) 
was used to modulate the intensity of the laser beams. The AOTF was synchronized to 
the EMCCD camera (Cascade II:512; Roper Scientific, Tucson, AZ, USA)in order to limit 
photobleaching during imaging.  Videos of the moving nanoparticles were acquired with 
the NIS Elements software package (Nikon). 
Analysis of SPT data 
Analysis of the videos was performed off-line using software developed by Braeckmans 
et al. [23].  First, the particles were localized in all frames of the SPT movie.  A selection 
of “real” particles is made according to user-defined criteria, including size, contrast 
relative to the local background and sphericity.  Subsequently, individual trajectories of 
the nanospheres are calculated using a nearest neighbor algorithm.  The positions of 
nanospheres that are closest to each other are connected in subsequent image frames, 
taking into consideration the maximum distance a particle can reasonably move from 
one frame to another.  The trajectories are further analyzed based on mean square 
displacement (MSD) analysis. The MSD is calculated for every available time lag (t) , i.e. 
the multiples of time between two subsequent images in an SPT movie.   
A weighted least squares fitting was performed of 
MSD = Γtα + 4 σ2 
to the MSD vs. t curves, yielding for each trajectory the parameters Gamma (Γ), alpha (α) 
and sigma (σ). Gamma is the so-called transport coefficient, alpha the anomalous 
exponent and sigma a parameter taking into account the limited precision with which a 
particle can be localized. The parameter of interest is alpha, which contains information 
on the mode of motion.  For free diffusion, α equals 1 while α < 1 and α > 1 represent 
sub- and super-diffusion, respectively. By analyzing the MSD versus t plots of many 
trajectories, a distribution of α values is obtained. In addition, the apparent diffusion 
coefficient, Da, was calculated corresponding to the first time lag according to: 
Da = MSD/(4t) 
The distribution of Da values was further processed using a maximum entropy method 
(MEM) that improves the resolution and at the same time smoothes the curve by only 
retaining the features that are statistically warranted by the data [22]. 
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SPT measurements in biofilms 
Bcc biofilms were cultured in uncoated 35 mm glass bottom culture dishes (MatTek, 
Ashland, MA, USA).  The dishes were inoculated with 2 mL of a standardized bacterial 
suspension in MH broth (∼108 CFU/mL) in the presence or absence of 10 µg/mL 
dornase alfa (Pulmozyme, Genentech, SF, USA) and were incubated at 37°C.  After 4h, the 
supernatant, containing non-adhered cells, was removed and adhered cells were 
carefully washed with PS.  Subsequently, 2 mL of fresh MH broth (with or without 10 
µg/mL dornase alfa) was added and the dishes were incubated for another 20h at 37°C 
to allow biofilm formation.  After 24h of biofilm formation, biofilms were gently washed 
with PS to remove nonadhering cells.  Biofilm cells were stained by adding 1 mL of a 
Syto 59 (Invitrogen) solution (5 mM in PS).  After 15 min of incubation at room 
temperature, protected from light, the biofilm was washed twice with PS.  The 
nanoparticle stock suspensions were sonicated for 10 min before dilution in PS (∼ 
0.002% solids).  One mL of this particle suspension was added to the biofilms, 
immediately before recording movies.  Movies of 5 s with a temporal resolution of 39.2 
ms (time between two subsequent images, time lag) and an image acquisition time of 3 
ms were recorded.  Dual color image acquisition allowed easy navigation within the 
biofilm.  Between 25 and 30 movies on different locations in the biofilm were recorded.  
Each experiment was carried out in triplicate at room temperature. 
Liposome preparation 
Liposomes were prepared by a dehydration-rehydration method as described 
previously [24].   In brief, for the preparation of neutral liposomes, 50 µmol of DPPC and 
25 µmol of cholesterol were dissolved in 1 mL of chloroform in a round-bottomed flask.  
For the anionic liposomes, 53 µmol of DOPC and 6.6 µmol of DPPG were dissolved in 1 
mL of chloroform.  The round-bottomed flask was connected to a rotary evaporator to 
dry the lipid film under controlled vacuum at 50°C.  The lipid film was rehydrated with 2 
mL of a sucrose solution in distilled water (1:1, w/w, sucrose to lipid).  Sucrose is 
needed to stabilize the liposomes during freeze drying.  Lipid suspensions were 
vortexed to form multilamellar vesicles and then sonicated for 5 min in an ultrasonic 
bath (Branson 3510), followed by two additional cycles of vortexing and sonication.  The 
resulting suspension was then mixed with 1 mL (40 mg/mL) of tobramycin in PS.  The 
mixture was frozen (-20°C) and immediately freeze dried.  After freeze drying, the 
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powdered formulations were stored at 4°C until use.  For rehydration, 200 µL of distilled 
water at 50°C was added.  The suspension was vortexed and incubated for 30 min at 
50°C.  These steps were repeated with 200 µL phosphate-buffered saline (PBS, pH 5.9).  
After incubation at 50°C, 1.6 mL of PBS was added, the mixture was vortexed and 
incubated for another 30 min at 50°C.  Non-encapsulated tobramycin was removed 
following three rounds of PBS wash (18300 x g, 15 min at 4°C) and the pellet was 
resuspended in 2 mL PS.  The size and zeta-potential of the liposomes were measured in 
HEPES (pH 7.3, 20 mM) using the Zetaziser Nano-ZS (Malvern, Worcestershire, UK).   
Quantification of the amount of encapsulated tobramycin 
The concentration of liposome encapsulated tobramycin was measured by agar 
diffusion, using a laboratory strain of Bacillus subtilis (ATCC 6633) as indicator 
organism.  B. subtilis ATCC 6633 spore suspensions were prepared as described in the 
European Pharmacopoeia [25].  In brief, B. subtilis was grown at 35-37°C for 7 days on 
Antibiotic medium 1 (AM1) supplemented with 0.001 g/L manganese sulphate.  After at 
least 7 days, the growth, which mainly consists of spores, was washed off using sterile 
water.  The obtained suspension was heated at 70°C for 30 min and diluted to give an 
appropriate concentration of spores (107 – 108 per mL).  The spore suspensions were 
stored at 4°C until use.  We used this suspension to prepare a 1% suspension of spores 
(4 mL/ 400 mL) in warm (47.5 °C) AM 11 agar.  The agar was poured into a sterile glass 
plate and was left to solidify for 15 min at room temperature.  To lyse the liposomes, 0.2 
% Triton X-100 was added to the liposomal solutions.  This level of Triton X-100 had no 
effect on the performance of the assay (data not shown).  Wells of 5 mm diameter were 
punched in the agar and filled with 200 µL of standard tobramycin solutions or with the 
sample.  The plate was covered with a steel lid and incubated for 20 hours at 35°C after 
4h of pre-diffusion at 4°C.  We subsequently measured the inhibition zones and the 
average of 4 measurements was used for data analysis.  A standard curve with known 
concentrations of free tobramycin (0.03125-1 µg/mL) was constructed and was utilized 
to calculate the amount of encapsulated tobramycin that was released after Triton X-100 
treatment.   
 
138 
 
Determination of the MIC of tobramycin 
MICs were determined in duplicate according to the EUCAST broth microdilution 
protocol using unsupplemented MH broth. In brief, bacterial suspensions were 
standardized at ∼5 × 105 CFU/mL before inoculation of a flat-bottomed 96-well plate 
filled with 100 µL of tobramycin serial dilutions in MH.  The range of tobramycin 
concentrations used was from 2 to 1024 mg/L.  Plates were incubated at 37°C for 20 h 
and the optical density was determined at 590 nm using a multilabel microtitre plate 
reader (Envision, Perkin Elmer LAS, Waltham, MA, USA). The MIC is the lowest 
concentration of antibiotic for which a similar optical density was observed in the 
inoculated and blank wells. 
Activity of liposome encapsulated tobramycin against Bcc biofilms 
Biofilms were cultured in round-bottomed 96-well plates.  An inoculum was prepared 
by suspending bacteria from a pure culture on MH agar in MH broth.  The inoculum was 
standardized at ∼108 CFU/mL and the wells of the microtitre plate were filled with 100 
µL of this suspension.  Plates were incubated at 37°C for 4h without shaking.  After 4h, 
the supernatant, containing planktonic cells, was aspirated from the wells.  Adhered 
cells were carefully washed with 100 µL of PS and 100 µL of fresh sterile MH broth was 
added.  Plates were incubated for an additional 20h at 37°C.  After 24h of biofilm 
formation, biofilms were washed with 100 µL of PS before treatment with free 
tobramycin (final concentrations of 140 µg/mL or 4XMIC of tobramycin in PS) or 
liposome encapsulated tobramycin (final concentrations of 140 µg/mL or 4XMIC of 
tobramycin in PS).  The anionic liposomal stock solutions were diluted in PS to obtain 
the concentrations used in the experiments.  After 24h of treatment at 37°C, cell 
numbers were determined by plate counting. 
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Results 
Properties of nanoparticles and liposomes 
The average sizes and average zeta-potentials of nanospheres and liposomes used in the 
present study are shown in Table 1.  For the liposomes, the concentrations of 
encapsulated tobramycin (i.e. the concentration that is released after breaking up all 
liposomes in the stocksolution with Triton X-100) are also shown in Table 1. 
 
Table 1: Characteristics of the nanospheres and liposomes used in the present study (n=3). 
Particle 
Average 
size (nm ) 
( ± SD) 
Average 
zeta-potential (mV)  
( ± SD) 
Total lipsomal tobramycin 
concentration (µg/mL)  
( ± SD) 
Carboxylate-modified 
nanosphere 
224.0 (± 0.7) - 48.4 (± 0.7) / 
DMEDA-modified 
nanosphere 
231.9 (± 1.2) 30.4 (± 0.6) / 
DPPC/cholesterol 
liposomes  
(2/1, molar ratio) 
426.3 (± 26.4) - 0.5 (± 0.1) 141 (± 35) 
DOPC/DPPG 
liposomes  
(8/1, molar ratio) 
228.5 ( ± 34.9) - 22.3 (± 0.5) 1128 ( ± 16) 
 
Transport of negatively charged nanoparticles in Bcc biofilms 
The mobility of carboxylate-modified polystyrene nanospheres (0.2 µm) added to Bcc 
biofilms was studied by analyzing individual trajectories of the nanospheres in the 
biofilm.  The distribution of both α values and Da coefficients of the carboxylate-modified 
nanospheres is shown in Figure 1.  Average α and Da values for all conditions are shown 
in Table 2.  For all strains investigated, negatively charged particles display subdiffusion 
( 0 < α < 1 ) when added to the biofilm.  This effect was the most pronounced in B. 
cenocepacia LMG 16656 and B. cenocepacia LMG 18829 biofilms and to a lesser extent in 
B. multivorans LMG 18825 and B. cepacia LMG 1222 biofilms. This is also reflected in the 
Da distributions where an immobilized fraction is seen in both B. cenocepacia LMG 
16656 and B. cenocepacia LMG 18829 biofilms. Thus it is clear that the negatively 
charged particles strongly interact with the biofilms.  In addition, on average the 
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particles diffuse slowly in the biofilm as their apparent diffusion coefficients are much 
lower than those in water (Dw = 1.96 µm2/s [26]).  The highest diffusion rates were 
observed in B. cepacia LMG 1222 biofilm (average Da = 0.42 µm2/s) while the lowest 
were observed in B. multivorans LMG 18825 biofilm (average Da = 0.15 µm2/s).  The 
mobility of the negatively charged nanospheres in both B. cenocepacia LMG 16656 and 
LMG 18829 biofilms is similar, yielding average diffusion coefficients of 0.26 and 0.28, 
respectively. 
 
Table 2: Average apparent diffusion coefficients, both in Bcc biofilms and in water [26], and 
average α values of the nanospheres in Bcc biofilms. 
 
Biofilm Condition Particle 
Av Da (µm2/s) 
(± SD) 
Av α 
Av Dw (µm2/s) 
(±SD) 
B. cenocepacia 
LMG 16656 
Control Carboxylate-modified 0.26 (± 0.29) 0.43 1.96 (± 0.02) 
Control DMEDA-modified 0.29 (± 0.21) 0.39 
1.88 (± 0.09) 
rhDNase DMEDA-modified 0.37 (± 0.44) 0.44 
B. cenocepacia 
LMG 18829 
Control Carboxylate-modified 0.28 (± 0.36) 0.48 1.96 (± 0.02) 
Control DMEDA-modified 0.23 (± 0.30) 0.23 
1.88 (± 0.09) 
rhDNase DMEDA-modified 0.54 (± 0.30) 0.49 
B. cepacia 
LMG 1222 
Control Carboxylate-modified 0.42 (± 0.25) 0.81 1.96 (± 0.02) 
Control DMEDA-modified 0.27 (± 0.28) 0.62 
1.88 (± 0.09) 
rhDNase DMEDA-modified 0.45 (± 0.26) 0.97 
B. multivorans 
LMG 18825 
Control Carboxylate-modified 0.15 (± 0.11) 0.77 1.96 (± 0.02) 
Control DMEDA-modified 0.38 (± 0.20) 0.65 
1.88 (± 0.09) 
rhDNase DMEDA-modified 0.42 (± 0.30) 0.67 
B. dolosa 
LMG 18943 
Control Carboxylate-modified 0.32 (± 0.36) 0.57 1.96 (± 0.02) 
Control DMEDA-modified 0.25 (± 0.30) 0.35 
1.88 (± 0.09) 
rhDNase DMEDA-modified 0.19 (± 0.30) 0.53 
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Transport of positively charged nanoparticles in Bcc biofilms 
The mobility of DMEDA-modified polystyrene nanospheres (0.2 µm) in different Bcc 
biofilms was also studied (Figure 2).  Positively charged nanospheres displayed 
subdiffusion in all Bcc biofilms when grown in the absence of dornase alfa.  Alfa  values 
for B. cepacia LMG 1222 show a bimodal distribution, with part of the particles 
displaying free diffusion.  Anomalous diffusion was most pronounced in B. cenocepacia 
LMG 18829 (mean α = 0.23).  In contrast, α  values closest to 1 were obtained in B. 
multivorans LMG 18825 and B. cepacia LMG 1222 biofilms, with mean α values of 0.65 
and 0.62, respectively.  This correlates with the highest average apparent diffusion 
coefficient (average Da = 0.38) of positively charged nanospheres in B. multivorans LMG 
18825 biofilms.  Although the average diffusion coefficient in B. cepacia LMG 1222 is 
much smaller, the distribution is clearly bimodal, with two groups of particles behaving 
differently.  The peak of the faster moving population represents particles with an 
apparent diffusion coefficient of 0.41 µm2/s.  Still, positively charged nanospheres 
diffuse much more slowly in the Bcc biofilms than in water (Dw = 1.88 µm2/s [26]).  
Together with the low α values of these particles in Bcc biofilms this clearly indicates a 
hindered transport, which could be due to interaction with negatively charged matrix 
components.  It was previously observed that the positively charged nanospheres 
interacted with fiber-like structures in Bcc biofilms, greatly impairing their mobility and 
this was confirmed in the present study.  As these fiber-like structures are likely eDNA, 
the experiments with DMEDA-modified nanospheres were repeated in Bcc biofilms 
grown in the presence of dornase alfa (10 µg/mL) (Figure 2).  The most pronounced 
effect of dornase alfa on the mobility of positively charged nanospheres was observed in 
B. cepacia LMG 1222 and B. cenocepacia LMG 18829 biofilms for which average diffusion 
coefficients approximately doubled, from 0.27 to 0.45 µm2/s and from 0.23 to 0.54 
µm2/s, respectively.  In addition the α distributions of the positively charged 
nanospheres displayed a shift to higher values, although this shift was less pronounced 
in B. cenocepacia LMG 16656 and B. multivorans LMG 18825 (Figure 2). 
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Figure 1: Mobility of 0.2 µm carboxylate-modified nanospheres in Bcc biofilms. 
 
Distribution of α values, describing the mode of movement, and Da values, describing the rate of movement for A) B. 
cenocepacia LMG 16656, B) B. cenocepacia LMG 18829, C) B. cepacia LMG 1222, D) B. multivorans LMG 18825 and E) B. 
dolosa LMG 18943.  Dotted curves show the average α and average Da value of the carboxylate-modified nanospheres in 
water [26]. 
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Figure 2: Mobility of 0.2 µm DMEDA- modified nanospheres in Bcc  biofilms. 
Distribution of α values, describing the mode of movement, and Da values, describing the rate of movement for A) B. 
cenocepacia LMG 16656, B) B. cenocepacia LMG 18829, C) B. cepacia LMG 1222, D) B. multivorans LMG 18825 and E) B. 
dolosa LMG 18943.  Green, solid lines represent the distribution for DMEDA-modified particles added to control biofilms.  
Red, dotted lines represent the distributions for DMEDA-modified particles added to rhDNase treated biofilms.  Grey 
dotted lines show the α and Da value distributions of the DMEDA-modified nanospheres in water [26].
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Activity of liposome encapsulated tobramycin against Bcc biofilms 
We tested the activity of both neutral and negatively charged tobramycin containing 
liposomes (0.2 µm) against Bcc biofilms (Figure 3).  When added at a final concentration 
of 140 µg/mL (Figure 3a), free tobramycin showed modest activity against B. 
cenocepacia LMG 18829, B. multivorans LMG 18825 and B. dolosa LMG 18943 and strong 
activity against B. cepacia LMG 1222.  This is in agreement with the MIC values 
observed.  The MIC for B. cepacia LMG 1222 is low (32 µg/mL) while these for B. 
cenocepacia LMG 18829, B. multivorans LMG 18825 and B. dolosa LMG 18943 were only 
slightly below (128 µg/mL) the tobramycin concentration used (140 µg/mL) in the 
present study.  Finally, the MIC of tobramycin for B. cenocepacia LMG 16656 (256 
µg/mL) is considerably above the concentration used in this experiment, explaining the 
lack of bactericidal activity (Figure 3A).  Both neutral and negatively charged liposomes 
containing 140 µg/mL of tobramycin (≈ 4XMIC) showed a bactericidal effect against B. 
cepacia LMG 1222 biofilms but no increased bactericidal activity compared to free 
tobramycin was observed.  In B. multivorans LMG 18825 biofilms, neutral liposomes 
containing 140 µg/mL tobramycin (≈ MIC) showed the same activity as free tobramycin.  
Previous research from our group has indicated that tobramycin at concentrations of 
4XMIC yielded a substantial bactericidal effect against Bcc biofilms [27].   Increasing the 
liposomal tobramycin concentration to 4XMIC was only possible for the negatively 
charged liposomes as the maximum achievable concentration of encapsulated 
tobramycin in neutral liposomes was 140 µg/mL.  However, at this increased 
tobramycin concentration, negatively charged liposomes only showed bactericidal 
activity against B. cepacia LMG 1222 (Figure 3B). 
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Figure 3: Activity of free and liposomal tobramycin against Bcc biofilms. 
 
A) Bactericidal effect of free and liposomal tobramycin (anionic and neutral liposomes) at a final 
concentration of 140 µg/mL against Bcc biofilms.  B) Bactericidal effect of free and liposomal tobramycin 
(anionic liposomes) at a final concentration of 4XMIC against Bcc biofilms. 
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D iscussion 
In the present study we investigated the transport of negatively and positively charged 
nanospheres in Bcc biofilms.  The transport of nanospheres can be used as a model to 
predict the transport of antibiotic-containing liposomes.  Liposomes are made up of 
phospholipids and can act as biodegradable delivery systems.  Antibiotics encapsulated 
in liposomes have lower toxicity and higher bioactivity and bioavailability [18, 28].  It 
has already been demonstrated that liposomal antibiotic formulations show increased 
bactericidal activity against biofilms compared to free antibiotics [29, 30].  However, a 
first condition is that efficient transport of liposomes in the biofilm matrix should occur.  
Therefore, as a first step in developing a drug-delivery system with activity against Bcc 
biofilms, we studied the transport of model nanospheres in these biofilms.  In a previous 
study we have shown that PEGylated neutral nanospheres displayed normal 
(unobstructed) diffusion in B. multivorans LMG 18825 biofilms and that these particles 
diffuse in the biofilm at similar rate as in water [26].  This was in contrast to the 
movement of carboxylate- and DMEDA-modified nanopsheres in a B. multivorans LMG 
18825 biofilm which was found to be strongly impeded [26].  In the present work we 
expanded the panel of Bcc strains to study the diffusion in biofilms of both carboxylate- 
and DMEDA-modified nanospheres.  The negatively charged nanospheres moved 5 to 13 
times more slowly in all Bcc biofilms tested compared to in water.  In all biofilms, a 
fraction of relatively immobile negatively charged particles, characterized by Da values 
close to zero, was observed.  This immobilization is probably caused by an electrostatic 
interaction between positively charged components of the biofilm and the negatively 
charged nanospheres, which correlates with the shift towards α < 1 observed for these 
particles, indicating anomalous subdiffusion.  It was previously observed that positively 
charged particles are immobilized on fiber-like structures, which were hypothesized to 
be eDNA [26] (Figure 4).  Here we tested this further by studying the transport of 
DMEDA-modified nanospheres in biofilms grown in the presence of dornase alfa. In 
general it was found that dornase alfa treatment reduced the extent of anomalous 
diffusion and improved the diffusion rate, supporting the view that positively charged 
particles can get trapped by binding to eDNA in the biofilm matrix.  As DMEDA-modified 
nanospheres interact with eDNA, the application of positively charged liposomes as 
antibiotic carrier systems can only be considered in combination with e.g. dornase alfa.  
However, as previous research has indicated that the use of dornase alfa could be 
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contraindicated in CF patients infected with B. cenocepacia [31], we did not test the 
effect of tobramycin encapsulated in positively charged liposomes.  Instead, the effect of 
tobramycin encapsulated in negatively charged liposomes was compared to that of 
tobramycin encapsulated in neutral liposomes.  Neutral liposomal formulations were 
tested as a reference as these appear, at first sight, less interesting to treat Bcc biofilm 
infections based on the mobility of neutral nanospheres which showed no enrichment in 
B. multivorans LMG 18825 biofilms.  In contrast, enrichement of carboxylate-modified 
nanospheres at sites close to the bacteria has been observed [26] (Figure 4).  Therefore, 
if anionic liposomes behave similarly in Bcc biofilms as anionic nanospheres, 
tobramycin could potentially be targeted near the cell clusters when encapsulated in 
anionic liposomes, resulting in an increased anti-biofilm effect.   
 
Figure 4: Confocal images of nanoparticles is a B. multivorans LMG 18825 biofilm [26]. 
 
Confocal image of  
A) 0.1 µm carboxylate-modified 
nanospheres and  
B) 0.1 µm DMEDA-modified 
nanospheres in a B. multivorans 
LMG 18825 biofilm.  The 
bacteria are shown in red (Syto 
59) and the nanospheres in 
green.  The insert in  A) shows 
anionic nanospheres adhered 
to the bacteria. 
 
 
At free tobramycin concentrations equal to 4XMIC, a substantial bactericidal effect 
against all Bcc biofilms was observed.  Unfortunately, this anti-biofilm effect could not 
be increased by encapsulating tobramycin in either neutral or anionic liposomes.  As the 
surface of Bcc cells is negatively charged it could be that the fusion of anionic liposomes 
with the bacterial cells is limited by repulsive forces at close proximity.  The bactericidal 
activity of tobramycin encapsulated in neutral liposomes at concentrations of 4XMIC 
could only be tested against B. cepacia LMG 1222 as this strain showed the lowest MIC 
(32 µg/mL) and not more than 140 µg/mL of tobramycin could be encapsulated in these 
neutral liposomes.  The neutral liposomal tobramycin formulation did not show an 
increased bactericidal effect compared to that of free tobramycin.  Although the 
observed relatively unobstructed motion of neutral particles in B. multivorans LMG 
18825 biofilms suggests no penetration difficulties for neutral liposomes in the biofilm, 
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we did not find a substantial anti-biofilm effect.  Still, the effect of the neutral liposomal 
tobramycin at a concentration of 140 µg/mL was not decreased compared to the effect 
of free tobramycin in B. multivorans LMG 18825 biofilms, indicating that the 
encapsulated tobramycin does enter the cell.  Possible explanations for the lack of an 
anti-biofilm effect of neutral formulations of liposomal tobramycin in B. cenocepacia 
LMG 16656, B. cenocepacia LMG 18829 and B. dolosa LMG 18943 are that a hydrophilic 
EPS layer in close proximity to the biofilm cells protects them from fusion with the 
liposomal carrier system.  Alternatively, it could be that the transport of nanospheres is 
not a good model for the transport of liposomes in Bcc biofilms, especially for the 
neutral liposomes which are twice the size of the nanospheres.  Smaller sized neutral 
liposomes with equal tobramycin encapsulation efficiency would allow to investigate 
this further but the low encapsulation efficiency of tobramycin into neutral liposomes 
[24] makes this impossible at present.   
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Conclusion 
Both positively- and negatively charged nanospheres show slow subdiffusion in Bcc 
biofilms.  While positively charged nanospheres likely interact with eDNA, negatively 
charged nanospheres probably bind to positively charged matrix components.  As 
previous research from a collaborating research group has indicated an enrichment of 
negatively charged nanospheres close to biofilm clusters, anionic liposomes could 
possibly serve as antibiotic delivery systems with high potential for treatment of Bcc 
biofilm infections.  However, anionic liposomal formulations with tobramycin 
concentrations of 4XMIC only displayed bactericidal activity against B. cepacia LMG 
1222 biofilms.  In contrast, free tobramycin at this concentration showed high 
bactericidal activity against all Bcc biofilms tested.  The fusion of the negatively charged 
liposome with the negatively charged bacterial membrane is likely limited by 
electrostatic repulsive forces at close proximity.  Although we observed unobstructed 
diffusion of neutral nanospheres, the use of a neutral tobramycin formulation did not 
result in an increased anti-biofilm effect compared to free tobramycin.  Additional 
research for the development of an optimal tobramycin carrier to treat Bcc biofilm 
infections is needed. 
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CF is the most common inherited disease in the European population, affecting 
approximately 1 in 2500 live births in Belgium [1].  The disease is caused by mutations 
in both cftr alleles, encoding a chloride channel with secretory function in different 
organs, including lung, liver, gut, pancreas and sweat glands.  The hallmark of CF and 
major cause of morbidity and mortality in CF patients are chronic lung infections.  Early 
lung infections, often by 1 year of age, are mainly caused by H. influenzae, S. aureus or P. 
aeruginosa [2].  These early infections can most of the time successfully be cleared, 
either with antibiotic therapy or spontaneously.  In later stages, P. aeruginosa is 
considered the major pathogen recovered from the CF lung and transient infections 
often progress to chronic P. aeruginosa infections which are difficult to treat.  Although 
infections with Bcc species are much less prevalent than P. aeruginosa infections in CF 
patients, the clinical outcome of Bcc infections is highly variable and often associated 
with a rapid decline in lung function [3].  Some Bcc infected CF patients even experience 
“cepacia syndrome”, characterized by necrotizing pneumonia and septicaemia, resulting 
in early dead [4].  As Bcc bacteria are intrinsically resistant to many antibiotics, produce 
a wide variety of potential virulence factors and have been shown to be capable of 
person-to-person transmission, these infections are highly feared among CF patients.  
Much effort has already been put in control strategies to limit the spread of these 
infections [5] because, once a patient is infected with Bcc, eradication is very difficult [6].  
In addition, biofilm formation has been associated with the persistence of Bcc lung 
infections as the biofilm mode of growth provides additional protection against 
antibiotics and host immune components [7].  Understanding the basis of the increased 
resistance associated with biofilm formation is the main goal of many researchers.   
In vitro biofilm formation is a common trait of Bcc strains.  During biofilm formation, 
bacteria produce EPS providing protection against many environmental factors 
resulting in increased resistance against both host immune factors and antibiotics.  
Although Bcc strains are intrinsically resistant to tobramycin, tobramycin shows high 
bactericidal activity against both stationary phase planktonic cultures and sessile cells at 
concentrations 4 times higher than the MIC [8].  However, a decreased susceptibility to 
tobramycin of sessile cells compared to planktonic cells has been observed [8].  This 
decreased susceptibiltiy could be due to a number of biofilm specific factors.  A possible 
explanation, that was further investigated in chapter VI, is that tobramycin interacts 
through the biofilm.   
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As the aminoglycoside antibiotic, tobramycin, is positively charged under physiological 
conditions, it can easily bind to negatively charged components of the biofilm.  In non-
mucoid P. aeruginosa biofilms, such ionic interactions have already been demonstrated 
to limit the penetration of tobramycin in the biofilm, resulting in increased tolerance to 
tobramycin [9].  eDNA, an important biofilm matrix component in many bacterial 
species, has been shown to protect P. aeruginosa biofilm cells by acting as a shield, 
binding aminoglycosides and AMPs [10, 11].  The presence of eDNA in Bcc biofilms was 
confirmed, although the amount of eDNA significantly varied among different Bcc 
strains.  rhDNase, at high concentrations (50 µg/mL), resulted in ≤ 50 % reduction of 
eDNA concentrations but, in contrast to what was previously observed in E. coli, S. 
aureus and P. aeruginosa [12, 13], it had no effect on Bcc biofilm dispersion.  A 
combination of tobramycin and rhDNase did not display an increased bactericidal effect 
compared to tobramycin alone.  Possibly, the eDNA is not sufficiently degraded to 
eliminate a potential shielding effect of the eDNA, like observed in P. aeruginosa 
biofilms.  As rhDNase concentrations used were already up to 5 times higher than 
concentrations measured in CF sputum after conventional rhDNase inhalation therapy 
[14], we did not investigate the effect of higher rhDNase concentrations.  Novotny et al. 
suggest targeting DNABII proteins, which have been shown to stabilize eDNA in Bcc 
biofilms [15].  DNABII proteins bind to and bend eDNA, contributing to the lattice 
structure of eDNA in different bacterial biofilms.  A dispersal effect of antisera directed 
against these DNABII proteins in B. cenocepacia biofilms has been observed [15].  After 
dispersal, the resulting biofilm and planktonic cells displayed an increased susceptibility 
to antibiotic therapy.  In contrast, treatment of B. cenocepacia biofilms with rhDNase 
resulted in more robust biofilms, suggesting a contra-indication of rhDNase therapy in 
CF patients infected with B. cenocepacia [15].   
In addition to eDNA, exopolysaccharides may also confer tolerance to aminoglycosides 
in Bcc biofilms.  Exopolysaccharides are known to play an important role in the 
adaptation of Bcc to different stress conditions and the type of exopolysaccharides 
produced as well as the amount is regulated in response to environmental signals [16].  
Cepacian, which is considered the major exopolysaccharide produced by most isolates of 
the Bcc, is negatively charged due to the presence of a carboxylate residue in the 
polymer repeating unit, allowing electrostatic interaction with tobramycin.  The 
polymer also contains acetyl substituents and the number of acetyl groups per repeating 
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unit is strain dependent [16].  A protective effect of cepacian against ROS has been 
described.  ROS, including NaClO, are produced in vivo by neutrophils in order to kill and 
degrade infecting microorganisms after phagocytosis.  ClO- concentrations in 
phagolysosomes have been estimated to be around 100 mM [17].  By scavenging NaClO, 
the backbone of cepacian is degraded and acetyl substituents are cleaved of [17].  The 
loss of these acetyl substituents hampers the ability of cepacian chains to form duplexes, 
reducing the viscosity of the polysaccharide network around Bcc cells [18].   Based on 
the effects of ROS on the structure of cepacian, we investigated whether the anti-biofilm 
effect of tobramycin would increase after a short (15 min) NaClO (60 µM) pretreatment  
of Bcc biofilms.  This combination therapy displayed significantly increased bactericidal 
activity compared to tobramycin monotherapy in several Bcc biofilms tested, including 
B. cenocepacia LMG 16656.  As this strain does not produce cepacian [19], it is likely that 
the polymer degrading effect of ROS is not limited to cepacian but that ROS also affect 
the structural integrity of other polysaccharides present in the biofilm matrix.  In vitro 
experiments indicated a substantial (3 log reduction) bactericidal effect of NaClO on 
planktonic B. pyrrocinia cultures when exposed to a 60 µM NaClO solution for only 15 
min [17].  However, the same NaClO treatment did not result in killing of bacteria when 
tested on Bcc biofilms (chapter VI).  At higher concentrations, starting from 100 µM 
NaClO, a small bactericidal effect was observed.  The higher concentrations needed to 
kill biofilm cells indicate that the biofilm mode of growth offers protection against ROS, 
probably by the production of exopolysaccharides.  In addition, through the formation of 
an exopolysaccharide network around the bacterial cells, bacterial surface antigens are 
masked, avoiding recognition by the immune system and subsequent phagocytosis [16].  
Therefore, the production of exopolysaccharides by Bcc species likely contributes to the 
persistence of these microorganisms and efficient degradation of these polysaccharides 
could increase the efficacy of the immune system and of antibiotics. 
Electrostatic interactions between tobramycin and the matrix could also be avoided by 
adding competitors for binding to matrix components, e.g. divalent cations, as has been 
investigated by Tseng et al. [9].  Divalent cations will occupy binding sites to which 
tobramycin is also capable of binding, thus improving tobramycin penetration through 
the biofilm.  However, it has to be taken into account that these divalent cations will also 
compete with tobramycin for the same binding sites on LPS in Gram-negative bacteria 
(chapter V). The initial step necessary for aminoglycoside activity in Gram-negative 
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bacteria is the binding to LPS followed by subsequent uptake of the antibiotic into the 
cell.  Divalent cations are well-known to stabilize the outer membrane of Gram-negative 
bacteria by cross-linking two adjacent LPS molecules, decreasing outer membrane 
permeability and acting as antagonists for aminoglycoside activity.  Mg2+ and Ca2+ have 
been shown to display the biggest antagonistic effect on gentamycin activity in P. 
aeruginosa.  In chapter V an antagonistic effect of 25 mM Mg2+ on tobramycin activity 
against P. aeruginosa was observed.  However, this antagonistic effect could not be 
confirmed for Bcc strains.  In contrast, for some Bcc strains, an increased susceptibility 
to tobramycin in the presence of 6.25 mM Mg2+ was observed.  This indicates that the 
combination of tobramycin with divalent cations to treat Bcc biofilm infections could 
potentially be beneficial.  However, the antagonistic effect of these cations on 
tobramycin activity against P. aeruginosa suggests a decreased activity of this 
combination therapy for the treatment of P. aeruginosa biofilm infections compared to 
tobramycin monotherapy.  As P. aeruginosa is the major pathogen isolated from CF 
patients, the potential of this combination therapy of tobramycin with divalent cations 
to treat CF lung infections seems relatively low.   
Another component present in Bcc biofilms, contributing to their resistance against 
antibiotics and their persistence in the CF lung is PNAG, a capsule polysaccharide.  As 
PNAG is positively charged, direct electrostatic interaction with tobramycin does not 
occur.  However, a biofilm produced by a B. multivorans mutant, incapable of producing 
PNAG, showed increased susceptibility to tobramycin compared to the wild type [20].  In 
chapter VI we tested if a combination of tobramycin and dispersin B, a selective PNAG 
degrading enzyme, displayed superior bactericidal activity against Bcc biofilms 
compared to tobramycin alone.  In some biofilms, the combination of tobramycin with 
100 µg/mL dispersin B  resulted in a 10-45% additional reduction in biofilm cell 
numbers compared to tobramycin treatment alone.  This increased effect, due to the 
addition of 100 µg/mL dispersin B, which did not cause any dispersal or cell death on its 
own, is likely associated with the degradation of a protective polymeric network in close 
proximity to the biofilm cells.  Positively charged PNAG can possibly form complexes 
with polyanionic matrix components, e.g. eDNA and cepacian, increasing the density of 
the polymeric network surrounding the bacterial cells, thereby limiting tobramycin 
penetration.  The lack of an increased anti-biofilm effect in some Bcc biofilms tested 
could either be due to the lack of PNAG production or limited PNAG degradation.  
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Besides being a diffusion barrier for antibiotics, the dense polymeric network could also 
block the access of dispersin B to PNAG, inhibiting degradation of the latter.   In contrast 
to PNAG degradation therapy, in which the polymer is seen as an obstacle to efficient 
antibiotic therapy, the presence of PNAG in Bcc biofilms could also positively contribute 
to the treatment of Bcc infection.  PNAG is produced on the surface of various multidrug 
resistant bacteria, including MRSA and members of the Bcc.   Thereby, immunotherapy 
based on PNAG as an antigen could provide a broad-spectrum therapy for either treating 
patients infected with PNAG-producing bacteria or as prophylaxis in patients at risk of 
developing multidrug resistant bacterial infections [21].  A fully human monoclonal 
antibody directed to PNAG has already successfully completed phase I clinical trials [21]. 
The development of a liposomal tobramycin delivery system could also prevent 
interactions between the antibiotic and matrix components, possible increasing the 
penetration rate of tobramycin in the biofilm (chapter VII).  The mobility of neutral, 
anionic and cationic nanospheres in Bcc biofilms was used as a model to predict the 
mobility of liposomal delivery systems in these biofilms.  Previous research from the 
Laboratory of General Biochemistry & Physical Pharmacy in Ghent observed free 
diffusion of neutral nanospheres in B. multivorans LMG 18825 biofilms and obstructed 
diffusion of both anionic an cationic nanospheres [22].  The subdiffusion of these anionic 
and cationic nanospheres was confirmed in all Bcc biofilms tested (chapter VII).  
Cationic particles were observed to interact with fiber-like structures, likely eDNA, 
which suggests that the use of cationic liposomes as delivery systems for tobramycin 
would benefit from co-administration of the liposomal tobramycin formulation with 
rhDNase.  As rhDNase therapy has been suggested to be contra-indicated in CF patients 
infected with Bcc [15] this was not further investigated.  As anionic particles were 
immobilized in close proximity to biofilm cell cluster, the use of anionic liposomal 
carriers for tobramycin looked promising in terms of “targeted” drug delivery.  
Unfortunately, tobramycin encapsulated in anionic liposomes displayed less activity 
towards Bcc biofilms than free tobramycin.  Possibly, the fusion of the anionic liposome 
with the negatively charged bacterial cell surface is inhibited by repulsive forces.  The 
passive diffusion of tobramycin out of the liposomes is expected to be slow as the lipid 
membranes of the liposome present with low permeability for hydrophilic drugs.  
Therefore, without triggered release of tobramycin, e.g. by heat or enzymatic reaction, 
the use of anionic delivery systems for tobramycin to treat Bcc biofilm infections would 
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present with low tobramycin bioavailability.  However, phospholipases, which are 
capable of degrading anionic liposomes [23], have been detected in CF sputum [24].  
This suggests that the lack of an in vitro bactericidal effect of tobramycin encapsulated in 
anionic liposomes against Bcc biofilms, does not necessarily mean there could be no 
activity in vivo.  Currently, Arikace, a neutral liposomal formulation of amikacin, is being 
evaluated in phase II clinical trials for the inhalation treatment of pulmonary infections 
with Gram-negative bacteria [25].  Arikace presented with superior activity against P. 
aeruginosa biofilms compared to free amikacin and the penetration of these liposomes 
(250-300 nm) in both CF sputum and P. aeruginosa biofilms has been demonstrated 
[26].  In B. multivorans LMG 18825 biofilms, the activity of both free and liposomal 
encapsulated tobramycin (same lipid composition as Arikace) was similar.  The 
observed bactericidal effect indicates that the liposomes are capable of reaching the 
biofilm cells and releasing their content.  However, the activity of the neutral liposomal 
tobramycin formulation against Bcc biofilms was observed to be strain specific.  This 
could indicate either differences in penetration of the liposome through different Bcc 
biofilms or differences in release of the encapsulated tobramycin.  It is well-known that 
the composition of the biofilm matrix is strain-specific, resulting in strain-dependent 
diffusion of the relatively large liposomal carriers (400 nm) among Bcc strains.  In 
addition, exopolysaccharides in close proximity to the cell surface, e.g. PNAG, could 
prevent fusion between the liposomal carrier and the bacterial surface.  Triggered 
release of liposome contents, like has been suggested in P. aeruginosa biofilms, could 
increase the bioavailability of the encapsulated tobramycin in Bcc biofilms.  In P. 
aeruginosa biofilms, the release of amikacin from the Arikace liposomal formulation is 
believed to be mediated by rhamnolipids, glycolipids often referred to as bacterial 
surfactants produced by P. aeruginosa [26].  Rhamnolipid production has also been 
observed in various Burkholderia species, but not in the Bcc [27].  Additional research is 
needed to develop a good drug delivery system for tobramycin to increase the 
effectiveness of eradication of Bcc in CF patients, in particular focusing on higher 
encapsulation efficiency of tobramycin in smaller liposomes and triggered drug release. 
Today, antibiotic resistance among pathogenic microorganisms is increasing, 
confronting clinicians with the inability to eradicate many life-threatening infections.  As 
is the case for Bcc infections, resistance can be both intrinsic and associated with the 
capability of forming biofilms.  Until today, no guidelines for optimal antibiotic 
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treatment regimen of CF patients suffering from chronic Bcc infections are available 
[28].  The discovery of new targets or the improvement of existing antibiotic treatments, 
for example by means of combination therapy, different administration routes or 
different antibiotic formulations, could drastically improve the prognosis of CF patients 
infected with Bcc. 
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Summary 
The Bcc is a group of at least 18 closely related opportunistic pathogens that are able to 
infect the respiratory tract of CF patients.  Although infections with Bcc species are much 
less prevalent than P. aeruginosa infections in CF patients, the clinical outcome of Bcc 
infections is highly variable and often associated with a rapid decline in lung function.  
Due to their intrinsic resistance to many antibiotics and the production of a broad range 
of virulence factors, Bcc lung infections are very difficult to treat.  In addition, biofilm 
formation has been associated with the persistence of Bcc infections in the CF lung, as 
the biofilm mode of growth provides additional protection against antibiotics and host 
immune components.  The aim of this thesis was to search for an antibiotic treatment 
with superior Bcc anti-biofilm efficacy compared to tobramycin. 
The first three chapters (Part 1) present an overview of the literature concerning CF, 
biofilms and the Bcc; three topics related to the content of this thesis. 
In chapter IV the potential of fosmidomycin to treat Bcc infections was investigated.  
Fosmidomycin inhibits Dxr, a key enzyme in the non-mevalonate pathway, which is 
essential for isoprenoid synthesis in Bcc.  The antimicrobial activity of fosmidomycin 
and eight fosmidomycin derivatives towards forty Bcc strains was investigated.  All Bcc 
strains were resistant, although the addition of glucose-6-phosphate reduced MIC values 
of FR900098, the fosmidomycin acetyl derivative, from 512 mg/L to 64 mg/L for B. 
multivorans and B. cepacia.  This increased susceptibility in the presence of glucose-6-
phosphate was associated with an increased expression of the genes involved in 
glycerol-3-phosphate transport, likely the only route for fosmidomycin import in the 
Bcc.  In addition, the upregulation of  fsr, encoding an efflux pump, was observed during 
treatment with fosmidomycin and FR900098.  Therefore, the lack of activity of 
fosmidomycin and fosmidomycin derivatives against Bcc bacteria is likely due to an 
insufficient uptake accompanied by increased efflux of these antibiotics in Bcc cells. 
Chapter V deals with the mode of uptake of tobramycin in different Gram-negative 
bacteria, including E. coli, P. aeruginosa and Bcc bacteria. The cellular uptake of 
aminoglycosides, including tobramycin, can be divided in three phases: an initial energy-
independent electrostatic interaction at the cell surface and subsequently two energy-
dependent phases.  However, fundamental differences exist in aminoglycoside uptake 
between different Gram-negative bacteria.  Aminoglycosides can cross the outer 
membrane either by diffusion through hydrophilic channels formed by porin proteins or 
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by a process referred to as self-promoted uptake.  In order to determine whether self-
promoted uptake is involved, the activity of tobramycin in the presence and absence of 
Mg2+ was investigated.  Increased tobramycin MICs in the presence of Mg2+ confirmed 
self-promoted uptake in P. aeruginosa.  In contrast, decreased MICs in the presence of 
Mg2+ for Bcc organisms suggested alternative uptake mechanisms.  Tobramycin activity 
against E. coli cells was unaltered in the presence of Mg2+.  In order to further investigate 
the mode of tobramycin uptake in these organisms, the activity of three tobramycin 
derivatives, i.e. tobramycin-OH-BODIPY, tobramycin-N-Me2 and tobramycin-OH-EDTA, 
on both E. coli and P. aeruginosa planktonic and biofilm cells was investigated.  Based on 
the MIC of tobramycin-OH-BODIPY for E. coli (32 µg/mL) and the high activity of 
tobramycin-OH-EDTA towards E. coli biofilms, we hypothesized that tobramycin is at 
least in part taken up through self-promoted uptake in E. coli, as both derivatives are too 
large to be taken up through porins.  However, the high MIC of tobramycin-OH-EDTA for 
E. coli (512 µg/mL) could not be explained.  The observed selective activity of 
tobramycin-N-Me2 against P. aeruginosa ATCC 27853 biofilms could be promising for 
treating P. aeruginosa lung infections in CF.  By selectively targeting the pathogenic 
species, the commensal flora of the patients will be less disturbed than by traditional 
antibiotics.  This will reduce the number and frequency of side effects as well as the 
selection of antibiotic-resistant organisms associated with antibiotic therapy. 
The contribution of Bcc biofilm matrix components, including eDNA, cepacian and PNAG, 
to tobramycin susceptibility was investigated in chapter VI.  To this end, the in vitro 
bactericidal activity of tobramycin in combination with rhDNase, NaClO and dispersin B 
was tested against different Bcc biofilms.  Exopolysaccharide degradation by NaClO 
pretreatment and specific PNAG degradation by dispersin B significantly increased the 
bactericidal effect of tobramycin against some of the Bcc biofilms tested, including 
strains of B. cenocepacia, B. cepacia and B. metallica.  In contrast, the presence of 
rhDNase during biofilm treatment and/or development had no influence on tobramycin 
activity against Bcc biofilms.  These results indicate that exopolysaccharides likely play a 
role in tobramycin susceptibility of Bcc biofilms and that a combination of tobramycin 
with exopolysaccharide degrading components could improve the eradication of Bcc 
biofilm infections. 
In chapter VII we investigated the potential of treating Bcc biofilms with liposomal 
tobramycin formulations.  Single particle tracking was used to study the transport of 
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positive and negative nanospheres in Bcc biofilms as a model for the transport of 
liposomes.  Negative nanospheres were immobilized close to biofilm cell clusters while 
positive nanopsheres interacted with fiber-like structures, probably eDNA. Based on 
these data, encapsulating tobramycin into negatively charged liposomes looked 
promising in terms of targeted drug delivery.  However, the anti-biofilm effect of 
tobramycin did not increase compared to free tobramycin when it was encapsulated 
into neutral or anionic liposomes.  Likely, the fusion of the anionic liposomes with the 
negatively charged bacterial surface of Bcc was limited by electrostatic repulsive forces 
at close proximity.  The lack of a substantial anti-biofilm effect of tobramycin 
encapsulated into neutral liposomes could be further investigated by increasing the 
liposomal tobramycin concentration.  However, this was hampered by the low 
encapsulation efficiency of tobramycin in these liposomes. 
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Samenvatting 
Het Bcc is een groep van minstens 18 nauw verwante species die luchtweginfecties bij 
mucoviscidose patiënten kunnen veroorzaken.  Hoewel de prevalentie van Bcc infecties 
laag is in vergelijking met P. aeruginosa infecties en de symptomen variabel zijn, 
resulteren Bcc infecties vaak in een snelle achteruitgang van de longfunctie.  Bcc 
infecties zijn moeilijk te behandelen omwille van hun intrinsieke resistentie tegen vele 
antibiotica en door de productie van een brede waaier aan virulentie factoren.  De 
mogelijkheid om een biofilm te vormen, die extra bescherming biedt tegen antibiotica en 
componenten van het immuunsysteem van de patiënt, draagt bij tot de persistentie van 
Bcc infecties in mucoviscidosepatiënten.  Het doel van dit doctoraatsproefschrift was om 
op zoek te gaan naar een verbeterde antibioticatherapie om Bcc biofilm infecties in 
mucoviscidosepatiënten te behandelen. 
De eerste drie hoofdstukken (deel 1) geven een overzicht van de literatuur over 
mucoviscidose, biofilms en het Bcc; drie onderwerpen met betrekking tot de inhoud van 
deze doctoraatsthesis. 
In hoofdstuk IV wordt het potentieel van fosmidomycine om Bcc infecties te 
behandelen nagegaan.  Fosmidomycine inhibeert Dxr, een sleutelenzym in de non-
mevalonaat pathway welke essentieel is voor de productie van isoprenoïden in Bcc.   De 
anti-microbiële activiteit van fosmidomycine en acht fosmidomycine derivaten tegen 
veertig Bcc stammen werd onderzocht.  Alle Bcc stammen vertoonden resistentie, 
hoewel het toevoegen van glucose-6-fosfaat de MIC waarden van FR900098,  een 
fosmidomycine acetyl derivaat, deed dalen van 512 mg/L tot 64 mg/L voor B. 
multivorans en B. cepacia.  Deze verhoogde gevoeligheid in aanwezigheid van glucose-6-
fosfaat ging gepaard met een verhoogde expressie van genen die betrokken zijn in het 
transport van glycerol-3-fosfaat.  Het glycerol-3-fosfaat transport systeem lijkt de enige 
weg voor fosmidomycine opname in Bcc cellen te zijn.  Tijdens behandeling met 
fosmidomycine en FR900098 werd ook een opregulatie van fsr, dat codeert voor een 
effluxpomp, waargenomen.  De resistentie tegen fosmidomycine en fosmidomycine 
derivaten in Bcc organismen is dus waarschijnlijk te wijten aan onvoldoende opname 
gecombineerd met een verhoogde efflux van deze antibiotica. 
In hoofdstuk V wordt de opname van tobramycine in verschillende Gram-negatieve 
micro-organismen besproken, waaronder E. coli, P. aeruginosa and Bcc species.  De 
opname van aminoglycosiden in Gram-negatieve micro-organismen kan onderverdeeld 
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worden in 3 fasen: een initiële elektrostatische interactie ter hoogte van de 
celmembraan die energie-onafhankelijk is, gevolgd door twee energie-afhankelijke 
fasen.  Toch bestaan nog fundamentele verschillen tussen Gram-negatieve bacteriën 
onderling.  Aminoglycosiden kunnen de buitenste membraan doorkruisen via diffusie 
doorheen hydrofiele kanalen, gevormd door porines, of via een “self-promoted uptake” 
mechanisme.  Het eventueel gebruik van het “self-promoted uptake” mechanisme wordt 
onderzocht door de activiteit van tobramycine in aan- en afwezigheid van Mg2+ te 
bepalen.  De verhoogde MIC waarden voor P. aeruginosa in de aanwezigheid van Mg2+ 
bevestigen het gebruik van “self-promoted uptake”.  Dit in tegenstelling tot de lagere 
MIC waarden voor Bcc species in de aanwezigheid van Mg2+, die een andere manier van 
opname suggereren.  De activiteit van tobramycin tegen E. coli bleef ongewijzigd in aan- 
of afwezigheid van Mg2+.  Om de opname van tobramycine verder te bestuderen werd de 
activiteit van drie tobramycine derivaten, (tobramycine-OH-BODIPY, tobramycine-N-
Me2 en tobramycine-OH-EDTA) tegen E. coli en P. aeruginosa planktonische en biofilm 
cellen onderzocht.  Gebaseerd op de MIC waarde van tobramycine-OH-BODIPY voor E. 
coli (32 µg/mL) en de hoge activiteit van tobramycine-OH-EDTA tegen E. coli biofilms, 
werd verondersteld dat tobramycine op zijn minst gedeeltelijk wordt opgenomen via 
“self-promoted uptake” in E. coli.  Deze hypothese werd voorop gesteld omdat deze 
derivaten te groot zijn om te worden opgenomen via porines en ze toch activiteit 
vertonen.  De hoge MIC waarde van tobramycine-OH-EDTA voor E. coli (512 µg/mL) kon 
niet worden verklaard.  Er werd ook een selectieve activiteit van tobramycine-N-Me2 
tegen P. aeruginosa ATCC 27853 biofilms waargenomen.  Een selectief antibioticum zal 
de commensale flora van de patiënt na antibiotica behandeling minder verstoren dan 
een traditioneel antibioticum.  Hierdoor kan het aantal en de frequentie van 
nevenwerkingen geassocieerd met antibioticatherapie en ook de selectie van 
antibiotica-resistentie micro-organismen teruggedrongen worden.   
De invloed van matrix componenten, waaronder extracellulair DNA, cepacian en PNAG, 
aanwezig in de biofilm van Bcc bacteriën, werd onderzocht in hoofdstuk VI.  De in vitro 
activiteit van tobramycine in combinatie met rhDNase, NaClO en dispersin B werd getest 
tegen verschillende Bcc biofilms.  De degradatie van exopolysacchariden door een korte 
NaClO voorbehandeling en de specifieke degradatie van PNAG door dispersin B 
resulteerde in een significant verhoogde activiteit van tobramycine in meerdere Bcc 
biofilms, waaronder deze gevormd door B. cenocepacia, B. cepacia and B. metallica 
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stammen.  De aanwezigheid van rhDNase tijdens biofilm vorming en tijdens 
tobramycine behandeling van een 24u oude biofilm had geen effect op de activiteit van 
tobramycine in Bcc biofilms.  Hieruit werd besloten dat exopolysacchariden 
hoogstwaarschijnlijk een rol spelen in de gevoeligheid van Bcc biofilms voor 
tobramycine en dat een combinatie van tobramycine met componenten die in staat zijn 
om exopolysacchariden af te breken de eradicatie van deze biofilms mogelijks kan 
verbeteren. 
In hoofdstuk VII wordt het potentieel van liposomaal tobramycine om Bcc biofilms te 
behandelen besproken.  Er werd gebruik gemaakt van single particle tracking om het 
transport van positieve en negatieve nanopartikels in Bcc biofilms te bestuderen als 
model voor het transport van liposomen.  Negatieve partikels werden geïmobiliseerd 
rondom cel clusters terwijl positieve partikels interactie vertoonden met draadachtige 
structuren, waarschijnlijk extracellulair DNA.  De encapsulatie van tobramycine in 
negatief geladen liposomen leek dus veelbelovend om tobramycine af te leveren dicht bij 
de biofilm cellen.  Helaas werd geen verhoogde anti-biofilm activiteit waargenomen van 
tobramycine geëncapsuleerd in negatief geladen liposomen, noch in neutrale liposomen.  
Mogelijks word de fusie van het negatief geladen liposoom met het negatief geladen 
buitenste membraan van Bcc cellen verhinderd door elektrostatische afstoting op korte 
afstand.  Het gebrek aan een substantieel anti-biofilm effect van tobramycine 
geëncapsuleerd in neutrale liposomen kan verder onderzocht worden door de 
concentratie aan geëncapusleerd tobramycine te verhogen.  Dit wordt echter 
belemmerd door de lage encapsulatie efficiëntie van tobramycine in deze liposomen. 
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